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Abstract 
Background:  
Fixed airflow obstruction (FAO) occurs in asthma despite adequate treatment 
and no or minimal smoking history. FAO in asthma is more common in older 
people or those with long-standing disease and associated with poor 
outcomes. Airflow obstruction occurs in the small airways and is thought to be 
due to airway remodelling and driven by inflammation. Changes to the lung 
tissue, which may result in alteration of the lungs elastic properties such as 
loss of lung elastic recoil, may also contribute. The underlying mechanisms 
leading to FAO in asthma are poorly understood.  
Aim:  
To explore the physiological properties of both the airways and lung tissue 
and airway inflammation in older non-smokers with asthma, and to assess 
how they may contribute to FAO.  
Method: 
Non-smoking adults >40 years old with asthma were treated with two months 
of high dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA). 
Subsequently standard lung function and small airway function was measured 
using the forced oscillation technique (FOT) and the multiple breath nitrogen 
washout test (MBNW). Lung elastic recoil was measured using the 
oesophageal balloon technique. Airway inflammation was measured using 
bronchoalveolar lavage fluid obtained during bronchoscopy. 
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Results: 
Non-smoking adults with asthma (n=19) demonstrated moderate FAO; small 
airway dysfunction, as measured by FOT and MBNW; increased lung 
compliance and loss of elastic recoil and variable airway inflammation. Worse 
airflow obstruction was associated with increased lung compliance. Increased 
airway resistance and small airway dysfunction in the acinar airways was 
associated with a loss of lung elastic recoil. Cross-sectional assessment of 
airway inflammation was not associated with lung function impairment.  
Conclusion:  
Changes to the lungs elastic properties results in increased compliance or 
reduced lung elastic recoil and make a significant contribution to FAO and 
small airway dysfunction in older non-smokers with asthma. ‘Lung 
remodelling’ is a potential pathological process leading to lung tissue changes 
and may be an alternate asthma paradigm. Underlying cellular mechanisms 
need further investigation. 
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Chapter 1 
1 Introduction and review of literature  
 4 
1.1. General Introduction 
Asthma is characterized by variable airflow obstruction that occurs 
intermittently and usually reverses either spontaneously or with bronchodilator 
therapy (1). However, in older people with asthma airflow obstruction can 
become fixed or irreversible (2-5). Fixed airflow obstruction (FAO) can occur 
despite appropriate treatment (3-5) and despite no smoking history (2, 4, 5) or 
exposure to noxious substances (6). The consequences of FAO in asthma are 
detrimental and associated with poor outcomes and quality of life (4, 5, 7-10) 
however the underlying mechanisms are not well understood.  
FAO in asthma is thought to be due to airway remodelling, structural changes 
to the airway wall that result in airway wall thickening (11-13). This causes 
subsequent narrowing of the airway lumen and airflow obstruction, which 
occurs in the small airways (14, 15). In addition to airway remodelling, 
structural changes outside the airway wall occur in asthma (16-18). That is 
changes in the surrounding lung tissue, a form of ‘lung remodelling’. Changes 
in the lung tissue can cause a loss of lung elastic recoil in asthma (19-21) and 
in older people (22). With loss of elastic recoil, the tethering force of the lung 
tissue to the airways is reduced and the force to keep airways open. 
Therefore alterations in lung tissue may also contribute to FAO in asthma. 
Chronic airway inflammation plays an important role in asthma and is typically 
associated with TH2 and eosinophilic inflammation (23-27). However there is 
increasing interest in the role of non-eosinophilic and neutrophilic 
inflammation. Increased airway neutrophils are seen with increasing age in 
both asthma (28-31) and healthy people (32). In addition, sputum neutrophilia 
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in asthma is associated with impaired lung function (33, 34) and severe and 
incompletely reversible airflow obstruction (10). 
Prevention and treatment of FAO in non-smokers with asthma remains a 
challenge due many unanswered questions about this asthma phenotype. 
The airways, lung tissue and inflammation all play an important role with the 
addition of the ageing process. This thesis will examine physiological 
abnormalities in the small airways and lung tissue, as well as explore airway 
inflammation, in older non-smokers with asthma and FAO to increase our 
understanding about the underlying mechanism of this phenotype.  
1.2. Asthma 
1.2.1. Definition 
Asthma is a heterogeneous disease characterized by chronic airway 
inflammation. It is defined by typical respiratory symptoms such as wheeze, 
shortness of breath, chest tightness and cough, which often vary over time 
and in intensity, and the presence of variable airflow obstruction (1, 35). 
Airflow obstruction occurs in response to inhaled stimuli, such as cold air or 
allergens and usually reverses either spontaneously or with bronchodilator 
therapy. The site of airflow obstruction is in the small airways (14, 15), 
although both the small and large airways are affected (36, 37).  
The current paradigm in asthma is that airflow obstruction is due to airway 
remodelling. Airway remodelling refers to structural changes in the 
composition, quantity and organization of the cellular and molecular 
components of the airway wall (11, 13, 38) and will be discussed in more 
detail later in this chapter. The interplay between airway remodelling and 
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complex inflammatory signalling processes results in airway hyper-
responsiveness (AHR). AHR is a hallmark of asthma and can be defined as 
an exaggeration of airway narrowing in response to low-dose stimulation of 
airway smooth muscle (39).  
1.2.2. Epidemiology 
Asthma is one of the most common chronic diseases (40) and affects all age 
groups. It is estimated that 300 million people worldwide have asthma with 
geographical differences in asthma prevalence (40, 41). The incidence is 
increasing and consequently significant health problems have arisen globally 
(42). Individuals affected by asthma place an increasing burden on society 
due to the disability, high health care utilization and poor quality of life it 
causes (1, 43, 44).  
1.2.3. Risk factors 
Risk factors associated with asthma include lung function abnormalities at an 
early age (45) and atopic conditions like atopic dermatitis and allergic rhinitis 
(46-48). An increased risk of asthma may also be associated with certain 
occupations such as nursing and cleaning (49) and active and/or second-
hand smoking (50-53), in particular maternal smoking (54). There is also a 
familial predisposition and genetic link associated with asthma. The 
ADisintegrin And Metalloprotease 33 (ADAM33) gene (55, 56) has been 
implicated in asthma development and disease progression, with 
polymorphisms showing an association with an accelerated forced expiratory 
volume in 1 second (FEV1) decline (56). Obesity is both a risk factor and 
disease modifier of asthma (57). Increased body mass index (BMI) is 
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associated with a greater risk of developing asthma (58, 59) and asthma 
severity (58). Respiratory infections, both viral and bacterial, are known to 
trigger asthma exacerbations however it is not known whether respiratory 
infections cause asthma or are a protective factor (60, 61). The interaction 
between infection and airway inflammation in asthma is complex and how 
infection affects individuals may be dependent on the specific type of 
infection, genetic susceptibility, age, presence of atopy and lung microbiome. 
These risk factors may be a consequence of complex interactions between 
genetic and environmental factors. 
1.2.4. Diagnosis 
The diagnosis of asthma is based on a history of typical respiratory symptoms 
and demonstration of variable airflow obstruction (1). Evidence of variable 
expiratory airflow obstruction should ideally be demonstrated early, as 
characteristic asthma features may improve spontaneously or with treatment. 
Variable expiratory airflow obstruction can be confirmed by using one of the 
following tests: peak expiratory flow, spirometry, bronchial challenge test or 
exercise challenge test (1). Diagnostic criteria for making the diagnosis of 
asthma are highlighted in table 1. 
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Table 1.1 Diagnostic criteria for asthma in adults. 
Adapted from GINA Global Strategy for Asthma Management and Prevention 
2017 (1). 
FEV1: forced expiratory volume in 1 second; PEF: peak expiratory flow 
(highest of three readings). 
  
Diagnostic feature of variable 
expiratory airflow limitation 
Criteria for making the diagnosis of 
asthma 
Documented excessive variability in lung 
function in one of more of the tests below  
AND documented airflow limitation 
The greater the variations, or the more 
occasions excess variation is seen, the 
more confident the diagnosis 
At least once during diagnostic process 
when FEV1 is low, confirm that FEV1/FVC 
is reduced 
Positive bronchodilator reversibility test 
(more likely to be positive if short acting 
and long acting bronchodilators are 
withheld for ≥4 hours and ≥15 hours, 
respectively) 
Increase in FEV1 of >12% and >200 mL 
from baseline, 10-15 minutes after 200-
400 mcg albuterol or equivalent (greater 
confidence if increase is >15% and >400 
mL). 
Excessive variability in twice-daily PEF 
over 2 weeks  
Average daily diurnal PEF variability >10% 
Significant increase in lung function after 4 
weeks of anti-inflammatory treatment 
Increase in FEV1 by >12% and >200 mL 
(or PEF by >20%) from baseline after 4 
weeks of treatment, outside respiratory 
infections 
Positive exercise challenge test Fall in FEV1 of >10% and >200 mL from 
baseline 
Positive bronchial challenge test Fall in FEV1 from baseline of ≥20% with 
standard doses of methacholine or 
histamine, or ≥15% with standardized 
hyperventilation, hypertonic saline or 
mannitol challenge 
Excessive variation in lung function 
between visits (less reliable) 
Variation in FEV1 of >12% and >200 mL 
between visits, outside of respiratory 
infections 
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1.2.5. Phenotypes 
The heterogeneous nature of asthma has lead to characterization of the 
disease by different phenotypes (10, 62, 63). The phenotypes are classified 
according to consistent groupings of demographic, clinical and 
pathophysiological features. However phenotypes are also evolving to include 
molecular and genetic features (62). Commonly recognized phenotypes 
include: early onset allergic asthma, non-allergic asthma, late-onset asthma, 
exercise induced asthma, asthma with fixed airflow obstruction and obesity 
related asthma (62). By phenotyping asthma, more targeted and personalized 
therapy can be used for specific phenotypic features. However ongoing work 
is needed to better identify and characterize asthma phenotypes.  
1.2.6. Management 
The goals of asthma management are to control symptoms and to reduce 
future risk of adverse outcomes (1). Pharmacological therapy will not be 
discussed in detail however includes inhaled short-acting beta-agonists, 
inhaled glucocorticosteroids with or without long-acting beta-agonists, 
leukotriene receptor antagonists and theophylline (1). Acute asthma 
exacerbations and/or difficult to control asthma may be treated with a short 
course of oral glucocorticosteroids (1, 64-67). Escalation in treatment is 
required for severe asthma and may include the addition of other therapies 
such as a long-acting muscarinic inhaler (68), biological agents (69-73) and 
bronchial thermoplasty (74-76). The patient population for whom these newer 
treatments are targeted needs ongoing research (74), as their role in asthma 
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treatment and which asthma patients will benefit the most is not yet well 
established.  
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1.3. Asthma In Older People 
Asthma in the older population is common (77-82) and the prevalence is 
increasing, which may in part be due to people living longer. The exact 
prevalence of asthma in older people is difficult to determine as it is often 
under or misdiagnosed (80, 83, 84). Asthma prevalence in people over the 
age of 65 years in European and US populations is reported to be between 
1.8–10.9% (85, 86). The highest rate of asthma has been reported in Australia 
(87), with the greatest burden in older individuals, where there is an increased 
prevalence of current asthma (>13% in women >75 years of age). 
Multiple factors contribute to the diagnostic challenge of asthma in older 
people, including variable clinical presentation, disease heterogeneity and 
poor perception of symptoms. Cigarette smoking or a history of passive 
exposure can be a confounding factor as smokers may not necessarily be 
excluded from studies in older asthmatics (88). Diagnostic tests such as 
spirometry are also problematic because older people often have difficulty 
performing lung function tests (89, 90). There are limitations in the reference 
values used for currently available physiological and biomarker tests, such as 
exhaled nitric oxide. Predictive equations may not incorporate age at the 
extreme upper end (i.e. > 80 years) and older non-white ethnicities (91). 
Furthermore there is no clear consensus on how to modify and incorporate 
older age into interpretation of these tests.  
Asthma in the older population is associated with poor quality of life and 
significantly higher medical care costs (85, 92, 93). Compared to younger 
people with asthma, there is also increased mortality and morbidity (92, 94-
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97). This can be a consequence of poor medication adherence due to 
difficulty administering inhaler medication (98, 99), contributed to by dexterity 
issues (100) and cognitive impairment (98, 101). Under-treatment as a result 
of misdiagnosis adds to poor quality of life and may impact morbidity and 
mortality in this older population (81, 102). The associated increase in 
mortality and morbidity and misdiagnosis in older asthmatics adds to the 
increased burden on society. 
Differences exist between asthma in younger and older people and can be 
attributed to various factors including the ageing process and effects of the 
disease itself (86, 94, 103). Structural changes (104-107), low grade 
inflammation (108) and immunosenesence occur as part of the ageing 
process. With increasing age, in both healthy people (32, 109) and in people 
with asthma (28, 109-111), there may be an associated increase in airway 
neutrophils. Eosinophil function may also be altered or reduced in older 
asthmatics (112).  
Other factors contributing to differences between young and old people with 
asthma (109, 113) include longer duration of disease (109, 114), under 
treatment (84-86, 115) and/or treatment unresponsiveness. Diminished airway 
beta-adrenoreceptor responsiveness occurs in older people with asthma 
suggesting dysfunctional airway beta-adrenoreceptors (116). Older 
asthmatics can have persistent lung function abnormalities despite treatment 
with inhaled and/or oral corticosteroids (3, 117) suggesting steroid insensitivity 
or unresponsiveness.  
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Studies on treatment of asthma in the older population are limited therefore 
treatment recommendations are based on evidence from younger asthmatics 
(1, 86, 94). A multidisciplinary management approach is recommended due to 
multiple clinical issues faced by older asthmatics (118). 
Although an asthma phenotype in the older population has not yet been well 
defined, older people with asthma can develop irreversible of FAO (5, 117). It 
is likely that the combined effects of asthma and the ageing process influence 
FAO development. Because the underlying mechanisms of asthma in older 
people and FAO are poorly understood, treatment remains a challenge. 
Potential mechanisms contributing to FAO in older people with asthma will be 
explored in this thesis. Before discussing the underlying pathophysiology in 
asthma, the structural changes that occur with normal ageing will be 
reviewed.   
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1.4. Normal Ageing of the Lung 
Lung function progressively declines with age, more so when associated with 
disease (119-121) and may be due to age-related structural changes to the 
respiratory system. These structural changes can be variable between and 
within subjects (86, 122) and can result in a decrease in chest wall 
compliance, reduction in respiratory muscle strength, loss of lung elastic recoil 
and airflow limitation (104). Adequate lung function and gas exchange can 
however be maintained by the ageing respiratory system, in the absence of 
disease (123). 
1.4.1. Chest wall 
The chest wall can change with age because the rib cage and its articulations 
(costal-cartilage and rib-vertebral) can undergo calcification with age. The 
intervertebral disc spaces can also narrow (104) resulting in a more rigid and 
stiff rib cage (104, 124). Kyphosis and an increase in the antero-posterior 
diameter can also change the shape of the chest wall (124, 125). A rounder 
thorax (‘barrel chest’) is formed and may be related to partial and/or complete 
vertebral fractures, as a result of age-related osteoporosis (126). Alterations 
to the chest wall consequently modify chest wall compliance, which decreases 
with age (127-130). Changes in the chest wall may also alter the shape of the 
underlying lung (131).  
1.4.2. Respiratory muscles 
The main muscle of respiration is the diaphragm and changes in its shape can 
impair the force it generates (132-134). The shape of the diaphragm can 
change as a consequence of age-associated changes to the rib cage (125), 
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reduction in chest wall compliance and increase in functional residual capacity 
(104, 128). Elderly people have significantly reduced diaphragmatic strength 
compared to younger people (132) and respiratory muscle strength may also 
be reduced due to deficient nutritional status (135), which is commonly seen 
in the elderly. Skeletal muscle undergoes age-related changes including a 
decrease in muscle mass, decrease in the number of muscle fibres as well as 
a loss of peripheral motor neurons (134, 136). This results in reduced skeletal 
muscle strength, which may also affect the respiratory muscles. Respiratory 
muscle function may be affected by other common co-morbidities in older 
people such as cerebrovascular disease and chronic heart failure (137).  
1.4.3. Airways 
Airways from older healthy lungs differ morphologically from those in young 
people (138). The airway walls in older lungs can be irregular and the airways 
may not taper off or may be blocked with square or rounded ends. These 
changes are thought to be due to mucus impaction or inflammatory changes 
in the airway wall. The airway changes seen in older lungs are also seen in 
people with obstructive airways disease but are more common and prominent 
in diseased lungs. Airway stiffness in older healthy lungs is increased 
compared to young healthy lungs, which suggests airway remodeling may 
also increase with age (138).  
1.4.4. Lung tissue 
The lung tissue is made up of a network of fibres including collagen, elastin 
and proteoglycans. The total lung content of collagen does not change with 
age (139), however collagen fibres become more stable and more resistant to 
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denaturation (140) due to increased numbers of inter-molecular links. 
Reported changes to elastin that occur with age are conflicting (139) as 
elastin content may increase (141). In contrast, elastic fibres in the respiratory 
bronchioles and alveoli can degenerate after the age of 50 years with the 
fibres appearing ruptured and coiled (105). These changes are prominent 
around the alveolar ducts therefore the alveolar ducts dilate, the alveoli 
enlarge and become wider and more shallow (104, 105). With age, the 
presence of pseudo-elastin can also cause changes to the spatial 
arrangement and cross-linking of the elastic fibres (142).  
The inter-alveolar wall distance increases with age (107, 143) and the 
surface-volume ratio decreases therefore surface area also decreases. This is 
thought to occur from the third decade of life onwards. Flattening of the 
internal surface of the alveoli may also occur and result in reduction in the 
alveolar surface (105). Airspace enlargement with age occurs in a relatively 
homogenous pattern, as opposed to being distributed heterogeneously as 
seen in emphysema due to smoking (105) (figure 1.1). Additionally, in contrast 
to smoking-related emphysema there is no alveolar destruction (105). Animal 
studies in senescence-accelerated mice have also shown similar changes of 
relatively homogeneous enlargement of alveolar duct size with age (144). 
Alveolar wall destruction was not demonstrated in these mice and cellular 
inflammation was not prominent, suggesting these changes were not due to 
inflammation, like that seen in emphysema (144). )
The ageing lung has been termed ‘senile emphysema’ (105, 145) because of 
the similarities in physiological functional changes with smoking-related 
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emphysema. Age-related changes to the lung tissue are thought to account 
for the reduction in lung elastic recoil pressure that occurs with age (22). 
Therefore structural airway and lung tissue changes that occur with ageing 
could accentuate functional abnormalities seen in older people with asthma. 
The next sections will review the structural and functional changes than can 
occur in asthma.  
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Figure 1.1 
From Verbeken et al (105). 
Example of normal lung (top panel) and ‘senile emphysema’ (bottom panel). 
The bottom panel demonstrates homogenous enlargement of the respiratory 
airspaces.  
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1.5. Asthma Pathophysiology: Structural Changes 
1.5.1. Airway remodeling 
The human airway is made up of different layers including the epithelium with 
an underlying sub-epithelial basement membrane, a sub-mucosal layer, 
mucous glands and extra-cellular matrix (ECM) comprised of fibroblasts 
embedded in connective tissue and airway smooth muscle (ASM). In asthma, 
the airways can undergo structural changes, termed airway remodelling (11-
13). Airway remodelling encompasses epithelial abnormalities (146-148), 
changes to the mucus-secreting structures (149-151) and ECM (152-155), 
increased ASM mass (156, 157) and increased vascularity (158) (figure 1.2). 
Airway remodelling can affect both the small and large airways (13, 36, 159, 
160) and the components of the airway wall that are affected varies 
depending on the size of the airway involved (36). Inflammatory changes 
occur in both the small and large airways either as a result of airway 
remodelling or a consequence. The inflammatory changes are either more 
significant or found predominantly in the small airways (11, 36, 37, 157, 159-
161). However studies also show there is also more inflammation in the larger 
airways (162). Nevertheless, airway remodelling causes airway wall 
thickening, which can occur in both the inner and outer airway wall (12, 13). 
These changes may be transient or permanent and subsequently result in 
airway lumen narrowing. Airway remodelling has been confirmed in multiple 
patho-histological studies (36, 149, 163) and radiologically (164, 165). 
) )
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Figure 1.2 
From Bai et al (13). 
A cartilaginous airway in a subject with fatal asthma showing structural airway 
remodelling changes.  
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A common finding in asthma is damage to airway epithelium (146-148), a 
change that is seen in mild (146) and newly diagnosed asthma, suggesting 
mucosal inflammation occurs early in the disease (166). Shedding of the 
epithelium can also occur at a higher rate in people with asthma compared to 
healthy people (167-169). 
Changes to the mucus-secreting structures include mucus gland hypertrophy 
(150, 151) and goblet cell hyperplasia resulting in mucus hyper-secretion 
(149, 170, 171). Gene expression profiles may contribute to increased mucus 
production in asthma. MUC5AC, a mucus expression gene is increased in 
people with asthma compared to healthy controls (171). Elevated production 
of CCL20 by ASM cells, possibly due to dysregulated expression of the anti-
inflammatory miR-146a-5p is also associated with increased levels of chronic 
mucus hyper-secretion in asthma (172).  
The ECM is made up of a network of inextensible fibres (collagen), elastic 
fibres (elastin) and other proteoglycans. Sub-epithelial fibrosis (155), sub-
epithelial thickening, increased numbers of activated fibroblasts and 
myofibroblasts (154) and increased collagen constitute some of the ECM 
changes in asthmatic airways (152, 153, 173). Sub-epithelial fibrosis may 
include increased levels of collagens 1, 3 and 5 in the sub-epithelial layer and 
sub-mucosal layer (13, 155, 174). These changes can contribute to increased 
ECM deposition and therefore airway remodelling.  
Elastic fibre structure and content differs between asthma and healthy 
controls (175, 176) and can vary between small and large airways (176). 
Elastic fibre changes in asthmatic airways include fragmentation; altered 
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structure (175, 176) or the elastic fibres may disappear altogether (175). In 
contrast to collagen, elastic fibres may be reduced in the immediate sub-
epithelial layer (17, 176) and increased in the sub-mucosal layer (176, 177). 
Conflicting data suggests elastic fibre content or the proportion of elastic 
fibres is no different between airways from asthmatics and healthy controls, 
(178). The proportion of elastic fibres is also no different between mild and 
moderate-severe asthma, even after inhaled and oral glucocorticosteroid 
treatment (178). 
Increased smooth muscle mass occurs as a result of ASM cell hyperplasia 
and/or hypertrophy (12, 157, 179). Variable ASM changes such as 
hyperplasia (180) occur predominantly in the central airways (157). In 
contrast, there may be no ASM hyperplasia but ASM hypertrophy in both the 
small and large airways, with little involvement of the central airways (13). 
Nevertheless, changes in the ASM can cause airway wall thickening and 
luminal narrowing, which can be further exacerbated by ASM contraction (37). 
ASM cell changes cause an increase in ASM thickness, which is associated 
with increased maximal airway narrowing when measured in vitro in bronchial 
segments (181).  
Vascular changes in asthma include angiogenesis and an increase in vessel 
size and number (12, 182). However findings are inconsistent because 
histological studies have evaluated bronchial circulation in the large airways 
and pulmonary circulation in the peripheral airways (12, 13, 182). Vascular 
changes may be due to an imbalance between primary angiogenic growth 
factors such as vascular endothelial growth factor (VEGF) and angiopoietin-1 
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(183). VEGF can increase abnormal blood vessel permeability (184), which 
leads to vessel dilation and oedema, further contributing to airway wall 
thickening. Recent quantitative CT analyses has suggested pulmonary 
vascular pruning or loss of peripheral pulmonary vasculature occurs in asthma 
(185), a phenomenon usually associated with chronic obstructive pulmonary 
disease (COPD). More vascular pruning was also found to be associated with 
asthma severity, control and an increased risk of asthma exacerbations (185). 
In contrast, another study in fatal asthma showed that pulmonary arteries 
adjacent to the peripheral airways showed no structural differences compared 
to healthy controls. However there was more eosinophilic inflammation in the 
pulmonary artery adventitial layer in fatal asthma, suggesting asthma may 
also be a disease of the pulmonary vasculature and not just the airways (161).  
1.5.2. Lung tissue changes 
The lung tissue is made up of an enormous number thin-walled alveoli lined 
by epithelium, alveolar septa comprised of interstitial cells and ECM (collagen, 
elastin, proteoglycans) and a thin liquid film cover, pulmonary surfactant 
(186). Changes in the lung tissue such as emphysema (187) are typically 
associated with smoking and COPD, however can also occur in asthma (16, 
18). The evidence in asthma is limited though substantiated in post-mortem 
studies with small numbers. Importantly, the lungs examined in these studies 
were from non-smoking adults (16-18).  
Emphysematous changes in non-smokers with asthma have been 
demonstrated in post-mortem lungs from older people (>40 years old) (16, 
18). The emphysematous changes were trivial on macroscopic examination 
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and when lungs were assessed using high-resolution computer tomography 
imaging (16, 18). However on histological examination, there was destruction 
of the acinar airspace walls (16, 18), consistent with emphysema (figure 1.3). 
Microscopically, mild diffuse centri-lobular emphysema was observed 
predominantly in both upper lobes and the middle lobe. Within these same 
lungs areas of normal tissue was also demonstrated, suggesting a 
heterogeneous distribution of lung tissue changes. Intra-alveolar chord 
diameter (Lm) was within normal limits (<300 mm) in areas of normal lung 
tissue and increased in emphysematous regions (16, 18). In addition, areas of 
‘senile lung’ such as alveolar duct ectasia, near homogenous alveolar 
hyperinflation and absence of tissue breakdown were also shown, consistent 
with age-related changes (145). Typical changes of airway remodelling were 
also seen in these post-mortem lungs, in keeping with the diagnosis of 
asthma (16, 18). Together these findings would support the distribution of 
tissue changes being heterogeneous, similar to what is thought to occur in the 
airways (i.e. heterogeneous airway remodelling) (36). 
) )
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Figure 1.3 
From Gelb et al (16).  
Microscopic section from the right upper lobe of a 72 year-old non-smoking 
female with life long asthma. This demonstrates mild centri-lobular 
emphysema with irregularly enlarged air spaces and fractured alveolar septa 
(arrows). TB: terminal bronchioles, BV: blood vessel. 
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Other structural changes observed in the lung tissue in asthma include an 
increase in ECM fibres (188). This may involve an increase in the amount of 
myofibroblasts (188, 189), a type of fibroblast thought to be involved in tissue 
repair (190). A marker of myofibroblasts, alpha-smooth muscle actin (α-SMA), 
is increased in lung tissue cells, alveolar walls and alveolar ducts in 
asthmatics (both fatal and non-fatal) compared to healthy controls (189). The 
increase in α-SMA cells is thought to either be due to an adaptive response to 
biomechanical airway abnormalities or due to genetic expression (189). 
Alveolar interstitial myofibroblasts are also increased in uncontrolled 
asthmatics compared to both well-controlled asthmatics and non-asthmatics 
(188).  
The lung tissue is connected to the outer wall of the small airways via alveolar 
attachments. Disruption or abnormalities of alveolar attachments have been 
demonstrated on histological examination of post-mortem lung from non-
smoking adults with fatal asthma (17) (figure 1.4). Compared to healthy 
controls without a diagnosis of lung disease, the number and proportion of 
abnormal alveolar attachments in asthmatic lungs were increased (17). 
Interestingly, emphysema was not demonstrated in these asthmatic lungs 
however adequate pathological assessment of lung specimens may have 
been limited by experimental techniques (17).  
) )
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Figure 1.4 
From Mauad et al (17). 
A and C: Small airway of a control subject. Alveolar septa attach directly to 
the outer layer of the airway (small arrows). Stained with haematoxylin and 
eosin. 
B and D: Small airway of a subject with fatal asthma. Mucus plugging, goblet 
cell metaplasia, thickened airway smooth muscle layer (ASM) and peri-
bronchial inflammation are demonstrated. The arrowheads indicate abnormal 
or ruptured alveolar attachments. Stained with haematoxylin and eosin. 
E: Elastic fibre staining in the outer wall (blue line) and peri-bronchial septa 
(asterisk) of a control subject. 
F: Elastic fibre staining in the outer wall (blue line) and peri-bronchial septa 
(asterisk) of a patient with fatal asthma. Elastic fibre content is decreased 
compared with (E). Weigert staining. 
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Figure 1. (A and C ) Small airway of a con-
trol subject. Alveolar septa attach directly
to the outer layer of the airway (arrows).
Stained with hematoxylin and eosin. (B
and D ) Small airway of a subject with fatal
asthma. Mucus plugging (m), goblet cell
metaplasia (gcm), thickened airway smooth
muscle layer (asm), and peribronchial in-
flammation are evident. The arrowheads
indicate abnormal or ruptured alveolar at-
tachments. Stained with hematoxylin and
eosin. (E) Elastic fiber staining in the outer
wall (blue line) andperibronchial septa (aster-
isk) of a control subject. Weigert staining.
(F ) Elastic fiber staining in the outer wall
(blue line) and peribronchial septa (aster-
isk) of a patient with fatal asthma. Elastic
fiber content is decreased compared with
(E ). Weigert staining. Scale bars: (A and
B ) 100 !m; (C–F ) 50 !m.
with chronic persistent asthma (27), such as mechanical stress
relaxation due to recurrent bronchoconstriction and hyperinfla-
tion, stretching of the connective tissue, and altered lung growth
(28).
Indeed, we cannot totally exclude that part of the elastic fiber
alterations observed in this study could reflect abnormal lung
growth due to chronic lung changes in asthma. It has been pre-
TABLE 3. NUMBER OF NORMAL AND ABNORMAL ALVEOLAR ATTACHMENTS, AND PROPORTION
OF ABNORMAL TO NORMAL ATTACHMENTS CORRECTED BY AIRWAY BASEMENT
MEMBRANE PERIMETER, IN FATAL ASTHMA AND CONTROL LUNGS
Abnormal AA:Normal AA/cm
Patients Normal AA Abnormal AA BM Perimeter
FA (n " 15) 12.90 (8.66–18.00) 2.57 (0.33–5.67) 0.18 (0.03–4.00)
CTRL (n " 9) 16.95 (12.50–23.33) 0.00 (0.00–2.33) 0.00 (0.00–0.12)
p Value 0.01 # 0.001 # 0.001
Definition of abbreviations: AA " alveolar attachment; BM " basement membrane; CTRL " control; FA " fatal asthma.
Values are expressed as geometric means and ranges.
viously demonstrated that adults with childhood-onset asthma
present larger lung volumes than patients with adult-onset asthma
and control patients (29, 30).
One could allege that our findings represent acute rupture due
to the final severe attack, what may be partially true. However,
considering that patients with severe asthma are prone to several
acute attacks during their lifetime, and that mechanical stretching
mucus%plugging%
A% B%
C% D%
E% F%
goblet%cell%m tapl sia%
thickened%ASM%
*%
*%
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ECM and elastic fibre content in the outer airway walls is also altered in 
asthma (17) and may therefore contribute to abnormal alveolar attachments. 
Outer airway wall ECM components such as collagen 1 and fibronectin are 
increased in asthma (191). Whereas elastic fibre content in the outer walls of 
the small airways and in the peri-bronchiolar septa (i.e. site of alveolar 
attachments) is decreased in asthma compared to healthy controls (17). 
Elastic fibre content in the peri-bronchial septa is correlated with the number 
of normal alveolar attachments in both asthma and healthy controls, 
suggesting elastic fibres may contribute to alveolar detachment. In contrast, in 
distal alveoli elastic fibre content was no different between fatal asthmatics 
and healthy controls (17). Similarly, no difference in the relative proportions of 
elastic fibre in lung tissue and alveolar/bronchial attachments zones were 
seen in lungs from fatal asthmatics when compared to non-asthmatic sudden 
death controls (178).  
The airways and lung tissue are a complicated structure and structural 
changes that occur in asthma are heterogeneous, in keeping with the nature 
of the disease. Changes in the distal lung, including the outer airway 
wall/adventitia, distal airways and alveoli likely contribute to alteration in 
airway-lung inter-dependence and airway mechanics. There are many 
intertwined and complex pathophysiological mechanisms that contribute to 
asthma however are poorly understood. Proposed mechanisms and the 
subsequent functional abnormalities will be discussed in the next sections.  
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1.6. Asthma Pathophysiology: Inflammation 
Inflammation is thought to be the main driving factor of airway remodelling 
and lung tissue changes in asthma. However, it is not clear whether 
inflammation is causative or complimentary to these changes and whether the 
same inflammatory processes occur in both the airways and lung tissue. 
Nonetheless, complex interactions between inflammatory cells from both the 
innate and adaptive immune system, genetic and environmental factors 
contribute to asthma pathogenesis (192-194). 
Inflammation involves expression and release of many cells and complex 
signalling pathways that are mediated by different inflammatory proteins such 
as cytokines, chemokines, growth factors, inflammatory enzymes and 
receptors (24). The inflammatory process may start with airway epithelial 
injury resulting in a defective bronchial-epithelial barrier therefore allowing 
microorganisms, environmental allergens and toxins to enter and initiate an 
inflammatory cascade (12, 195, 196). Damage to the epithelium itself from 
environmental or mechanical stress can also stimulate the release of 
inflammatory mediators, which further drives the inflammatory process (12, 
148). Epithelial damage and the inflammatory cascade may be associated 
with an impaired repair process, disruption of normal cell development (148) 
and increased proliferation of both normal and abnormal ECM proteins such 
as fibroblasts and myofibroblasts (148, 154).  
Inflammation in the airways may also activate a pro-inflammatory process that 
can cause changes in the lung tissue. A proteolytic cascade has been 
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proposed as an underlying mechanism leading to subsequent lung tissue 
destruction (16, 18, 197, 198). 
1.6.1. Measurement of airway and lung tissue inflammation 
Various techniques have been used to measure airway inflammation using 
sputum (199-201) and/or bronchoalveolar lavage (BAL) and endobronchial 
biopsies obtained during bronchoscopy (202-206). Lung tissue samples can 
also be obtained by transbronchial biopsy however this can be challenging 
because of the invasive nature of the technique (207-209). Therefore lung 
tissue from asthmatic lungs is often obtained post-mortem (16, 18, 160, 191, 
210). Less invasive measures have been used as a surrogate marker 
inflammation, such as exhaled nitric oxide and peripheral blood eosinophils, 
as a measure of eosinophilic inflammation (211).  
Airway inflammation in asthma is heterogeneous, with granulocytes such as 
eosinophils and neutrophils, contributing to the inflammatory process. The 
amount and type of granulocytic cells in sputum has been used to identify four 
distinct inflammatory asthma phenotypes (201). These phenotypes have been 
classified according to the predominant inflammatory cell type present, 
namely eosinophilic, neutrophilic, mixed granulocytic and paucigranulocytic 
asthma (201, 212) (table 2). Although there is no standardized definition, a 
≥2-3% cut off for eosinophils and ≥61% or 65.3% for neutrophils in sputum is 
often used to define sputum eosinophilia and neutrophilia, respectively (62, 
212-214). The cut off points used to determine the amount of inflammatory 
cells present can vary between studies depending on the type of sample used 
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(i.e. sputum versus BAL and biopsy) (215). References ranges also need 
adjustment with age as neutrophils can increase with age (216).  
)
)
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Table 1.2 Inflammatory phenotypes in asthma. 
 
 
 
 
Adapted from Gibson et al (212). 
Four distinct inflammatory phenotypes can be identified based on the amount 
of eosinophils and/or neutrophils present.  
  
Inflammatory phenotype Induced sputum cut-points 
Neutrophilic asthma Neutrophils >61% 
Eosinophilic asthma Eosinophils >3% 
Mixed granulocytic asthma Eosinophils >3% 
Neutrophils >61% 
Paucigranulocytic asthma Eosinophils <3% 
Neutrophils <61% 
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Asthma is typically associated with eosinophilic and TH2 driven inflammatory 
pathways (23, 194, 217). However non-eosinophilic and neutrophilic 
inflammation can occur and may be driven by TH1 and TH17 inflammatory 
pathways (218-220). These pathways consist of distinct immune responses, 
which are regulated by sub-populations of CD4+ T cells known as T helper 2 
(TH2), T helper 1 (TH1) and T helper 17 cells (TH17), respectively (24) (figures 
1.5 and 1.6). 
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 Figure 1.5 
From Papi et al (221). 
Mechanisms and characteristic pathological features of asthma 
immunopathology. 
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Figure 1.6!
From Lambrecht et al (193). 
Relative roles of T-helper 2 (TH2) and innate lymphoid cells (ILC) in two forms 
of eosinophilic asthma.  
) )
 35 
1.6.2.)Airway inflammation  
1.6.2.1. TH2 airway inflammation 
TH2 cells are responsible for driving the inflammatory process in allergic 
eosinophilic asthma (193). Specialized antigen-presenting cells are activated 
by inhalation of aeroallergens, which then differentiate naïve T-lymphocytes 
into TH2 cells. Upstream regulation of TH2 cell differentiation involves a 
cascade of events in the airway epithelium regulated by interleukin-33 (IL-33), 
IL-25 and thymic stromal lymphopoietin (TSLP). Downstream, TH2 cells 
release cytokines such as IL-4, IL-5, IL-9 and IL-13. Release of these 
cytokines leads to activation of airway epithelial cells, chemo-attraction of 
effector cells (mast cells, eosinophils and basophils), IgE switching in B-cells, 
airway eosinophilia, mucous hyper-secretion (192) and subsequent airway 
remodeling. 
Non-allergic eosinophilic inflammation can occur and involves activation of 
TH2 innate lymphoid cells (ILC2). ILC2s are activated by prostaglandin D2 and 
epithelium-derived cytokines IL-33, IL-25 and TSLP, which are released when 
epithelium is damaged by air pollutants, microbes and glycolipids (192, 193, 
222). Activated ILC2s also produce IL-5 and IL-13, which results in 
eosinophilia, mucous hyper-secretion and airway hyper-responsiveness (192, 
193) (figure 1.6).  
TH2 and eosinophilic inflammation has long been strongly associated with 
atopy and allergy, type I hypersensitivity reactions and a good response to 
steroids (62). This type of inflammation is more common in mild-to-moderate 
asthma and seen in the majority of people with asthma (10, 223). TH2 
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associated asthma can be further classified into phenotypes based on the age 
of asthma onset (62). Although a specific age-cut off has not been defined, 
early-onset and later-onset asthma are recognized eosinophilic phenotypes, 
with the former usually occurring pre-adolescence and the latter after 20 years 
old. Early-onset TH2 asthma is characterized by allergic symptoms and atopic 
disease. Disease severity can range from mild to severe and may be 
associated, but not always, with TH2 proposed biomarkers such as IgE, high 
FeN0, sputum eosinophilia and increased airway periostin (62, 214, 224). It is 
often responsive to corticosteroid and TH2-targeted therapy (225-228). Later-
onset eosinophilic asthma is characterized by increased eosinophils numbers 
compared to normal, in either sputum, bronchoscopic or blood samples (>2% 
often used in sputum samples). In contrast to early-onset allergic asthma, the 
disease is often severe and associated with sinusitis, nasal polyps or aspirin-
exacerbated respiratory disease but not allergic symptoms. Persistent 
eosinophilia occurs despite corticosteroid therapy (10, 223, 229). The TH2 
process in later-onset asthma probably differs and is more complex than 
early-onset asthma because of the lack of allergic features (62). Despite the 
lack of association with allergic features, treatment targeted at a TH2 related 
cytokine pathway (IL-5) in late-onset persistent eosinophilic asthma can 
reduce blood and lung eosinophils, systemic steroid requirements and the 
number of exacerbations (230).  
1.6.2.2. TH1 and TH17 airway inflammation 
Non-eosinophilic inflammation can occur in asthma without the presence of 
TH2 cytokines (213, 231). Neutrophilic inflammation may dominate this 
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process and involves the release of ILC3 and cytokines such as IL-17 by TH1 
and TH17 cells (218) or type 3 ILCs. This process also activates macrophages 
with subsequent release of neutrophil chemokines such as CXC motif 
chemokine ligand (CXCL-8) and further neutrophil recruitment (193) (figure 
1.5). These mechanisms are poorly understood however the presence of 
neutrophils is thought to reflect bacterial colonization (232). Furthermore, 
treatment with corticosteroids inhibits neutrophil cell apoptosis (233-235) 
therefore promoting neutrophil survival and may contribute to neutrophil 
activation. Corticosteroids can also suppress TH2 immunity, which may result 
in up-regulation of TH1 and/or TH17 immune responses (236).  
A neutrophilic asthma phenotype has been associated with adult-onset and 
severe asthma (10, 206, 237, 238). However there is no clear consensus 
regarding what level of neutrophilic inflammation defines this phenotype. 
Neutrophilic inflammation is often seen in asthmatics treated with 
corticosteroids (239) and as discussed above, could suggest either 
corticosteroid unresponsiveness or that corticosteroids may play a role in the 
development of neutrophilia. Increased airway neutrophils are associated with 
lower lung function, thicker airway walls as measured by computed 
tomography (CT) scan and increased matrix metalloproteinase (MMP) 
expression but not with AHR (30, 33, 232, 240, 241). The presence of airway 
neutrophilia in asthma is controversial, as studies have included smokers or 
ex-smokers and when smoking status and corticosteroid use are controlled 
for, this phenotype of neutrophilic asthma does not exist (242, 243). 
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Additionally, older age may be a confounding factor because of the 
association with age and airway neutrophilia (28-30, 216).  
The role of TH17 inflammation in asthma is not completely understood 
however is associated with neutrophilic inflammation (244) and has been 
implicated in severe asthma. TH17 cells are a subset of CD4+ T cells that 
release IL-17, which act on epithelial cells to release CXCL-1 and CXCL-8, 
which are chemokines that attract neutrophils. IL-6 is also released and 
enhances TH17 cell activation.  IL-17 cytokines are thought to be pro-
inflammatory and have been associated with an increase in proteolytic 
enzymes (neutrophil elastase and MMP-9) in animal studies (245, 246), which 
could potentially contribute to lung tissue breakdown.  
1.6.3. Lung tissue inflammation  
Inflammation and changes to the lung tissue is not commonly associated with 
asthma because it is typically thought of as a disease affecting the airways. 
Contribution of lung tissue to asthma pathogenesis is not well recognized 
because evidence is limited and based on a small number of post-mortem 
and bronchoscopy studies (160, 208, 209, 247, 248). Inflammation and 
breakdown of lung tissue in asthma may occur as a result of inflammation 
extending from the outer or adventitial layer of the small airways to the 
surrounding alveolar walls. This is based on inflammation occurring 
predominantly in the adventitial layer in the small but not large asthmatic 
airways (160, 247, 248).  
Inflammatory process occurring in the lung or alveolar tissue has also been 
demonstrated in living stable asthmatics (208). The predominant inflammatory 
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cells were eosinophils and macrophages and were greater in number in the 
alveolar tissue compared to airway tissue (208). Inflammation is also 
accentuated during the night in nocturnal asthmatics, suggesting circadian 
variation may contribute to lung tissue inflammation (208). Nocturnal decline 
in lung function is associated with eosinophils in the alveolar but not proximal 
airway tissue (208). Additionally, in nocturnal asthmatics a greater number of 
CD4+ lymphocytes were found in alveolar tissue during the night, compared 
to non-nocturnal asthmatics (209). Alveolar tissue but not airway CD4+ cells, 
which are cells that can drive eosinophil recruitment, also correlate with 
nocturnal worsening of lung function (209). 
1.6.3.1.  Lung tissue breakdown and proteolytic cascade 
It has been proposed that bronchiolar inflammation results from recurrent 
asthma attacks, which in turn activates a pro-inflammatory proteolytic pathway 
that can cause tissue breakdown (16, 18, 197, 198, 249). This pathway is 
mediated by an autocrine epidermal growth factor (EGFR) signalling cascade, 
also initiated by inhalation of aeroallergens or noxious stimuli (249). Protective 
mucociliary responses occur in the epithelium via IL-17 and IL-18, which 
activates IL-8 to induce mucin production and promote neutrophil recruitment 
(198, 249). Mucin production can also be induced by proteases including 
neutrophil elastase and cathepsin G and by eosinophils, macrophages and 
mast cells via activation of the EGFR ligand-initiated signally cascade (249). 
These proteases together with activated MMPs are part of the proteolytic 
cascade, which could potentially cleave and disrupt terminal bronchiole-lung 
tissue attachments (249). Consequently lung tissue breakdown may lead to 
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mild emphysema (18, 198), similar to the terminal bronchiole-lung tissue 
uncoupling seen in smokers with emphysema (250). A pro-inflammatory 
proteolytic cascade can explain lung tissue breakdown in both these 
situations.  
Indirect evidence of MMPs contributing to this proposed mechanism of lung 
tissue breakdown in asthma has been demonstrated in autopsy studies (191). 
Increased content of MMP-1, MMP-2 and MMP-9 was found in the outer area 
of the small airways (i.e. areas of the airway wall in close proximity to alveolar 
tissue) in those who died from asthma compared to non-asthmatics who died 
from other causes (191). Composition of ECM proteins in the outer airway wall 
was also altered in the asthmatic patients; fibronectin was increased and 
collagen III was reduced (191). Additionally, in the peri-bronchiolar lung tissue 
of the asthmatic patients MMP-9 and collagen I content was increased (191) 
(figures 1.7 and 1.8). The presence of proteolytic proteases (MMPs) and 
changes to the outer airway wall in fatal asthmatics could therefore alter the 
mechanical properties between the airways and lung tissue.  
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Figure 1.7 
From Dolhnikoff et al (191). 
The distal lung is a major site of extracellular matrix (ECM) remodelling in fatal 
asthma, with an imbalance of collagens I and III and increased fibronectin and 
matrix metalloproteinase (MMP) content. This diagram summarises the 
differences in ECM composition in the small airways between healthy controls 
and patients with fatal asthma. !: Significantly lower compared with that seen 
in healthy controls. ": Significantly higher compared with that seen in healthy 
controls.  
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Figure 1.8 
From Dolhnikoff et al (191). 
Fibronectin and matrix metalloproteinase-9 (MMP-9) content (in square 
micrometers per micrometer) in the small airways and peri-bronchiolar lung 
tissue in asthmatic patients and control subjects. IS: inner area of the small 
airways, OS: outer area of the small airways, PP: peri-bronchiolar 
parenchyma or lung tissue. The median is represented as horizontal bars. 
Fibronectin: *P < 0.02 compared with control subjects. MMP-9: *P < 0.05 
compared with control subjects.  
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There is also contradictory evidence showing MMP-9 is reduced in both 
airway and lung tissue in asthma compared to healthy controls (188). 
Although within the asthma group, those with uncontrolled asthma showed 
increased MMP-9 content compared to the controlled asthmatics (188). 
Additionally, the amount of tissue-inhibitor of MMP-3 was increased in the 
asthmatics compared to healthy controls in both airway and lung tissue (188). 
Inflammation in asthma is now recognized as being more diverse, with 
eosinophilic and neutrophilic inflammation often co-existing. The type of 
inflammation present relates to various clinical features of asthma (62) and 
importantly, the lack of eosinophilia and response to corticosteroids does not 
rule out asthma. It is likely that more than one inflammatory cell and pathway 
are involved in the various asthma phenotypes and contribute to inflammation 
and alteration to the inflammatory profile over time (222). Inflammation of the 
lung tissue should not be ignored because it is likely to play a role in airway-
lung tissue uncoupling and therefore alter the mechanical function and inter-
dependence (160, 191, 247, 248). The functional consequences of airway and 
lung tissue changes in asthma will be discussed in the next section.  
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1.7. Asthma Pathophysiology: Functional changes 
Airway remodeling and lung tissue changes in asthma can result in airway 
narrowing and subsequent variable airflow obstruction (1). Other functional 
changes that can occur in asthma include AHR, gas trapping and 
hyperinflation; increased airway resistance and ventilation heterogeneity and 
altered airway and lung mechanics. These changes can manifest clinically 
with wheeze, cough, dyspnea and chest tightness.  
1.7.1. Airflow obstruction, AHR and hyperinflation 
Airflow obstruction is commonly measured and quantified using spirometry 
(251). Spirometry requires a forced exhalation manoeuver to derive the 
indices Forced Expiratory Volume in 1 second (FEV1) and Forced Vital 
Capacity (FVC). A reduced spirometric ratio (FEV1/FVC) and/or bronchodilator 
reversibility is indicative of airflow obstruction (1, 251). FEV1 declines with age 
(119, 120, 145, 252, 253) and is probably attributed to age-related structural 
airway and tissue changes (105). The degree of airflow obstruction is an 
important marker of disease severity and useful for prognosis (254-257). 
Longitudinal studies have demonstrated a more rapid decline in lung function 
in people with asthma (257), more so if there is a history of smoking (119, 
120, 252). Mucous hyper-secretion in asthma is also associated with a faster 
decline in FEV1, regardless of the smoking history (252, 258).  
Airway hyper-responsiveness (AHR), a typical hallmark of asthma (39), is an 
exaggerated narrowing of the airway in response to a provoking stimulus 
(259) and can be measured using a bronchial provocation challenge test 
(260). AHR is associated with various clinical features of asthma including 
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disease severity (261, 262), an increased rate of FEV1 decline (263) and fixed 
airflow obstruction development (2). AHR may increase the risk of severe 
asthma exacerbations (264) and may be reduced or even abolished with 
asthma treatment (265, 266).  
Changes in lung volumes such as hyperinflation and gas trapping also occur 
in asthma (267, 268). Hyperinflation can be measured using body 
plethysmography and demonstrated by an increase in functional residual 
capacity (FRC). Increased FRC may occur during an exacerbation and be 
transient or can persist despite treatment improving airflow obstruction (20, 
268-275). The degree of hyperinflation during acute asthma exacerbations 
may correlate with the severity of airflow obstruction (267, 268, 276) and FRC 
may increase to volumes as high as the baseline total lung capacity (TLC) 
(267, 268). Gas trapping can be determined by an increase in residual volume 
(RV) or RV/TLC (277, 278). Airway closure and prolonged expiratory time 
constants are thought to contribute to hyperinflation and gas trapping (276). 
Persistent inspiratory muscle contraction during expiration in the presence of 
bronchospasm (276, 279) and loss of lung elastic recoil are also thought to 
play a role (269, 274, 280, 281).  
1.7.2. Small airways 
The respiratory or traceho-bronchial tree is made up of dichotomously 
branching airway structures divided into approximately 23 airway generations 
(282, 283) (figure 1.9). The proximal airways, made up of the first 15 
generations, constitute the anatomical dead space and are referred to as the 
conducting zone or airways (282). From generation 16 onwards are the 
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respiratory bronchioles, alveolar ducts and sacs. These are referred to as the 
transitional and respiratory zones and make up the acinar airways where gas 
exchange occurs (282). As the airway generation advances, the number of 
airways increases exponentially, however both the airway length and diameter 
get smaller (282). The velocity of air flow and gas transit within the lung also 
changes and transitions from bulk convective flow in the conducting airways 
to diffusion down a concentration gradient in the acinar airways (282). With 
successive airway generations the total airway cross-sectional surface area 
increases dramatically and as a result resistance to airflow decreases (282).  
) )
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Figure 1.9 
From Weibel et al (283). 
Tracheo-bronchial tree made up of 23 airway generations. 
)
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Also known as the distal or peripheral airways, the small airways are the main 
site of airflow obstruction in asthma (14, 15, 284, 285). The small airways 
correspond to airway generations 8-23, are less than 2 mm in diameter and 
do not contain cartilage in their walls (283). In healthy lungs, resistance to 
airflow in the small airways is low because they make up a large cross-
sectional surface area however only contribute to 10-20% of total airway 
resistance (285). Therefore the small airways have been coined with the term 
‘silent zone’ (284) because airflow obstruction or small airway dysfunction is 
not easily identified until disease has affected a significant portion of the small 
airways. )
Conventional lung function tests such as spirometry may miss early or mild 
disease in the small airways, thus more sensitive methods to detect 
abnormalities early are required. Currently available tests that may be more 
sensitive than spirometry (286-291) include the multiple breath nitrogen 
washout test (292) and forced oscillation technique (293). Both tests are 
performed at tidal breathing and do not require a forced expiratory 
manouevre. Therefore these tests may be more attractive than spirometry, as 
they are unlikely to alter smooth muscle tone because a forced expiratory 
manouevre is not used (294). These tests will be discussed in more detail 
later in this section.  
1.7.3. Small airway dysfunction 
Small airway dysfunction has been measured using indices derived from the 
FVC manoeuvre such as the forced expiratory flow at 25-75% of FVC (FEF25-
75%) (295). However, the FEF25-75% may not be clinically useful (296) and its 
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reproducibility and sensitivity has been challenged (297, 298). A reduced 
FEF25-75% measurement, in the presence of normal spirometry, is thought to 
reflect ‘noise’ or be due to reduced lung volume rather than airways disease 
(296). There is also a poor correlation between FEF25-75% and other markers of 
small airway dysfunction such as gas trapping (7). 
Small airway dysfunction can also be characterized by the amount of 
ventilation heterogeneity (VH) in the lungs (292), in other words assessing the 
unevenness or efficiency of gas mixing within the lungs (299, 300). A degree 
of uneven gas mixing exists in healthy lungs because of airway structure 
asymmetry, anatomical inter-lobar differences and gravitational effects 
between the lung apex and base (282, 283). Differences in the lungs resistive 
and elastic properties also contribute to sequential filling and emptying of the 
lung (301, 302). This results in variation in time constants for gas emptying, 
where better-ventilated lung units have a preference to empty faster than less 
well-ventilated lung units (302). Hence alterations to the lungs mechanical 
properties (i.e. the resistive and elastic properties) that occur in disease such 
as asthma can also increase VH because small airway obstruction can 
increase airflow resistance. 
1.7.4. Ventilation Heterogeneity 
1.7.4.1.Multiple Breath Nitrogen Washout 
VH can be measured using the multiple breath nitrogen washout (MBNW) 
(292) test, a non-invasive lung function technique that was first described in 
1950 (299). The MBNW test provides information about the degree of VH or 
efficiency of gas mixing within the lungs, possible mechanisms behind 
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abnormal ventilation distribution and the location of underlying pathological 
processes (292). The test involves measurement of the expired concentration 
of an inert tracer gas (i.e. nitrogen, N2) at the mouth, which is washed out by 
inhalation of 100% oxygen (02) over a series of tidal breaths. If VH is 
increased (i.e. abnormal) there is a delay in clearance of the tracer gas 
therefore more breaths will be required to ‘washout’ the N2. The MBNW test 
can also assess lung volume (FRC), gas trapping and measures of 
anatomical and respiratory dead space (303).  
1.7.4.1.1. MBNW Indices 
The anatomical and physiological basis of the MBNW test is centered on the 
principles of gas transport and mixing (304). Compartmentalization of VH 
distribution (292, 305-307) allows indices to be derived, which reflect VH or 
specific ventilation (ventilation per unit lung volume) within either the 
conducting or acinar airways (308). Uneven ventilation or differences in 
specific ventilation in lung units larger than the acini (i.e. the more proximal 
airways), where gas transport occurs by convection, is termed convection-
dependent inhomogeneity (CDI) (308). In the more distal airways where gas 
transport occurs by diffusion, uneven ventilation in this lung region is termed 
diffusion-convection-dependent inhomogeneity (DCDI) (308). Relative 
contributions to gas mixing from interactions between the convection- and 
diffusion-dependent airways occurs in an intermediate zone and form what is 
called the ‘diffusion-convection front’ (304). This quasi-stationary diffusion-
convection front determines where CDI and DCDI mechanisms operate and is 
thought to arise around the acinar entrance in healthy adult lungs (309). 
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VH arising from CDI and DCDI mechanisms are expressed as the clinical 
indices Scond and Sacin (306). These indices have been derived from 
theoretical (310), experimental (311) and lung modeling (305, 312, 313) 
analyses of MBNW normalized phase III slopes, which are described in more 
detail below and in chapter 2. Although the exact anatomical location of these 
indices are not known, Scond is thought to be affected by the mechanical 
properties of the lung units that are larger than the acini (i.e. in the conducting 
airways). Sacin on the other hand is thought to arise due to heterogeneity of 
the cross-sectional areas of airway openings in the terminal airways and the 
acini (313) (figure 1.10). A global measure of VH can also be derived from the 
MBNW test, lung clearance index (LCI), which describes the lungs overall gas 
mixing efficiency. An increase in Scond, Sacin or LCI indicates increased VH 
in the conductive-dependent airways, diffusion-dependent airways or poor 
overall gas mixing efficiency, respectively.  
)
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Figure 1.10 
From Verbanck et al (313). 
Schematic representation of predicted changes of normalized phase III slopes 
versus lung turnover or breath number and corresponding changes in MBNW 
indices Scond and Sacin, following structural alterations in the proximal or the 
lung periphery. 
)
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1.7.4.1.2.Expirogram and phase III slopes 
The MBNW expirogram or washout curve is obtained by measuring N2 
concentration at the mouth over consecutive breaths after 100% 02 is inhaled. 
The washout curve exhibits 4 distinct phases with the shape of the curve 
reflecting both anatomical (i.e. dead space) and physiological properties 
associated with gas mixing in the lungs. The N2 washout curve phases can be 
described using the single breath N2 washout test (figure 1.11) (292). Phase I 
reflects the dead space that contains pure 02; phase II is the ‘bronchial phase’ 
where N2 concentration increases rapidly as the gas exchanging units start to 
empty sequentially; phase III is the ‘alveolar phase’ and is the key MBNW 
parameter, as the slope represents differences in N2 concentration between 
gas exchanging units as they continue to empty. The phase III slope is usually 
calculated between 25% and 75% of the expired volume to avoid contribution 
from phase IV. Phase IV shows a rapid increase in the expired N2 
concentration and reflects the onset of airway closure in the dependent 
portions of lung at lower lung volumes.  
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Figure 1.11 
From Robinson et al (292). 
Example of a typical single-breath washout (SBW) trace. Nitrogen gas (N2) 
expirogram showing calculation of phase III slope (SIII) between 25% and 
75% of the expired volume, to avoid the contribution of phase IV. The four 
phases of the expirogram are also demonstrated: phase I (absolute dead 
space), phase II (bronchial phase), phase III (alveolar phase) and phase IV 
(fast rising phase at end of expiration). VT,exp: expired tidal volume.  
) )
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If ventilation were even between all gas-exchanging units, the phase III slope 
would be flat, as N2 would be washed out evenly or homogeneously. 
However, the normal lung has different compartments that fill and empty at 
different rates, therefore there is always some unevenness in ventilation and 
hence the phase III slope cannot be flat. A change in the phase III slope 
indicates a change in the distribution of ventilation (i.e. N2 washes out from 
different lung units at slower rates) and becomes steeper with disease 
indicating more uneven or heterogeneous ventilation. 
1.7.4.1.3. MBNW equipment 
The MBNW set up requires equipment to measure flow, the ability to deliver 
and allow inhalation of 100% 02, a gas analyser and a computer and software 
to record and process data (292). Subjects inhale 100% 02 which ‘washes out’ 
N2. N2 concentration is measured at the mouth and subjects continue to inhale 
100% 02 until alveolar N2 is reduced to 1/40th of the initial concentration (figure 
1.12). Measurement of both flow and inert tracer gas (N2) concentration 
should be synchronized accurately and precisely to minimize measurement 
error (292).  
) )
 56 
 
 
 
 
 
 
 
 
 
 
Figure 1.12 
From Robinson et al (292). 
Example of a typical multiple-breath washout (MBW) trace. Time series 
display of (a) volume and (b) nitrogen gas (N2) from a N2 MBW test. The 
volume trace shows stable 1 litre tidal breathing.  
 
) )
 57 
The MBNW technique has evolved over the years and equipment has become 
more sophisticated with advances in technology (292). Reference equations 
for predicted values exist (287, 314-316), although a standardized reference 
equation is lacking, in part because of variations in equipment (317), 
technique, analysis and upper age limit in the populations studied. However, 
consensus guidelines have been established with recommendations for 
equipment specification, validation and measurement techniques (292). 
Differences between currently available MBNW equipment (hardware and 
software) will be discussed in chapter 2 (317).  
1.7.5. Ventilation heterogeneity in asthma 
VH contributes to the clinical manifestations and underlying 
pathophysiological mechanisms in asthma. VH is increased in asthma (315, 
318, 319) and more so during exacerbations (318). VH indices are associated 
with different clinical features of asthma, such as AHR (113), response to 
bronchodilator (319) and inhaled corticosteroid therapy (320, 321) and asthma 
control (321, 322). In both stable and unstable asthma (i.e. during asthma 
exacerbations), VH in the diffusion-dependent airways (Sacin), yet not Scond, 
is correlated with FEV1 (318), suggesting the acinar airways play a significant 
role in airflow obstruction in asthma (318).  
VH also increases with age (314, 316), with an accelerated increase seen in 
Sacin and LCI after the age of 60 years, as opposed to a steady linear 
increase in Scond (314). This may explain some of the differences seen in VH 
between young and older people with asthma (113). Sacin is higher in older 
compared to younger asthmatics, despite a similar FEV1 (113), which 
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suggests the underlying mechanisms in asthma may vary with age. In young 
adults with asthma, VH in the conductive-dependent airways (Scond) is a 
major determinant of AHR. Conversely, in older people AHR is predicted by 
VH in the diffusion-dependent airways (Sacin) (113), suggesting the acinar 
rather than conductive airways contribute to VH in older people with asthma.  
1.7.6. Respiratory Impedance 
1.7.6.1. Forced Oscillation Technique 
The forced oscillation technique (FOT) is another non-invasive lung function 
tool that can measure small airway function by assessing the mechanical 
properties of the respiratory system (294). FOT was first described by DuBois 
in 1955 (323) and involves external sinusoidal oscillations being applied to the 
lungs during tidal breathing (294). The external oscillations are small pressure 
signals generated by a loud speaker and are of varying frequencies that are 
higher than the tidal breathing rate, upon which the oscillations are 
superimposed. This allows respiratory impedance (Zrs) (323), the resistive and 
elastic properties, to be measured and therefore provides information about 
the lungs’ mechanical properties.  
1.7.6.1.1. FOT Indices 
Respiratory impedance encompasses the properties of flow and pressure and 
describes their relationship with respect to a frequency domain (324). 
Mathematical modelling has allowed partitioning of the contributions from the 
airways and lung tissue to respiratory impedance. The different properties of 
the airways and lung tissue allow them to exhibit distinct relationships with 
different oscillation frequencies (324, 325).  
 59 
Respiratory impedance is comprised of two components – resistance (Rrs) 
and reactance (Xrs) (294). Rrs, the in-phase or ‘real part’, describes the 
resistance of airflow through the respiratory system and reflects airway caliber 
(294). Xrs, the out-of-phase or ‘imaginary part’, describes the elastic properties 
or oscillatory stiffness of the respiratory system and incorporates the concepts 
of inertance and capacitance. Inertance refers to the mass-inertive forces of 
air moving in the conductive airways and dominates at higher oscillation 
frequencies. Whereas capacitance refers to the elastic properties of the lung 
periphery and dominates at lower oscillation frequencies (294). Xrs can be 
thought of as reflecting airway closure and subsequent unevenness of VH; if 
more airways are closed the lungs will appear more ‘stiff’ because the applied 
oscillation signals cannot reach the peripheral lung (294). The concept of Xrs 
not widely understood because of the complexity of the parameters however it 
is important to consider both Rrs and Xrs in interpreting respiratory mechanical 
properties (294). 
FOT allows simultaneous measurement of Rrs and Xrs over a range of 
frequencies (usually from 3-35 Hz) (294). It is thought that measurements 
over higher frequency signals (>20 Hz) do not reach the small airways 
therefore reflect contribution from the larger airways (326). This is because 
signals at higher frequencies are absorbed by the respiratory system before 
reaching the small airways (294, 326, 327). Measurements over lower 
frequencies (<15 Hz) reflect contribution from the small airways because 
these signals penetrate deeper into the lungs (294, 326). However, there is no 
clear consensus on which frequency range best reflects small airway function 
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and the anatomical location of the transition between the small and large 
airways is yet to be determined (326). 
At frequency ranges between 4-10 Hz, which reflects mainly resistance of the 
airways, the healthy respiratory system demonstrates frequency independent 
Rrs. In other words, resistance changes very little with increasing or varying 
frequency (328, 329). In contrast to Rrs, Xrs is frequency dependent. That is, 
Xrs is negative at low frequencies, where lung and chest wall elastance 
dominate and becomes more positive at higher frequencies, where airway 
inertia begins to dominate (329). The frequency at which Xrs crosses zero (i.e. 
when Xrs transitions from negative to positive) is called the resonant frequency 
and occurs when the elastic and inertial forces are equal and opposite in 
magnitude (figure 1.13).  In healthy lungs resonant frequency is thought to 
occur between 8-10 Hz (293). 
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Figure 1.13 
From Oosteveen et al (293). 
Frequency dependence of (a) resistance and (b) reactance in health (solid 
lines) and obstructive airway disease (interrupted lines) in adults. Arrow 
indicates resonant frequency. 
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Both single-frequency and composite signals have been
used in clinical practice. When the FOT is applied to explore
the patterns or mechanisms of frequency dependence of Zrs in
health and disease, the simultaneous application of several
frequency components, i.e. the use of composite signals, such
as pseudorandom noise or recurrent impulses, is preferred.
The single-frequency FOT may be used in the tracking of
relatively rapid changes in Zrs, e.g. those occurring within the
respiratory cycle, or as an accessory device for monitoring
airway patency, and it may also be useful in the evaluation of
changes in the bronchomotor tone.
Recommendations for measurements
Set-up
The subject is connected via a mouthpiece to the set-up that
most commonly utilises a loudspeaker to deliver the forced
oscillatory signal (fig. 2). The P and V9 signals are measured
next to the mouthpiece. To enable spontaneous breathing of
the subject, a shunt pathway open to the atmosphere is
necessary; this is usually a wide-bore side tube (with a high
impedance to present a small leak for the high oscillatory
frequencies and a low resistance against spontaneous breath-
ing) placed in parallel to the loudspeaker. A mechanical
resistor may also be used for this purpose. A bias flow to flush
the dead space is optional and can preferably be introduced
between the loudspeaker and the pneumotachograph. When a
bacterial filter is placed between the set-up and the patient for
hygienic purposes, the measured Zrs should be corrected for
the impedance of this filter. The dead space of the filter should
be minimal to avoid shunting effects at high Zrs.
Apparatus
The FOT system should impose a load against spontaneous
breathing ofv0.1 kPa?s?L-1 below 5 Hz. When using composite
signals, the loudspeaker should be able to develop a peak-to-
peak pressure variation of 0.2 kPa at the airway opening. The
largest P developed in the system should not exceed 0.5 kPa.
The differential pressure transducer used for flow measure-
ment together with its connections to the pneumotachograph
should be symmetrical and of low compliance, providing a
common mode rejection ratio of at least 60 dB up to the
highest frequency investigated [10]. The pressure transducers
should have a low sensitivity to accelerations, or at least be
protected against vibrations. The flowmeter and the pressure
transducer should be linear (within 2%) up to at least 1 L?s-1
and up to 0.5 kPa, respectively.
Calibration
The calibration should take into account the relative static
gain and the relative frequency characteristics of P and V9
measuring devices. To check the overall accuracy of the
measurement set-up, the use of a reference impedance, whose
theoretical impedance is known from physical principles, is
recommended. The magnitude of the impedance of this device
should be comparable at all measured frequencies to that of
the highest Zrs encountered or expected in the measured
subject population, i.e. reference impedance with a magnitude
ofy1.5 kPa?s?L-1 andy4 kPa?s?L-1 are suggested for calibration
in adult and infant studies, respectively. After proper calibra-
tion, a maximum error of 10% or 0.01 kPa?s?L-1, whichever is
greater, is allowed over the frequency range of interest. Proper
calibration and evaluation of the accuracy of FOT set-ups is
particularly important since it has been shown that systematic
differences in Zrs were obtained with different devices [11].
Input signals
It is important to ensure that the test signal is applied for
long enough to include several breathing cycles. The amplitude
of the signal should be large enough to guarantee a satis-
factory signal-to-noise ratio, but not too large so as to avoid
discomfort for the subject, nonlinear behaviour of the res-
piratory system and synchronisation between breathing and
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Fig. 1. – Schematic illustration of the frequency dependence of respira-
tory impedance of adults in the medium frequency range, in health
and disease. Compared to the normal impedance data (–), in airway
obstruction, respiratory resistance (- - -) is higher (a) and negatively
frequency-dependent, whereas respiratory reactance is lower (b).
Arrow indicates resonant frequency.
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Fig. 2. – Schematic arrangement of the forced oscillatory respiratory
impedance (Zrs,in) measurement. Pap: airway opening pressure; V9:
airflow.
1028 E. OOSTVEEN ET AL.
 62 
1.7.6.1.2.)FOT Equipment 
The FOT set up requires equipment that enables a route to measure flow and 
pressure and another route where external pressure signals or oscillations 
can be applied to the lungs. A computer and software are connected to these 
two routes and used to generate signals, record and process data (figure 
1.14). The external oscillations can be mono- or multi-frequency and are 
delivered as a continuous sinusoidal signal (pseudo-random noise) (293, 
294). Both in-house and commercial FOT devices are in use and utilize 
different hardware and software, however the general principle of the 
technique remains the same. Attempts to standardize the technique have 
been made with recommendations in the consensus guidelines (293). 
Predictive values for the indices measured by FOT are also available, 
however these values are limited to the Caucasian population (293, 329).  
) )
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Figure 1.14 
From Navajas et al (330). 
Schematic diagram showing the setup for measuring respiratory impedance. 
LS: loud speaker, MC: micro-computer, PT: pressure transducer, PN: 
pneumotachograph, BR: bias resistor. 
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1.7.7.)Resistance and reactance in asthma 
In both adult and paediatric asthma, including during stable states (331), Rrs is 
increased or higher than normal and exhibits frequency dependence (i.e.  
increased Rrs occurs predominantly at low frequencies and subsequently 
reduces with increasing frequency) (289, 331-333). In patients with respiratory 
symptoms and a normal FEV1, Rrs is increased (289) suggesting FOT may be 
a sensitive tool for discriminating between disease and health. Rrs is also 
comparable to plethysmographic or oesophageal pressure techniques used 
for estimating resistance to breathing (333), indicating Rrs as measured by 
FOT could be used as an alternate technique to determine airway resistance. 
Rrs may be normal in asthma and can increase following a histamine 
challenge test (328). Frequency dependence of Rrs is demonstrated post 
histamine challenge only in asthmatics and not healthy controls, with the 
increase in resistance being most marked at lower frequencies (328) (figure 
1.15). The addition of FOT to assessment of AHR can therefore provide 
information about localization of the response in the respiratory system (328). 
) )
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Figure 1.15 
From Wouters et al (328). 
Top panel: Mean respiratory resistance (Rrs, kPa(L/s)) before (closed circles) 
and after (open circles) histamine challenge in healthy controls and 
asthmatics. 
Bottom panel: Mean respiratory reactance (Xrs, kPa(L/s)) before (closed 
squares) and after (open squares) histamine challenge in healthy controls and 
asthmatics. 
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Healthy((
Asthma(
 66 
Xrs may be abnormal in asthma, with values being more negative compared to 
normal (289, 328, 334). Similarly to Rrs, following a histamine challenge test 
Xrs becomes more abnormal – it decreases or becomes more negative at all 
frequencies (328) (figure 1.15). This is probably due to the presence of more 
peripheral airflow obstruction and oscillation signals subsequently not 
reaching the lung periphery. Xrs can also be partitioned into inspiratory and 
expiratory Xrs values at 5Hz. This may allow differentiation between COPD 
and asthma, which can be a challenge when FEV1 is similar between the two 
obstructive airway diseases (335).  The difference between inspiratory and 
expiratory Xrs is greater in COPD compared to asthma and thought to be due 
to enhanced dynamic airway narrowing in COPD (335). This probably reflects 
the contribution of lung tissue (i.e. emphysema) and loss of elastic recoil that 
occurs in COPD. 
1.7.8. Lung tissue mechanics – elastic recoil and compliance 
Alteration to the lung tissue can occur in asthma (16-18) and may contribute 
to the functional changes described above because of changes in the lungs 
elastic recoil properties. Lung elastic recoil can be described as lung 
compliance or the ease with which the lungs can expand or stretch. 
The lung is a complex 3-dimensional structure enclosed within the thoracic 
cage, which encompasses the respiratory muscles and chest wall. The lung is 
separated from the chest wall by the pleural space and has a tendency to 
recoil inwards. The chest wall on the other hand has to tendency to recoil 
outwards. Negative pressure within the pleural space prevents the lungs from 
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collapsing. The lungs (alveoli) are also held open by a balance between tissue 
forces and alveolar surface tension (186). 
1.7.8.1. Elastic recoil measurement 
Lung compliance is defined as the change in lung volume for any given 
applied pressure. Static compliance represents lung compliance during 
periods of no airflow, such as during an inspiratory pause. Dynamic 
compliance refers to lung compliance during periods of airflow (i.e. during 
inspiration).   
To measure compliance and the lungs elastic recoil properties, the pressure 
or force required to drive air in and out of the lungs and the volume or amount 
of air being driven needs to be measured. The distending pressure across the 
lung (trans-pulmonary pressure, PL) determines the volume of the lung. 
Therefore changes in the distending pressure determine changes in lung 
volume. The distending pressure of the lung itself (PL) is equal to the 
difference between the pressure inside the lung or alveolar pressure (PALV) 
and pressure in the pleural space (PPL). At the end of a normal breath (i.e. at 
FRC) when there is no airflow, PALV, pressure at the mouth (PAO) and 
atmospheric pressure (PATM) are equal. Therefore PL can be derived easily 
when there is no airflow because PALV is zero (figure 1.16).  
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Figure 1.16 
From Benditt et al (336). 
Schematic showing equations for trans-pulmonary (PL), trans-chest wall (PCW) 
and trans-respiratory system (PRS) pressures. PPL: pleural pressure, PATM: 
atmospheric pressure, PALV: alveolar pressure, PAO: pressure at the airway 
opening.  
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1.5. Background 
1.5.1. A brief history 
The first measurements of the elastic properties of the lungs were completed in 1817 by 
Carson, a Scottish physician, who attached a water manometer to the trachea of a deceased 
animal and noted an increase in the tracheal pressure when the chest was opened. It was 
this increase in tracheal pressure that he attributed to the elasticity of the lung. Donders 
subsequently made similar measurements on humans and noted pressure fluctuations 
within the pleural space. In 1879 the first measurement of pleural pressure was made by 
inserting a water filled balloon connected to a mercury manometer into the intrapleural 
space of an animal.  
The first direct pleural measurement in humans was made by Aron in 1900 however it was 
in an emphysema subject being treated with suction drainage tube. It was not until the mid-
20th Century that a less invasive method was developed to estimate pleural pressure. This 
allowed for accumulation of large amounts of in vivo human data during the 1950s and 
1960s which allowed for clear descriptions of respiratory muscle action and lung elastic 
properties.  
1.5.2. Physiological basis for test 
When pressures applied naturally by the respiratory muscles are applied the lung and chest 
wall change volume because they are three-dimensional mechanical structures. The lung 
and chest wall move together although they are joined by the pleural space. The lung is a 
passive structure and has a tendency to recoil to a smaller volume than the lung and chest 
wall together, because of this the pressure in the pleural space (denoted Ppl) is slightly 
negative. The chest wall has a tendency to recoil outwards (only at lung volumes below 
about 70%TLC), and thus prevents the lung from collapsing.  
At the end of a relaxed exhalation 
to FRC, alveolar pressure (Palv), 
mouth pressure (PAO) and 
atmospheric pressure (Patm) are 
equal. Therefore, the distending 
pressure of the lung (PL) is equal to 
the pressure inside the lung (Palv) 
minus the pressure in the pleural 
space (PPL). The distending 
pressures across the lung (called 
transpulmonary pressure) 
determine the volume of the lung. 
Changes in distending pressure 
result in changes in lung volumE. 
 Palv is measured by 
assessing PAO during a static 
manoeuvre with an open glottis 
where Palv = PAO = Patm. Ppl can 
be measured directly by placing a 
catheter in the pleural space, 
however this is not possible in 
 
Figure 1.2: From Benditt, Respiratory Care, 2005 
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The trans-pulmonary pressure or pressure across the respiratory system can 
be derived by measuring the pleural pressure. A surrogate measure of the 
pleural pressure can be obtained by measuring the oesophageal pressure, 
using an oesophageal balloon placed in the lower third of the oesophagus 
(337, 338). In this position the oesophagus is adjacent to the pleural space. 
Volume is derived by simultaneous measurement of airflow at the mouth. A 
static (or quasi-static) pressure-volume (P-V) curve can be constructed using 
these pressure and volume measurements. Static compliance can be derived 
from the P-V curve by measuring the chord shape of the linear portion of the 
curve from FRC plus 0.5-1 L (19, 339) (figure 1.17). An exponential function 
(340) can also be fitted to the P-V curve to derive indices, which describe and 
provide objective measures of the lungs elastic properties. The exponential 
function is thought to provide a better measurement of the lungs elastic recoil 
properties than the static compliance measurement because it incorporates 
the volume over a meaningful range and does not linearize a curvilinear 
relationship (340) (figure 1.18). Details of this measurement will be discussed 
in chapters 3 and 4.  
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Figure 1.17 
Courtesy of Norbert Berend presentation. 
Schematic showing calculation of static compliance (CL) from the pressure-
volume curve. Vol: volume, PL: trans-pulmonary pressure. 
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Figure 1.18 
Schematic showing the pressure-volume (P-V) curve fitted with the Colebatch 
equation (V = A – Be-KP) (340) to derive indices reflecting the lungs elastic 
properties. V: volume as % of total lung capacity (TLC); P: trans-pulmonary 
pressure; and A, B and K are constants. A: is the horizontal asymptote of the 
Y-axis, B: is the distance on the Y-axis between A and the extrapolated Y-axis 
intercept of the curve.  
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Within the pleural space and lungs there is also a pressure gradient, whereby 
the pleural (PPL) and alveolar pressures (PALV) change between the apex and 
base of the lung. The pressure at the apex is more negative than that at the 
base because of gravity. PPL increases by about 0.25 cmH20 per centimetre 
of vertical distance from the apex to the lung base (1.19). Therefore PALV and 
PRS also changes from apex to base and at rest, alveoli at the top of the lung 
are more fully expanded than those at the bottom at FRC. Thus different 
alveoli operate on different portions of the P-V curve, with alveoli at the bottom 
expanding more than those at the apex, as they are better ventilated. At TLC, 
although the pressure gradient still exists, theoretically all alveoli are the same 
size but are operating on the flat portion of the P-V curve.  
 
Figure 1.19 
Courtesy of Norbert Berend presentation. 
Schematic demonstrating the pleural pressure gradient, where pleural 
pressure is more negative at the apex compared to the base.  
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1.7.9. Loss of lung elastic recoil 
Changes to the lung tissue may result in a loss of lung elastic recoil and/or 
increased lung compliance (18, 341). Loss of elastic recoil can occur in 
asthma and has been demonstrated objectively using the P-V curve (19-21, 
117, 342) (1.20). A leftward shift in the P-V curve and/or a steeper curve 
indicates a loss of elastic recoil and/or increased compliance (16, 18-21, 117, 
343). Loss of elastic recoil leads to a reduction in the driving pressure during 
maximal expiratory flow (Vmax) (117) therefore reduced expiratory airflow. The 
tethering force of the lungs, which holds the airways open, is also reduced 
therefore leads to airway instability and airways that are prone to premature 
closure and collapse (274, 344). Premature airway collapse leads to a 
reduction in Vmax at a given lung volume (345, 346). It has also been 
speculated that a chronic reduction in expiratory Vmax may be due to early loss 
of lung elastic recoil (117). The underlying mechanisms are not clear however 
micro-emphysema has been suggested as a cause of loss of elastic recoil in 
non-smokers with asthma (16, 18). In the absence of emphysema, another 
simple explanation is difficult to determine, however stress relaxation has also 
been implicated (347-349). 
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Figure 1.20 
From Finucane et al (19). 
Mean pressure-volume curves for emphysema, asthma and healthy controls 
corrected for variation in lung size by expressing lung volume as a percentage 
of the predicted total lung capacity (TLC). The emphysema curve is steeper 
and left ward shifted indicating increased compliance and loss of elastic recoil. 
The asthma curve is left ward shifted indicating loss of elastic recoil. 
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Surrogate measures of lung elastic recoil may include measures of lung 
volume (hyperinflation or an increase in FRC or TLC) and gas trapping 
(increase in residual volume) (269, 350). An increased TLC can occur during 
severe asthma attacks and is thought to be a physiologic marker of loss of 
lung elastic recoil (350, 351). Treatment of acute asthma attacks can improve 
both an increased TLC (267, 268, 273, 284, 351) and loss of lung elastic 
recoil, implying loss of lung elastic recoil may be reversible (350, 352). 
Optimization of asthma control in long-standing asthma may also improve the 
loss of lung elastic recoil (18). On the other hand, loss of lung elastic recoil 
may be irreversible and is thought to reflect the growth response to 
hyperinflation during growing years (342) or reflects the response to sustained 
inspiratory efforts (353). Irreversibility may not be the correct term to describe 
the lack of change in lung elastic recoil, however in stable asthma lung elastic 
recoil does not change or improve post bronchodilator therapy (21). 
Elastic load provided by the lung tissue is transmitted to the airways through 
alveolar attachments (354), which are attached to the adventitia or outer 
airway wall (355). This creates mechanical airway-lung inter-dependence, 
which is important for maintaining a patent airway lumen. Airway-lung tissue 
interdependence can be lost due to uncoupling of airway-lung attachments 
and the consequences are similar to what is described above with the loss of 
lung elastic recoil. Airways become more unstable and prone to closure (356) 
and collapse (274, 344). This mechanism may also explain the loss of deep 
inspiration bronchodilation in spontaneous bronchoconstrictive episodes 
(357).  
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The mechanisms causing the functional changes described above may be 
similar to what is seen in smokers without emphysema (250). Compared to 
non-smokers, smokers without emphysema have abnormal and a reduced 
number of alveolar attachments (250). These structural changes were 
associated with inflammation in the small airways and loss of elastic recoil. 
Loss of alveolar attachments could therefore represent early stages of lung 
tissue destruction and could explain the loss of elastic recoil. As discussed in 
the previous section, lung tissue and the outer airway wall are altered in 
asthma. Hence changes such as alveolar detachment (17), micro-
emphysema (18), loss of elastic fibre integrity (17, 176) in the airway wall and 
inflammation and/or airway remodeling in the outer airway wall appear to 
contribute to asthma pathogenesis. Therefore it is not unreasonable to 
suggest asthma is a disease of both the airways and the lung tissue. 
Involvement of lung tissue may underpin the mechanisms of FAO in asthma, 
which will be discussed in the next section.   
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1.8. Fixed Airflow Obstruction in Asthma 
Asthma with irreversible or fixed airflow obstruction (FAO) (3, 5, 8, 358-362) is 
a recognized asthma phenotype that can develop despite appropriate 
treatment (252, 253). Consistent findings show that inhaled corticosteroids are 
beneficial for asthma control, reducing exacerbations and airway inflammation 
and improving lung function (228, 363). However corticosteroids are not 
effective at preventing FAO in some patients. FAO is typically associated with 
COPD, which is usually due to cigarette smoke or exposure to other noxious 
particles such as occupational dust, chemicals, biomass and coal cooking 
(364). However unlike COPD, FAO in asthma can occur despite no or minimal 
smoking history (5, 85).  
FAO in asthma is associated with poor outcomes and has been classed as a 
sub-type of severe or refractory asthma (365, 366). In addition to being 
associated with moderate to severe disease (2, 5, 367, 368), individuals with 
asthma and FAO have worse lung function, a faster decline in lung function, 
more frequent exacerbations and poor quality of life (4, 5, 7-10). The presence 
of FAO also has implications on mortality, as post-bronchodilator FEV1 has 
been shown to be a predictor of asthma-related (369) and overall mortality 
(370).  
Current evidence on FAO in asthma is largely based on a small number of 
longitudinal studies and cross-sectional studies (2, 5, 18, 33, 358, 362, 367, 
371, 372). However the disease is highly variable and heterogeneous, 
therefore only limited insight can be gained from cross-sectional data. 
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Identifying those at risk of developing FAO is challenging due to many 
unknowns about the underlying pathophysiology. 
1.8.1. Definition and Prevalence of FAO 
A standardized definition for FAO in asthma is lacking despite irreversibility in 
asthma being recognized for decades (3, 359, 360, 362, 373). The absence of 
a standardized definition may be due the lack of a clear consensus on what 
constitutes reversibility in airflow obstruction (251, 374, 375). This may partly 
be due to there being no consensus on how to express a bronchodilator 
response, the variables that should be used and the type, dose and inhalation 
mode of the bronchodilator agent (251). Nevertheless, a bronchodilator 
response is usually expressed as either the percent of the initial spirometric 
value, percent of the predicted value and/or the absolute change (251). 
Published guidelines recommend using the percent change from baseline and 
absolute changes in FEV1 and/or FVC when assessing for a positive 
bronchodilator response.  An improvement in FEV1 and/or FVC by >12% and 
>200ml compared to baseline suggests a ‘significant’ bronchodilator response 
(251).  
Various descriptions and lung function parameters have been used to define 
FAO. The definition can be tainted by the inclusion of current smokers (368) 
and/or ex-smokers (376, 377). With respect to the defining parameters, 
studies have used percent predicted post-bronchodilator spirometric ratio 
(378) with FEV1 (2, 117, 358, 379) or FEV1 alone (3-5, 368, 372). Lung 
volume parameters such as TLC (2) have also been incorporated into the 
FAO definition, as a decrease in hyperinflation post-bronchodilator may also 
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indicate a significant bronchodilator response (380). The cut off values for 
spirometric ratio and/or FEV1 also varies between studies. A post-
bronchodilator spirometric ratio of <75% (379) is commonly used (2, 117, 
379), however some studies have used the lower limit of normal (365, 378) as 
the cut off. In addition, the percent predicted pre or post bronchodilator FEV1 
cut off varies from as low as <50% up to <70 or <85% (2, 4, 5, 117, 358, 372, 
381) and the percent change in FEV1 cut off from <9% to <15% (5, 358, 381). 
The type of bronchodilator medication used, dose and route of administration 
is also not consistent (382-386). Salbutamol is frequently used as the 
bronchodilator agent, however other agents such as albuterol and ipratropium 
bromide have also been used (382, 386). Theophylline and oral 
corticosteroids have also been used in attempt to achieve maximal lung 
function (3).  
Discrepancies in the definition of FAO in asthma make it difficult to estimate 
the true prevalence. Therefore the reported prevalence of FAO in adults is 
highly variable. It has been reported to be 23% in a non-smoking asthmatic 
Danish population (5) followed over a period of 10 years. Other studies have 
reported a prevalence of 16% in mild asthma (358), up to 49% in severe 
asthma (2) and in the range of 35-50% in the adult asthmatic patients (63). A 
recent meta-analysis estimated the incidence of FAO in non-severe asthma 
patients to be between 8-16% (381).  
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1.8.2. Risk factors 
A number of risk factors have been linked to the decline in lung function and 
development of FAO in asthma including a lack of ICS treatment (387) and 
chronic mucus hyper-secretion (252, 258). 
An irreversible component to asthma may occur early in life, as loss of lung 
function can occur at a young age (388, 389). This may be because early lung 
insult while lungs are still maturing and growing may predispose the airways 
to remodelling and irreversible damage. If the initial loss of function occurs at 
an early stage, further decline over the years may then be minimal (390). Low 
FEV1% predicted (391), AHR (391), wheezy bronchitis and asthma in 
childhood (392) are associated with an increased risk of reduced lung function 
in adulthood. 
A limited number of prospective longitudinal studies have demonstrated an 
association between FAO and lung function at enrolment (5, 258, 358). FAO 
was associated with lower FEV1, less bronchodilator reversibility and less 
severe AHR in adult asthmatics after 26 years of follow up (358). In these 
adults with FAO, they were also found to be using less corticosteroids at 
follow up (358). In contrast, a greater degree of AHR in childhood was 
associated with an increased risk of FAO in adulthood (371, 388, 393). 
Furthermore, another study in non-smoking adults with asthma showed a 
higher degree of bronchodilator reversibility and long term oral corticosteroid 
treatment was associated with FAO after 10 years of follow up (5).  
Older age (367, 394) has been associated with FAO development, as has the 
age of onset, duration and severity of asthma (3, 4, 359, 372), although the 
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evidence is also conflicting. Adult-onset asthma is associated with more rapid 
decline in lung function (2, 229, 395), increased AHR (2) and increased risk of 
FAO. Yet in another study, adult-onset disease was not related to disease 
severity, disease duration or lung function impairment (396).  
Male sex has been associated with the development of FAO and thought to 
reflect different gender-specific driving factors (367, 372, 394, 397, 398). On 
the other hand severe asthma is more commonly seen in females (399). This 
may be related to ICS having less of an effect on lung function decline in 
females, both in the short-term and long-term (400, 401). Female sex 
hormones, differences in airway geometry and deposition of ICS may explain 
the gender differences in ICS response (366, 402), therefore possibly 
contributing to FAO development.  
Atopy and allergic symptoms are not diagnostic of asthma however they often 
co-exist and may have a protective effect against FAO (367, 381). Atopic 
dermatitis, rhino-sinusitis (368, 388) and atopy have been shown to have a 
reduced risk of FAO in asthma (381). A family history of atopic dermatitis, pets 
in the home and dust sensitivity also have a protective effect against FAO 
(367). The mechanism leading to a protective effect is unknown however 
suggested to be due to influences of characteristic ‘twitchy’ airways on airway 
structure, mechanical force, inflammation and related repair (367). Aspirin 
sensitivity on the other hand is associated with an increased risk of FAO 
(367). 
Ethnicity and genetics are thought to play a role FAO developing in asthma. 
Black ethnicity (367, 394) is associated with an increased risk of FAO, yet 
 82 
Hispanic ethnicity appears to be protective (367). These ethnic differences 
suggest genes contributing to asthma susceptibility may vary between races. 
Specific genes such as ADAM33 have been implicated in asthma 
development and progression and thought to play a significant role in airway 
remodelling (55). However the role of the ADAM33 gene and other genes in 
FAO pathogenesis is unknown.  
Lung function declines at an accelerated rate in asthma (5, 256, 257), even 
more so in smokers (119, 252) and in those with FAO (8) (figures 1.21 and 
1.22). Unsurprisingly a history of smoking is associated with an increased risk 
of FAO (367, 377, 381, 403) and may be related to smoke-induced 
inflammatory changes (404). It could be argued that in studies that include 
smokers, some subjects have predominantly COPD rather than asthma. It is 
likely that the synergistic effect of cigarette smoke combined with asthma 
contribute to an increased risk of FAO. A recently published study has 
demonstrated two distinct asthma phenotypes in smokers with low FEV1/FVC 
(88). One group had features characteristic of TH2 inflammation, what is 
traditionally associated with asthma. The other group of smokers had low 
levels of circulating eosinophils (88). The authors suggest different biological 
pathways contribute to FAO in smokers with asthma.  
Chronic or recurrent respiratory infection with specific pathogens may play a 
role in FAO development in asthma (405, 406). Seropositivity to Chlamydia)
pneumoniae infection has been associated with asthma and may promote FAO 
development in non-atopic people with adult-onset asthma (405). C.)
pneumoniae is also associated with lower FEV1 (405) and can accelerate the 
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loss of lung function in non-atopic people with a new diagnosis of asthma 
(406).  
Occupational exposures may be linked with an increased risk of FAO in 
asthma. Ongoing exposure to agents causing asthma is associated with poor 
prognosis and faster decline in lung function (407). Removal from the 
occupational exposure can result in either no recovery or complete recovery 
of impaired lung function (407, 408). 
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Figure 1.21 
From Lange et al (252). 
Changes with age in height-adjusted forced expiratory volume in one second 
(FEV1) according to sex, smoking status and the presence or absence of 
asthma. Lung function declines with age, more so with the presence of 
smoking. 
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Figure 1.22 
From Ulrik et al (5). 
Lung function measured at two time intervals, 10 years apart, in non-smoking 
adults with asthma. Lung function declines more rapidly in those with fixed or 
non-reversible airflow obstruction. FEV1 % pred: percent predicted forced 
expiratory volume in 1 second, NRAO: non-reversible airflow obstruction, 
RAO: reversible airflow obstruction. 
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1.8.3. Mechanisms 
FAO in asthma adds an additional complexity to this already heterogeneous 
disease. The mechanisms leading to FAO are largely unknown and there is 
limited data assessing both structural and functional changes together in this 
phenotype. The processes that may contribute to FAO include airway 
remodelling and/or lung tissue changes (18, 163), which have both been 
discussed earlier in this chapter.  
1.8.3.1. Response to glucocorticosteroids 
ICS has demonstrated a beneficial effect on lung function decline (401, 409-
411). However this is not a consistent finding as the response to ICS in 
asthma can be variable or non-existent and may not necessarily prevent FAO 
from occurring (2, 3, 362). Glucocorticosteroid receptor abnormalities (412) 
may contribute to the lack of response to ICS.  
FAO could potentially be due to airway remodelling being an irreversible 
process, which may be related to therapy, specifically glucocorticosteroid 
duration and dose. How glucocorticosteroids affect the different components 
of the airway wall is largely unknown and therefore the effect on airway 
remodelling is also unknown. Nevertheless, prolonged ICS treatment can 
reduce reticular basement membrane (RBM) thickening (413, 414), in 
conjunction with lung function improving (413, 414). Whereas lower dose ICS 
and/or shorter treatment periods may have no effect on RBM thickening (413, 
415). A study using computer tomography (CT) imaging showed partial 
reversibility of airway wall thickness with ICS treatment (416). This was 
thought to reflect either a steroid-responsive component contributing to 
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inflammatory processes and a steroid-unresponsive component contributing 
to remodelling processes, both leading to airway wall thickening (416). The 
fact that FAO can develop despite steroid therapy suggests steroids may 
have a minimal effect on airway remodelling.  
1.8.3.2. Inflammation 
The role of inflammation in FAO development in asthma is unclear, as both 
eosinophilic (2, 372, 417) and neutrophilic (33) airway inflammation are 
associated with an increased risk of FAO. Exhaled nitric oxide, a surrogate 
marker of eosinophilic inflammation (381), has been shown to be associated 
with FAO. Serum periostin, also thought to be related to eosinophilic 
inflammation, was strongly associated with FAO in well-controlled asthmatics 
on ICS treatment a recent study (418). In contrast, blood eosinophils and 
FeN0 levels were not (418). Sputum but not peripheral blood eosinophilia in 
non-smoking adults with asthma was also associated with FAO, despite 
treatment with ICS/LABA for more than one year (2). This suggests refractory 
airway inflammation may contribute to FAO development (2), which may be 
due to glucocortocosteroid insensitivity or resistance.  
Impaired lung function and neutrophilic inflammation can persist despite 
corticosteroid treatment reducing eosinophilic inflammation (419), suggesting 
an alternate non-eosinophilic inflammatory pathway may play a role. The 
variable response to ICS may be due to the presence of inflammatory 
pathways, other than TH2 and eosinophilic inflammatory pathways, which has 
been demonstrated in severe asthma phenotypes (237). Furthermore airway 
neutrophilia has been associated with FAO (33), older people with asthma 
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(28) and severe asthma (206, 238, 420), suggesting airway neutrophilia 
reflects either steroid resistant and/or more severe disease. On the other 
hand, neutrophils may play a protective role because steroids inhibit 
neutrophil cell apoptosis (233, 234), which may contribute to neutrophil 
activation and increased neutrophil numbers. 
As discussed in the previous chapter, TH17 inflammation may have a role in 
FAO because of its association with neutrophilic inflammation (244, 246, 421) 
and pro-inflammatory role as demonstrated by the association with increased 
proteolytic enzymes (245, 246). 
Transcriptomics and gene analysis have been used in attempt to identify 
underlying mechanisms leading to FAO (422). A recent study using Gene Set 
Variation Analysis to assess sputum, nasal and endobronchial brushings and 
biopsies has shown that patients with severe asthma and FAO exhibit 
different gene expression profiles compared to those without FAO (422). 
Identified pathways involved IL-13 associated disease pathways including 
eosinophilic inflammation and remodeling involving impaired IFN-a function 
(422), which could be potential treatment targets. 
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1.9. Asthma-COPD Overlap 
Asthma and COPD are usually regarded as separate disease entities (423) 
however both diseases are now recognized as being highly heterogeneous 
and can overlap. The term Asthma-COPD overlap (syndrome) or ACO(S) has 
been used to define this condition where features of both asthma and COPD 
are present (1, 424).  
ACO has been reported to have a prevalence of about 20% in patients with 
obstructive airway disease and 2% in the general population (424-428). 
Patients with ACO have poorer outcomes including more frequent acute 
exacerbations and hospitalizations, health status impairment and increased 
mortality (425, 426, 428, 429). Co-morbidities are common in both diseases 
separately (COPD, severe asthma and asthma in the elderly) and therefore 
also contribute to significant disease burden (430, 431). The impact and 
significance of co-morbidities in ACO needs to be explored further as there 
may (425, 432, 433) or may not (428, 434) be an association with increased 
co-morbidities. 
ACO may originate during childhood as long-standing childhood asthma may 
develop into incompletely reversible or FAO in adulthood (377, 435). The risk 
is higher in children with severe asthma (435) and in those who smoke (377). 
The association with childhood asthma and smoking leading to ACO has also 
been demonstrated using CT scans (436). This study used CT scans to 
measure airway dimensions and showed that in adult smokers with a history 
of childhood asthma, the airways were smaller compared smokers without 
childhood asthma (436). Other factors in childhood that may influence the risk 
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of ACO developing in adulthood include maternal factors during pregnancy 
such as smoking (437), atopy and infection (424). Factors that may affect lung 
growth during childhood such as premature birth, infection and genetic 
susceptibility also have to potential to contribute to ACO development later in 
life (438, 439).  
The underlying mechanisms of ACO developing from childhood asthma are 
unknown. Unsurprisingly airway inflammation and airway remodelling are 
thought to contribute, as these processes also occur in childhood asthma 
(437). However, it is not known whether this contributes to incomplete lung 
growth and therefore development of ACO. Other factors demonstrated in a 
severe childhood asthma cohort (440) such as high exhaled nitric oxide, high 
healthcare use and high daily ICS dose, were identified as a cluster with 
‘early-onset atopic asthma with advanced airflow limitation’. The authors 
proposed that these features, which are suggestive of severe eosinophilic 
childhood asthma, could lead to incompletely reversible airflow obstruction 
(440). A similar cluster was found in another study and this group of children 
responded the best to ICS/LABA therapy (441). However, the role of 
eosinophilic inflammation and ICS use in childhood asthma leading to ACO is 
questionable because another longitudinal study showed that adults with the 
lowest lung function had used ICS in childhood (371). 
It is widely accepted that asthma is typically associated with eosinophilic and 
TH2 driven inflammation (62) and in COPD neutrophilic inflammation 
dominates (442). However there is there is also heterogeneity of airway 
inflammation within and between the two diseases, with the presence of 
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eosinophilic and neutrophilic inflammation seen in both (443, 444). The 
pattern of airway inflammation in ACO has not been studied extensively. 
However a large cross-sectional study of >4000 patients with airway disease, 
with 9% of the participants diagnosed with ACO (445), showed highly variable 
airway inflammatory profiles within this group (i.e. eosinophilic, neutrophilic 
and mixed) in keeping with the concept of ACO being a heterogeneous 
disease. The role of systemic inflammation in ACO is also unknown although 
systemic inflammation in ACO is similar to that seen in COPD (425, 446, 447).  
Clinical practice guidelines regarding diagnosis, treatment and management 
of ACO are limited because evidence to date is scarce. Recommendations by 
expert opinion consensus (1) proposes diagnosing ACO based on the 
presence of typical features associated with either COPD or asthma. 
Treatment is then tailored towards the disease with the predominant features 
(1). FAO in asthma may fall under the category of ACO however there is no 
clear definition for either phenotype, further adding to the challenge of 
managing these conditions. The debate around ACO which has been in 
existence for years when the ‘Dutch hypothesis’ was presented in 1961 (448), 
seems to be more conflicting with the introduction of more physiological and 
molecular biomarkers. There are many unanswered questions regarding both 
phenotypes and ongoing research is essential to help characterize patients 
and guide treatment decisions for both FAO in asthma and ACO. 
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1.10. Summary 
FAO in asthma is important because of the associated poor outcomes. Airway 
remodelling is thought to be the underlying process, with the small airways 
being the main site of pathology and inflammation being the driving factor. 
The contribution of lung tissue and the lungs elastic properties to airflow 
obstruction in asthma is under-recognized and likely plays a significant role, 
particularly in older people because of the changes that occur with ageing. 
Simple non-invasive tools to assess the contribution of the small airways and 
the lungs elastic properties are somewhat limited. Furthermore, the underlying 
mechanisms and physiological basis for FAO in older non-smokers with 
asthma remains largely unknown. 
1.10.1. Aims 
Therefore the aims of this thesis were to: 
1. Assess a method of measuring small airway function using modern and 
currently available commercial devices. 
2. Measure and quantify the lungs elastic properties in older non-smokers 
with asthma and FAO. 
3. Determine the relationship between small airway function and the lungs 
elastic properties in this cohort. 
4. Assess airway inflammation and determine its contribution to lung 
function impairment in this cohort. 
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Chapter 2 
2 In vitro and in vivo functional residual capacity and 
in vivo ventilation heterogeneity measurement 
comparisons between multiple breath nitrogen 
washout devices.  
 
 
 !
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2.1 Introduction 
Abnormalities in the small airways can be detected using the multiple breath 
nitrogen washout (MBNW) test, which provides a more sensitive measure of 
small airway function compared to spirometry (1-3). MBNW provides insightful 
information about the small airways, using indices that provide mechanistic 
information about ventilation heterogeneity (VH) in the conductive and 
diffusion dependent airways (Scond and Sacin) and assess global gas-mixing 
efficiency in the lung (Lung Clearance Index, LCI). These indices rely on 
accurate functional residual capacity (FRC) measurement (4). 
Advances in technology have allowed the development of new commercial 
MBNW devices, however there are still limited published data comparing 
measurements between devices. Previous studies have compared in-house 
and/or commercial devices against standard body plethysmography as well as 
mass spectrometry, often considered the gold standard (5-8).  Many of these 
studies have used lung models, assessed measurements in the paediatric 
population and used inert gases rather than nitrogen (N2) (9-11). Limited 
published data have also shown inconsistencies between lung model and 
adult measurements (6).  
Furthermore, the effect of software upgrades in a rapidly evolving field has not 
been extensively studied. Previous studies in one specific device have shown 
software changes can have a significant impact on results (12, 13). 
Recommendations for MBNW techniques have been published in the 
European Respiratory Society/American Thoracic Society (ERS/ATS) 
Consensus statement (4) yet on-going work is still needed to improve 
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standardisation of equipment, technical specifications and algorithms for 
calculation of its indices.   
The aim of this study was to evaluate FRC and VH indices (Scond, Sacin and 
LCI) measured using two commercial MBNW devices: Exhalyzer® D (“EM”), 
ECO MEDICS AG, Duernten, Switzerland and EasyOne Pro® LAB (“ndd”), 
ndd Medical Technologies, Zurich, Switzerland. We also examined a third, 
independent, previously published (2) in-house device at the Woolcock 
Institute of Medical Research (“WIMR”), which measures N2 directly in 
contrast to the commercial devices. FRC from the devices were compared 
against a known volume using a syringe lung model (in vitro) and against 
plethysmographic lung volume in healthy and asthmatic adult subjects (in 
vivo). In addition, we compared FRC analyses using two different software 
versions of the ndd device as a software update involving major changes to 
N2 calculation had recently become available; previous data (14, 15) has 
shown significant FRC underestimation using the older, widely available 
software. VH indices were compared between the three devices in healthy 
and asthmatic adult subjects (in vivo). 
2.2 Methods 
2.2.1 Study design 
In vitro and in vivo measurements were performed using the three different 
MBNW devices, in random order as determined by a computer generated 
randomisation sequence. The study was approved by the Northern Sydney 
Local Health District Human Research Ethics Committee (protocol number 
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LNR/16/HAWKE/11). Written informed consent was obtained from all recruited 
participants. 
2.2.2 The lung model 
In vitro measurements were performed using an optimised syringe lung model 
(Figure 2.1). A 3-litre (L) volume calibration Hans Rudolph® syringe (5530 
Series) was modified to produce the physiological expirogram encountered 
during in vivo testing. This was accomplished by incorporating an attachment 
on the front of the syringe consisting of 18 flexible Tygon® (S3 E-3603) tubes 
of varying lengths (internal diameter of 0.048 cm and lengths ranging from 10-
49.5 cm, permeability coefficients: CO2=360x10-11, N2=40x10-11 and 
O2=80x10-11 cm2.s-1.cmHg-1, to produce the phase I and II portions of the 
expirogram, and a 3D-printed helical mixer device inserted at the syringe 
entrance to optimise gas mixing and produce a smooth phase III.  
The target FRC was calculated by adding the known syringe volume to the 
dead space of the lung model attachments. The syringe volume was adjusted 
via a stopper on the syringe plunger to pre-determined positions. The dead 
space of the attachments was 0.310 L, determined from the Computer-Aided 
Design specifications and confirmed with water displacement.  
  
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Figure 2.1 
Physical lung model comprised of (a) 3-L Hans Rudolph® syringe, (b) an 
attachment made from 18 flexible tubes, (c) a helical mixer device inserted at 
the syringe entrance and (d) the adjustable syringe stopper. 
 !
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2.2.4 In vitro study 
In vitro measurements were performed in triplicate on each device using four 
different FRC volumes (1.51 L, 1.81 L, 2.11 L and 2.31 L). A standardised 
adult protocol (tidal volume of 1-1.3 litres) (2, 4, 16-18) was used. After at 
least 5 syringe strokes with a stable end expiratory volume, the washout 
phase was commenced and 100% oxygen was switched on. Syringe strokes 
were continued until end-tidal N2 concentration decreased to 1/40th of the 
starting end-tidal N2 concentration (4). Between each measurement, at least 
10 strokes were performed prior to expel any residual oxygen within the 
syringe lung model and to ensure N2 had returned to baseline. A single 
operator (KOT) performed all measurements under Ambient Temperature and 
Pressure Dry (ATPD) conditions.  
2.2.5 In vivo study 
Healthy volunteers were recruited from the WIMR and defined as current non-
smokers with <10 pack-years smoking history and with no history of acute 
respiratory illness within the preceding month. Subjects with asthma were 
recruited if they had a physician diagnosis of asthma; history of asthma 
symptoms, previously documented significant bronchodilator reversibility on 
spirometry and/or a positive bronchoprovocation challenge test and on 
inhaled bronchodilator and/or inhaled corticosteroid medication. Short acting 
β-agonists were withheld for 6 hours and long-acting β-agonists for 24 hours 
before testing. 
All participants were over the age of 18 years and completed a standardised 
interview on respiratory and general health prior to performing pulmonary 
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function tests (PFTs) in the following order: MBNW, spirometry and body 
plethysmography. All tests were performed in a single session at the 
Woolcock Institute of Medical Research.   
Spirometry and body plethysmography were performed according to 
ATS/ERS Guidelines, using a Medisoft BodyBox 5500 (Medisoft Corporation, 
Sorrines, Belgium) (19, 20).  
MBNW was performed as previously described (17). Tests were performed in 
triplicate in the seated position, using a nose clip and device-specific bacterial 
filter and mouthpiece attachments. Tests were conducted according to 
ERS/ATS consensus statement guidelines (4), using a standardised adult 
protocol (tidal volume of 1-1.3 litres) (2, 16-18). After at least 5 breaths with a 
stable end expiratory lung volume, the washout phase was commenced and 
100% oxygen was switched on. Breaths were continued until end-tidal N2 
concentration decreased to 1/40th of the starting end-tidal N2 concentration 
(4). The time interval between measurements was standardised to twice the 
previous washout time (4). 
2.2.6 MBNW hardware and software 
Details of the WIMR, EM, and ndd devices can be found in the appendix. 
Briefly, the WIMR device measures N2 directly via a side-stream N2 analyser 
(2). The commercial devices both measure N2 indirectly, based on side-
stream CO2 and O2 in the EM device and molar mass and CO2 in the ndd 
device (6). Daily calibration and/or verification of each device were performed 
as described in the appendix.  
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FRC was calculated as the net volume of N2 expired divided by the difference 
between end tidal N2 concentration at the start and end of the washout portion 
of the test (4). FRC values were corrected for the pre-capillary dead space 
volume for each device. Lung volume turn over values (TO) were calculated 
for each breath over the washout as the cumulative expired volume (CEV), 
the sum of all tidal breaths over the washout, divided by FRC (21). LCI is a 
volume ratio and defined as the number of TO required to reduce alveolar N2 
concentration to 1/40th of the starting concentration (i.e. CEV/FRC) (4).  
The phase III slope of each breath was determined by linear regression from 
50-95% of the exhaled volume of air, with manual adjustments performed to 
maximize inclusion of phase III and exclude contributions from phase II and IV 
(4). Each breath of all three MBNW test was analysed individually, whereby 
the alveolar phase III slope of nitrogen concentration versus expired volume of 
each breath, was divided by the corresponding mean nitrogen concentration 
(normalised slope, Sn). The normalised slopes were then plotted against lung 
turnover (CEV/FRC) and Scond was calculated as the linear regression slope 
between turnovers 1.5 and 6. Sacin was derived from the normalised slope of 
the first breath minus the contribution of the conductive airway ventilation 
heterogeneity (Mean Sn of first breath – Scond x mean lung turnover of 1st 
breath) (17). Methods of N2 estimation and Scond and Sacin calculation were 
according to device specific software.  
MBNW data were analysed using software specific to each device. For the 
WIMR device custom-written software (Solver Version 1.3.2.18) was used. 
For the EM device Spiroware Version 3.1.6 was used. For the ndd device, the 
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same measurements were analysed using two different software versions and 
described in the appendix: clinical software Version 2.00.01.05 (termed “ndd 
v2.00”), and the recent upgrade released in March 2016, Version 2.01.00.09 
(termed “ndd v2.01”). The ndd v2.01 software contains updates to both the N2 
calculation method and improved flow-gas delay synchronisation. Scond, 
Sacin and LCI were only analysed using ndd v2.00.  
Measurements were included for analyses if acceptability criteria were met. 
For the in vitro study, measurements were deemed acceptable if three tests 
were within 10% of the mean FRC (20) value across the triplicate measures. 
For the in vivo study, measurements were deemed acceptable if two or more 
tests were performed adequately according to the ERS/ATS Consensus 
statement (4). Tests were excluded if there was evidence of leak during 
testing, tidal volume of the first breath or more than a third of breaths during 
washout was outside 1-1.3 L, and if the end-tidal N2 concentration did not 
reach the recommended 1/40th of initial concentration during data acquisition. 
2.2.7 Statistical analysis 
Data were analysed using IBM SPSS Version 24 and graphs generated using 
GraphPad Prism Version 6.0. Summary data are presented as mean 
±standard deviation (SD) for normally distributed data and median (inter-
quartile range, IQR) for non-normally distributed data. Accuracy of in vitro 
FRC was assessed as per the consensus guidelines (4) (FRC values within 
5% of known volume for at least 95% of values) and expressed as absolute 
(L) difference (measured FRC – lung model FRC) and relative (%) difference 
(absolute difference x 100/lung model FRC). In vivo FRC was compared with 
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body plethysmography FRC (FRCpleth). FRC differences between devices 
were assessed using Bland and Altman plots with 95% limits of agreement 
and by non-parametric one-way repeated measures ANOVA (Friedman’s test) 
and post-hoc tests. In vivo Scond, Sacin and LCI were compared separately 
in healthy and asthmatic subjects between the three devices and analysed 
using one-way repeated measures ANOVA. P-values <0.05 were considered 
statistically significant. 
2.3 Results 
2.3.1 In vitro FRC comparison 
A total of 108 measurements were performed across the three MBNW 
devices (Table 2.1). Differences between measured and lung model FRC are 
shown in Figure 2.2 and Table 2.2.  FRC accuracy was within the specified 
5% accuracy range of the lung model FRC for 100% of WIMR measurements 
and 97% of EM measurements. All FRC measurements using ndd v2.00 were 
underestimated and not within the specified 5% accuracy range. Using ndd 
v2.01, accuracy improved though only 36% of measurements were within the 
5% accuracy range.  
 !
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Table 2.1 In vitro FRC (in litres) measurements on each device.  
Data presented as mean ± SD. FRC: functional residual capacity, WIMR: 
Woolcock in-house device, EM: Exhalyzer® D device, ndd v2.00: EasyOne 
Pro® LAB device Version 2.00.01.05, ndd v2.01: EasyOne Pro® LAB device 
analysed in Version 2.01.00.09.  
  
Lung model FRC  
volume n WIMR EM ndd v2.00 ndd v2.01 
2.31 9 2.30 ± 0.02 2.39 ± 0.02 1.78 ± 0.14 2.16 ± 0.04 
2.11 9 2.10 ± 0.02 2.17 ± 0.02 1.72 ± 0.12 2.00 ± 0.03 
1.81 9 1.84 ± 0.02 1.88 ± 0.02 1.37 ± 0.11 1.72 ± 0.03 
1.51 9 1.53 ± 0.03 1.53 ± 0.02 1.25 ± 0.05 1.43 ± 0.02 
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Figure 2.2 
Bland Altman plots of in vitro functional residual capacity (FRC) 
measurements on each device.  
Data plotted as measured FRC minus lung model FRC, expressed as the 
absolute difference vs mean of measured and lung model FRC. Absolute 
differences (closed circles), mean difference and upper and lower limits of 
agreement (mean difference ±SD of differences) are shown as dotted lines. 
WIMR: Woolcock in-house device, EM: Exhalyzer® D device, ndd: EasyOne 
Pro® LAB device analysed in Version 2.01.00.09. 
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Table 2.2 Differences in vitro FRC measurements from the lung model FRC for 4 
different lung volumes. 
Data presented as mean absolute difference (Absolute, L) and mean 
percentage difference (%) from the lung model FRC. FRC: functional residual 
capacity, WIMR: Woolcock in-house device, EM: Exhalyzer® D device, ndd 
v2.00: EasyOne Pro® LAB device Version 2.00.01.05, ndd v2.01: EasyOne 
Pro® LAB device analysed in Version 2.01.00.09. 
  
Device  WIMR EM ndd v2.00 ndd v2.01 
Lung 
model  
FRC 
volume 
n Absolute % Absolute  %  Absolute %  Absolute  %  
2.31 9 -0.01 ± 0.02 -0.2 ± 
0.8  
0.07 ± 0.02 3.3 
±1.0 
-0.54 ± 0.14 -23.4 
± 6.1 
-0.15 ± 0.04 -6.3 ± 
1.7 
2.11 9 -0.01 ± 0.02 -0.43 
± 0.9 
0.06 ± 0.02 2.85 
± 0.9 
-0.39 ± 0.12 -18.5 
± 5.7 
-0.11 ± 0.03 -5.2 ± 
1.5 
1.81 9 0.03 ± 0.02 1.59 
± 
1.35 
0.07 ± 0.02 3.66 
± 1.0 
-0.44 ± 0.11 -24.1 
± 6.4 
-0.09 ± 0.03 -4.7 ± 
1.6 
1.51 9 0.02 ± 0.03 1.68 
±13.1 
0.02 ± 0.02  1.12 
± 1.3 
-0.26 ± 0.05 -17.1 
± 3.0 
-0.08 ± 0.02 -5.0 
±1.2 
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2.3.2 In vivo FRC comparison 
Twenty-nine subjects (20 healthy controls and 9 asthmatics) were included in 
the analyses and their characteristics are outlined in Table 2.3. Mean (±SD) 
FRC measured by the WIMR (3.27±0.82 L) and EM (3.56±0.92 L) devices did 
not differ significantly from FRCpleth (3.44±0.77 L) or from each other.  FRC 
measured by ndd v2.00 (2.71±0.64 L) was significantly lower than FRCpleth, 
WIMR and EM (p<0.0001) (Figure 2.3 and Table 2.4). The same pattern of 
FRC differences was observed in healthy control and asthmatic subjects.  
When the ndd data was re-analysed using ndd v2.01 software, end tidal N2 
concentrations became systematically higher, such that only 9 of the 29 
subjects had measurements that reached an acceptable end-tidal N2 
concentration by the end of the washout. However a majority of the 
measurements exhibited a stable plateau at the end of the washout. For the 
purposes of this study, all 29 subjects were included for analysis to allow 
comparison of the effect on FRC. FRC increased when re-analysed using ndd 
v2.01 (3.06±0.71 L) and was still significantly lower than FRCpleth (p=0.011) 
and the EM device (p=<0.0001); however did not differ from the WIMR device. 
 
  
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Table 2.3 Subject demographics and standard lung function measurements. 
Data presented as mean ± SD. BMI: body mass index, FEV1: forced 
expiratory volume in 1 second, FVC: forced vital capacity, TLC: total lung 
capacity, FRCpleth: functional residual capacity measured using body 
plethysmography. 
  
 
All subjects 
n=29 
Controls 
n=20 
Asthmatics 
n=9 
M:F 12:17 8:12 4:5 
Age (years) 37 ± 12 36 ± 12 37 ± 13 
Height (cm) 172 ± 12 174 ± 12.5 168 ± 10 
BMI (kg.m
2
) 24.1 ± 3.63 23.9 ± 3.48 24.6 ± 4.10 
Smoking history (pack years) 2.5 ± 3.2 2.75 ± 3.31 0.70 ± 0.00 
FEV1 (L) 3.66 ± 0.93 3.75 ± 0.93 3.47 ± 0.95 
FVC (L) 4.75 ± 1.17 4.77 ± 1.16 4.71 ± 1.25 
FEV1/FVC 0.77 ± 0.06 0.79 ± 0.05 0.74 ± 0.08 
TLC (L) 6.51 ± 1.38 6.55 ± 1.41 6.42 ± 1.41 
FRCpleth (L) 3.44 ± 0.77 3.49 ± 0.78 3.34 ± 0.80 
  145 
 
)
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 
Bland Altman plots of in vivo functional residual capacity (FRC) 
measurements on each device.  
Data plotted as body plethysmography FRC (pleth) minus multiple breath 
nitrogen washout (MBNW) FRC, expressed as the absolute difference vs 
mean of pleth and MBNW FRC. Absolute differences (closed circles), mean 
difference and upper and lower limits of agreement (mean difference ±SD of 
differences) are shown as dotted lines. WIMR: Woolcock in-house device, 
EM: Exhalyzer® D device, ndd: EasyOne Pro® LAB device analysed in 
Version 2.01.00.09.  
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Table 2.4 Differences in in vivo FRC measurements from body plethysmography FRC 
on each device. 
Data presented as mean absolute difference (Absolute, L) and mean 
percentage difference (%) from body plethysmography FRC. FRC: functional 
residual capacity, WIMR: Woolcock in-house device, EM: Exhalyzer® D 
device, ndd v2.00: EasyOne Pro® LAB device Version 2.00.01.05, ndd v2.01: 
EasyOne Pro® LAB device analysed in Version 2.01.00.09. § Missing data for 
1 subject. 
  
Device  WIMR EM ndd v2.00 ndd v2.01 
 n Absolute % Absolute  %  Absolute  %  Absolute  %  
Controls 20 -0.13 ± 
0.46§ 
-3.3 
±13.0  
0.17 ± 
0.41 
4.7 ±11.8 -0.73 ± 
0.36 
-20.6 
±8.9 
-0.36 ± 
0.32 
-10.1 
±8.4 
Asthmatics 9 -0.24 ± 
0.45 
-6.8 
±13.8 
0.01 ± 
0.39 
0.12 
±12.0 
-0.73 ± 
0.59 
-20.7 
±15.3 
-0.42 ± 
0.57 
-11.2 
±15.8 
All 
subjects 
29 -0.17 ± 
0.45 
-4.4 
±13.1 
0.12 ± 
0.40  
3.3 ±11.8 -0.73 ± 
0.43 
-20.6 ±11 -0.38 ± 
0.40 
-10.5 
±10.9 
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2.3.4 In vivo Scond, Sacin and LCI comparisons: between devices in 
healthy control and asthma subjects 
In vivo VH indices measured in healthy and asthma subjects using each 
device are outlined in figure 2.4. Due to less than a third of the subjects not 
meeting acceptability criteria when the ndd data was reanalysed using ndd 
v2.01 software, only ndd v2.00 data was used for these comparisons.  
In the healthy subjects Scond was comparable across all three devices 
(median (IQR) Scond: WIMR 0.011 (0.009-0.022) L-1, EM 0.015 (0.013-0.023) 
L-1 and ndd v2.00 0.014 (0.008-0.020) L-1. In the asthmatic group, Scond 
measured by the WIMR (0.020 (0.014-0.023) L-1) and EM (0.025 (0.019-
0.032) L-1) devices were both comparable to ndd v2.00 (0.021 (0.013-0.027) 
L-1). However, Scond on the WIMR device was significantly lower compared 
to the EM device (p=0.03) but the differences were small. 
Sacin in the healthy subjects was comparable between the WIMR (0.095 
(0.069-0.119) L-1) and ndd v2.00 (0.100 (0.080-0.129) L-1) devices, yet 
significantly lower on the EM device (0.059 (0.050-0.077) L-1; p=0.03 and 
p<0.0001 for comparisons with WIMR and ndd v2.00, respectively. In the 
asthmatic subjects, Sacin was similar between the WIMR (0.082 (0.059-
0.131) L-1) and EM (0.066 (0.050-0.095) L-1) and ndd v2.00 devices (0.114 
(0.070-0.137) L-1). However Sacin was significantly lower on the EM 
compared to the ndd v2.00 device (p=0.003).  
LCI in the healthy subjects was significantly lower on the WIMR (6.93 (6.48-
7.11)) compared to the EM (7.18 (6.89-7.57); p<0.0001) and ndd v2.00 
devices (7.18 (6.64-7.63); p<0.0001), and comparable between the EM and 
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ndd v2.00 devices. In the asthmatic subjects, LCI was comparable between 
all three devices (WIMR: 6.81 (6.69-7.38), EM: 7.30 (6.72-7.62), ndd v.200: 
6.92 (6.46-7.54)). Although LCI was comparable in the asthmatic group, the 
difference in the raw median values were more variable compared to the 
healthy controls and likely related to small numbers.  
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Figure 2.4 
In vivo Scond, Sacin and LCI measurements on each device in healthy (top 
panel) and asthma subjects (bottom panel). 
Data presented as median (inter-quartile range). Scond: ventilation 
heterogeneity in conductive-dependent airways, Sacin: ventilation 
heterogeneity in diffusion-dependent airways, LCI: lung clearance index, 
WIMR: Woolcock in-house device, EM: Exhalyzer® D device, ndd: EasyOne 
Pro® LAB device Version 2.00.01.05. 
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2.4 Discussion 
2.4.1 Summary of results 
This is the first study to compare in vitro and in vivo FRC measurements and 
in vivo VH indices in healthy and asthmatic adults, between two currently 
available commercial and one in-house MBNW device. The WIMR device 
measured in vitro FRC closest to the known lung model volume. Mean 
overestimation of in vitro FRC and FRCpleth was 3% by the EM device, in 
comparison to a mean 21% underestimation by the ndd device. However on 
re-analysis using ndd v2.01 underestimation was minimised to 5% (in vitro) 
and 11% (in vivo), respectively. There were statistically significant differences 
in FRC measurements between commercial MBNW devices although this 
difference was relatively small between EM and ndd v2.01. Furthermore, the 
pattern of differences (i.e. over-estimation or under-estimation of FRC) 
between devices was consistent using both the in vitro physical lung model 
and in in vivo measurements.  
In vivo VH measurements in were variable across the three devices in both 
the healthy control and asthma subjects, although with some indices the 
differences were small. In each group, Scond measured highest using the EM 
device, followed by the ndd v2.00 then WIMR devices. Sacin was highest 
using the ndd v2.00, followed by the WIMR and EM devices. LCI on the other 
hand did not follow a similar pattern to Scond or Sacin measurements in either 
group. The pattern of in vivo differences in Scond, Sacin and LCI across the 
devices did not follow the same pattern of differences seen with in vitro and in 
vivo FRC measurements.  
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2.4.2 Comparison to other studies 
The Consensus recommendations based on expert opinion stated that 95% of 
the in vitro FRC measurements should be within 5% of the target volume (4). 
WIMR and EM devices fulfilled this criterion, however the ndd v2.00 device 
did not achieve 5% accuracy for any measurements. When measurements 
were re-analysed using ndd v2.01, 36% fulfilled this criterion. Both 
commercial devices were reported previously to be highly accurate in 
measuring FRC using a physical lung model (14). This lung model was water-
based and incorporated BTPS (body temperature, ambient pressure, 
saturated) correction whereas ours did not. Despite this, our results showed 
the same pattern of over/underestimation in vitro and in vivo. This is 
consistent with their in vivo results in 10 healthy adults, where EM 
overestimated FRCpleth by 14% and ndd underestimated by 23% (14). A 
recent study with healthy control and cystic fibrosis subjects also reported the 
same pattern, i.e. higher FRC measurements using the EM device compared 
to the ndd device (15). Other in vitro and in vitro paediatric studies exist (9, 
11), however they used different tracer gases, SF6 and helium, which limits 
comparison.  
Only one other study has compared LCI between the EM and ndd devices in 
both children and young adults using healthy controls and subjects with cystic 
fibrosis (15). LCI measured using the EM device was significantly higher than 
the ndd in all age groups and in both health and disease (15). In contrast, our 
results showed LCI was similar between both commercial devices in both the 
healthy and asthma subjects. Poncin et al as expected, also showed LCI to be 
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higher in disease compared to healthy controls, regardless of the device. In 
our study, LCI was higher in those with asthma compared to healthy control 
subjects but only using the EM and not the ndd device. Different ndd software 
versions, differences in FRC measurements and smaller numbers in our study 
may explain these observed differences. 
Other paediatric (9) and adult (8) studies have compared LCI using different 
wash out devices and tracer gases. Differences in LCI were observed in the 
paediatric study, which compared measurements between the mass 
spectrometer and EM devices (9). The mass spectrometer device used SF6 as 
the tracer gas, whereas the EM device used 02. In this study, the EM device 
also measured LCI higher compared to the mass spectrometer, in both 
healthy control and cystic fibrosis paediatric subjects (9). This was thought to 
be related to the greater number of breaths required to complete the washout 
on the EM compared to the mass spectrometer device (9). The number of 
breaths required to complete the washout on the EM device also increased 
proportionally to the volume of trapped gas, which makes sense because the 
EM device also measured FRC higher than the mass spectrometer. 
Unsurprisingly, LCI was significantly higher in those with cystic fibrosis 
compared to healthy controls, regardless of the device (9). On the other hand, 
the study in healthy adults using small numbers showed comparable LCI 
values between two other devices, the mass spectrometer and an ultrasonic 
flow sensor prototype system, despite statistically but not clinically 
significantly differences in FRC (8). The use of different devices and tracer 
gases in these studies limits comparisons to ours. 
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To our knowledge there have been no other studies comparing Scond and 
Sacin between different MBNW devices. Furthermore, there is no gold 
standard MBNW device to compare our Scond and Sacin results to. 
2.4.3 Impact of N2 estimation method and Scond and Sacin calculation 
method  
Differences in FRC across the three devices are more likely attributed to 
device and software variations. This includes the method used to calculate N2 
concentration. The WIMR device measures N2 directly, while the EM device 
uses Dalton’s law to compute N2 by simple subtraction of other constituent 
gases in the expired air; these two methods were found to be similar. In 
contrast, the ndd v2.00 device uses the concept of a prototype expirogram, 
derived from the shape of the molar mass versus expired volume curve in the 
early breaths of the washout. The expired N2 volume for each breath is then 
determined by scaling the prototype expirogram to match the end-expiratory 
N2 concentration for that breath. Potential inaccuracies could occur if 
expirogram shape changed greatly during the course of the washout, as 
typically observed in more severe obstructive airways disease. Ndd v2.01, 
however, used a combination of molar mass measurements as well as 
Dalton’s law to compute N2, on a point-by-point basis for the entire 
expirogram. This could partly explain the improved accuracy of ndd v2.01 and 
reduced FRC discrepancy between the new software and the WIMR and EM 
devices.  
VH indices rely on FRC accuracy; therefore variation in FRC is likely to impact 
these. Differences in LCI between devices would be expected to mirror the 
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differences seen in FRC measurements because LCI is a volume ratio 
determined by the number of lung turnovers (TO = CEV/FRC). An increase in 
FRC should therefore result in an increase in LCI, which was observed in our 
study with the EM device and other studies (9, 15). Additionally, the same 
trend may be expected with Scond, as Scond incorporates normalised phase 
III slopes (therefore N2 concentration) and lung turnovers. However, our 
results have not shown Scond differences to follow the same pattern as FRC. 
The ndd device underestimated FRC, yet Scond measurements were 
between that of the EM and WIMR devices, in both healthy and asthmatic 
subjects. Sacin on the other hand may not necessarily be affected by FRC, as 
it takes into account the first breath of the wash out. On the other hand, the 
calculation of Sacin also incorporates Scond therefore may be affected by 
variations in FRC, however there is no evidence to confirm or refute this.  In 
our study, the pattern of differences in Sacin did not follow the same trend 
seen in FRC measurements and in fact was in the opposite direction.  
We can speculate that the variability in VH indices between the devices may 
be due to different methods of N2 estimation, as each device and their 
respective software calculate Scond and Sacin using different methods. 
However, this is unlikely to be the only explanation for the observed inter-
device differences because unpublished data from our lab has demonstrated 
comparable Scond and Sacin results using the three different calculation 
methods employed by each of the devices in this study. This analysis was 
however only performed on measurements from one device (EM) in 39 
healthy subjects and the effect disease may have is unknown. Other possible 
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factors contributing to variability in Scond and Sacin include analysis of the 
expirogram and phase III slope. The WIMR and EM devices allow manual 
adjustment of the phase III slopes whereas the ndd device does not. One 
person performed all the analyses and minimal slope adjustments were made, 
only as deemed necessary according to the consensus statement (4). A 
previous study in children with cystic fibrosis and healthy controls also 
showed automated Scond analysis and calculation was comparable to 
manual analysis, using MBNW measurements from one device (EM) (22). 
Therefore the contribution from variations in phase III slope analysis may be 
negligible however this needs further evaluation using all the devices.  
2.4.4 Impact of other software changes 
The other major change in ndd v.2.01 involved modifications to the estimation 
of delay between the flow and respective gas measurement points, which are 
more robust to variation in breathing patterns particularly very brief pauses in 
flow (personal communication with the manufacturer); differences in delay 
time potentially have a large effect on FRC calculations (23, 24).  
Newer software versions are currently available at the time of writing 
(v.2.2.0.15 onwards), which involve major changes to the user interface, but 
fundamentally employ the same indirect N2-based FRC calculation and delay 
estimation method. Thus our results have significant implications on the 
reanalysis of old data and are relevant to ndd v2.01 as well as any newer 
versions. Furthermore, they illustrate the importance of analysis methods and 
any pre-processing algorithms that may be used, and the need for software 
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transparency (25). They also highlight the importance of ongoing validation, 
and that standardisation efforts are gradually working.   
It should be noted this study was unable to confirm whether collecting data 
using ndd v2.01 would have further improved FRC accuracy for the ndd 
device. A large proportion of in vivo tests re-analysed using the new software 
failed to meet end of test criteria, possibly due to underestimation of N2 in the 
old software. Due to this technical limitation further analysis of the VH indices 
using the updated ndd software was not performed. One could speculate that 
if acceptable end-tidal N2 concentration had been met, in vitro FRC may have 
been slightly closer to the true lung volume and in vivo FRC closer to FRCpleth. 
Furthermore, if in vivo FRC was closer to FRCpleth then VH indices using the 
ndd device may have been more comparable to the other devices.  
2.4.5 Impact of patient factors 
Other factors that may affect FRC and VH measurements include the effect of 
breathing patterns during the washout. Different mouthpieces, resistances, 
the nature of the real-time displays of volume and patient breathing 
incentives, even different open bypass systems delivering oxygen (15) may 
have affected breathing patterns. However, dead space correction was 
applied in each device and the same 1L-breathing protocol was used. More 
importantly, the direction of over/underestimation was preserved regardless of 
in vitro and in vivo FRC comparisons, i.e. independent of BTPS correction, 
breathing pattern and presence of CO2. Thus it is unlikely that patient factors 
contributed significantly to the differences between devices. In addition, the 
differences between MBNW FRC and FRCpleth on each device were of similar 
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magnitude between healthy controls and subjects with asthma with well-
preserved spirometry. It is unknown whether the same results would hold in 
subjects with more airway obstruction, or other patient groups such as COPD.  
It is difficult to know whether patient factors contributed to differences in VH 
indices because FRC was not comparable between all three devices. Median 
LCI values were higher in the healthy compared to asthmatic subjects using 
the WIMR and ndd devices. This does not make physiological sense and is 
not consistent with findings from other studies (9, 15). In addition, the 
inconsistencies in the pattern of differences in Scond and Sacin in healthy and 
asthmatic subjects between devices are odd. The small numbers in our study 
limits any definitive conclusions that can be drawn regarding the impact of 
patient factors in relation to disease.  
2.4.6 Limitations 
Our study had a number of limitations: Firstly, we compared differences 
between devices both in vitro and in vivo only using FRC, but only in vivo 
comparisons between Scond, Sacin and LCI were performed. There are 
however no known lung models to evaluate these other indices. Nevertheless, 
high quality FRC measurement is necessary for evaluation of these indices. 
Secondly, between-session variability for FRC has not been defined therefore 
it is not known whether differences between in vivo measurements are within 
the limits of normal test variability. Thirdly, the applicability of our results to the 
paediatric population is unknown. However the simplistic design of the lung 
model could be easily adapted to a smaller syringe. Also, we only evaluated 
the standardised 1-L breathing protocol (26) hence the effect of the free 
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breathing protocol used by other groups (21) and especially in infants and 
children is unknown. Furthermore, the syringe is an ATPD rather than BTPS 
model, which is less representative of actual physiological situation but more 
practical for routine laboratory use. Despite this, the same pattern of accuracy 
was seen in vitro and in vivo suggesting that incorporation of BTPS correction 
has a minimal effect on the relative errors reported. Finally, as discussed 
above we did not evaluate the accuracy of data collected using the ndd v2.01, 
which is scope for further work.  
2.5 Conclusion 
We have shown differences in the measurements of FRC between three 
MBNW devices in a physical syringe model of the lung. The syringe lung 
model used in this study was simple, portable, and relatively easy to produce 
compared to that used in other studies (6, 27, 28). It would allow a simple and 
practical way to calibrate or check the MBNW setup since it tests the 
combined accuracy of volume and N2 concentration measurement during a 
more realistic expirogram and the correct alignment of these signals. The use 
of such a syringe model may be beneficial for comparison between devices 
and laboratories, and for quality assurance monitoring. FRC differences were 
also reflected in vivo in healthy and asthmatic subjects, in relation to 
plethysmographic FRC. While further work is required to improve accuracy, 
the in vivo differences observed are small and likely not clinically significant. 
Differences in VH indices were observed across the devices in healthy and 
asthmatic subjects. The differences were not consistent between the indices 
across the devices and the contribution from differences in FRC measurement 
  159 
cannot be ignored. Differences are likely to reflect the method of calculating 
N2 concentration and other software and phase III analysis factors. How these 
FRC errors translate to accuracy of other indices has been explored for LCI in 
other studies (9, 15), however ours is the first study to explore Scond and 
Sacin. Further studies to include systematic phase III slope analysis with 
larger numbers and different disease states are required to explore the 
variability in these indices. Nevertheless, our results show that the state of the 
art is closer towards better comparability and standardisation for FRC 
accuracy across existing MBNW devices.  
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Chapter 3 
3 Lung elastic recoil and ventilation heterogeneity of 
diffusion-dependent airways in older people with 
asthma and fixed airflow obstruction. 
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3.1 Introduction 
The small airways are the site of airflow obstruction (1, 2) and are abnormal in 
asthma (3). As discussed in previous chapters, one measurement of small 
airway function is Sacin, derived from the multiple breath nitrogen washout 
(MBNW) test (4-6), and reflects ventilation heterogeneity (VH) in diffusion-
dependent airways. Other measures derived from the MBNW test include 
Scond, which reflects VH in the convective-dependent airways and lung 
clearance index (LCI), which reflects overall VH.  
In asthma Sacin is correlated with airway hyper-responsiveness (7), asthma 
control (8) and improves with ultrafine inhaled corticosteroid treatment (9). 
Theoretically, heterogeneity of diffusion-dependent ventilation can arise due to 
the heterogeneity of cross-sectional areas of airway openings in terminal 
airways and the acini (10). Therefore, Sacin may be affected by structural 
changes in those airways. The elastic properties of the lung may also affect 
Sacin, as the phase III slope, a marker of VH derived from the single breath 
nitrogen washout, correlates with lung compliance in explanted lungs of 
smokers and in healthy lungs (11). Scond, on the other hand, is thought to be 
affected by the mechanical properties of the conducting airways, that is the 
lung units larger than the acini (12). Therefore Scond may not be affected by 
structural changes in acini.  
Reduced lung elastic recoil makes a large contribution to airflow obstruction in 
asthma (13, 14), particularly in older individuals with long-standing disease 
who may develop fixed airflow obstruction (FAO) (15-17). FAO typifies chronic 
obstructive pulmonary disease, but can occur in people that have never 
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smoked, despite adequate treatment (14, 15), and is associated with poor 
outcomes (16, 18).  
Since loss of elastic recoil is associated with age (19, 20) and asthma (21, 22) 
and Sacin is more abnormal in older asthmatics compared to younger (7), we 
hypothesised that the increase in Sacin in older people with asthma was due 
to loss of lung elastic recoil. Therefore the primary aim of this study was to 
examine the relationships between Sacin and lung elastic recoil pressure and 
compliance. Secondary aims of this study were to (i) examine the relationship 
between other MBNW indices, Scond and LCI, and the lungs elastic 
properties and (ii) examine the relationship between MBNW indices and other 
clinical parameters: standard lung function, age of asthma onset and 
symptoms. 
3.2 Methods 
3.2.1 Subjects 
Adult subjects were recruited from a volunteer database and from referrals by 
local respiratory physicians. Subjects were eligible if they were aged 40 years 
or older, as abnormalities in elastic recoil are increasingly common from 
middle age onwards (13). All subjects were non-smokers, had a physician-
confirmed diagnosis of asthma based on typical symptoms, previous evidence 
of variable airflow obstruction and a history of asthma medication use. 
Exclusion criteria were a past smoking history of ≥5 pack-years, an asthma 
exacerbation within the past 8 weeks, the presence of significant cardiac 
disease or respiratory disease other than asthma. Written informed consent 
was obtained from all subjects.  Ethics approval was granted by the Sydney 
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Local Health District Human Research Ethics Committee 
(#HRECT/14/CRGH/75).  
3.2.2 Study design and lung function measurements 
Eligible subjects were treated with maximal dose inhaled corticosteroid/long-
acting β-agonist (ICS/LABA) using Fluticasone/Eformoterol 250μg/10μg 
metered dose inhaler via a holding chamber, two puffs twice daily for two 
months.  The rationale was to optimize asthma control and to ensure that any 
abnormalities that were related to steroid-responsive inflammation would be 
eliminated by this standardised asthma treatment (23). If subjects developed 
an exacerbation during the study period, lung function testing was delayed for 
a minimum period of at least one month after clinical improvement. ICS/LABA 
and short acting beta-agonist medications were withheld for at least 24hr and 
6hr prior to testing. 
Subjects completed the 5-item Asthma Control Questionnaire (ACQ-5) (24) 
and performed standard lung function (spirometry, body plethysmography and 
diffusing capacity) (25-27) and MBNW (Exhalyzer® D, ECO MEDICS AG, 
Duernten, Switzerland) as described in the previous chapter, both during 
enrolment and after two months of treatment. Post-bronchodilator spirometry 
was performed after one month of treatment to assess for the presence of 
FAO. FAO was defined as a spirometric ratio less than the lower limit of 
normal (28) and/or no significant bronchodilator response post 400 mcg of 
inhaled Salbutamol (29). At the end of the two-month treatment period in a 
single session following standard lung function and MBNW measurements, 
the lungs elastic properties were assessed. MBNW indices (Sacin, Scond and 
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LCI) were derived as previously described (30). Predicted values were 
reported according to published reference equations (19, 28, 30-32). 
3.2.2.1 Measurement of the lungs elastic properties 
The elastic properties of the lung were measured, as previously described 
using simultaneous measurements of gas flow (volume) and intra-
oesophageal pressure (33, 34). Gas flow at the mouth was measured with a 
differential pressure pneumotachograph. Change in lung volume was obtained 
by integration of the instantaneous flow signal (33). Intra-oesophageal 
pressure was measured with a ± 75 cmH20 transducer (DC030NDC4) 
connected via a catheter with a distal 10 cm balloon (Marquat Genie 
Biomedical). The phase difference between pneumotachograph and the 
balloon catheter was measured at 0.2 seconds using a rapid syringe push in a 
physical model. Volume and pressure calibration were performed prior to 
testing each subject. A 3-L syringe was used to calibrate volume and a water-
manometer was used to calibrate pressure. 
The balloon catheter was inserted via the nose into the lower third of the 
oesophagus (figure 3.1), after applying topical lignocaine gel and spray to the 
nose and throat. Catheter placement was determined using a standard 
equation (33) and once in position was secured to the nose using surgical 
tape. The balloon was then inflated with 0.5 ml of air. Immediately prior to 
each measurement both the oesophageal pressure transducer and mouth 
pressure transducer were zeroed to atmospheric pressure and the flow 
transducer was zeroed to conditions of no airflow. During the measurement, 
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trans-pulmonary pressure (Pst(L)) was determined as the difference between 
mouth and balloon pressure and shown in real time on a monitor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 
Adapted from Benditt et al (35). 
Schematic of equipment required for recording pressure signals from an 
oesophageal balloon catheter. 
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Measurements were performed in duplicate in the seated position, using a 
nose clip and mouthpiece (SureGard L/F Filter (purple) RJVKB2). Stable tidal 
breathing was established then subjects performed three slow breaths to TLC. 
Subjects then inhaled again to TLC after which the airway opening was 
occluded (figure 3.2) Subjects were instructed to relax down to FRC against 
the closed mouthpiece. During the passive deflation to FRC, 2-3 second 
interruptions were performed to allow recording of stable pressure at each 
volume (figure 3.3). Static Pst(L) and lung volume were measured during this 
interrupted deflation from TLC (33, 36). At least five deflation manoeuvres 
were obtained during one measurement. The measurement ended with 
another period of stable tidal breathing and three slow breaths to TLC.  
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Figure 3.2 
Breathing protocol for measurement of the lungs elastic properties. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 
Volume and pressure recording during deflation manoeuvre (measured from 
total lung capacity (TLC) to functional residual capacity (FRC)). 
 !
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Pressure-volume (P-V) curves were constructed from all acceptable points (at 
least 30-40 points) obtained during all acceptable deflation manoeuvres. 
Points obtained near TLC were also used to avoid bias by a disproportionate 
number of values in the lower volume range (33). Using the equation of 
Colebatch (33, 37), the following  exponential function was fitted to the P-V 
curve data points using a least-squares method; V = A – Be-KP, where 
V=volume as %TLC; P=transpulmonary pressure; and A, B and K are 
constants (figure 3.4). “A” is the horizontal asymptote of the Y-axis, “B” is the 
distance on the Y-axis between “A” and the extrapolated Y-axis intercept of 
the curve. Therefore, “B/A” is an index that describes lung compliance with 
low values indicating leftward shift of the PV curve or reduction in recoil 
pressure. “K” is a shape factor that is an index of elastic recoil and is directly 
related to alveolar size and lung distensibility (38) with a greater curvature 
(higher K) indicating increased lung compliance. Both a reduced B/A and 
increased K are indicative of a loss of lung elastic recoil (i.e.: increased lung 
compliance). “B/A” and “K” are independent of lung size and their predicted 
values were calculated using equations of Colebatch et al (19). 
The exponential function was fitted to the P-V curves between 50 to 100% of 
TLC, with the TLC being referenced to the value obtained by body 
plethysmography. A lower limit of 50% was defined by Colebatch et al 
because the constants B/A and K are influenced by the range of data over 
which the exponential is fitted (33). Explicitly defining a lower limit for the 
exponential fit of the P-V curve also improved reproducibility of P-V curve 
analysis (33).  
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Figure 3.4 
The pressure-volume (P-V) curve fitted with the Colebatch equation: V = A – 
Be-KP (33). V: volume as %TLC; P: transpulmonary pressure; A, B and K are 
constants. A: horizontal asymptote of the Y-axis, B: distance on the Y-axis 
between “A” and the extrapolated Y-axis intercept of the curve, K: shape 
factor of the exponential analysis of the P-V curve and reflects lung 
compliance. 
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3.2.3 Statistical analyses 
Data are presented as means ±SD for normally distributed data and as 
medians (interquartile range IQR) for non-normally distributed data. 
Spirometry, lung volumes, diffusing capacity, MBNW and lung elastic recoil 
data are expressed as raw values, z-scores and/or percent predicted. 
Differences between spirometry and MBNW during enrolment and at the end 
of the study period were compared using paired t-tests. Correlations between 
pre-bronchodilator MBNW and pressure-volume indices were assessed using 
Spearman’s rank test. P<0.05 was considered significant.  
3.3 Results 
A total of 21 subjects were enrolled and two were excluded because they 
were unable to complete the lung function tests. Elastic recoil measurements 
were performed in 18 of the remaining 19 subjects (11 male). Anthropometric 
and lung function data are presented in Table 3.1. All subjects were taking an 
ICS with or without LABA; five subjects were also taking a long-acting 
muscarinic antagonist. One subject was on long-term low dose oral 
corticosteroids (Prednisone dose 5 mg) for rheumatoid arthritis.  
Subjects were older, with a mean ±SD age of 63 ±9 years and long duration of 
asthma (38.2 ±22 years). Five subjects were ex-smokers (pack year history 
2.2 ±2.5 years). Subjects had mildly uncontrolled asthma symptoms (ACQ-5: 
1.03 ±0.92). Post-bronchodilator (BD) spirometry after one month of treatment 
showed moderate FAO: mean ±SD z-score forced expiratory volume in 1 
second (FEV1) -2.1 ±0.7, forced vital capacity (FVC) -0.6 ±1.0 and FEV1/FVC -
2.5 ±0.9. After two months, baseline spirometry had not changed (pre-BD 
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FEV1 -2.1 ±0.7, FVC -1.0 ±1.1 and FEV1/FVC -2.4 ±0.9; paired t-test: p=0.3, 
p=0.3 and p=0.6 for FEV1, FVC and FEV1/FVC respectively); there was 
minimal gas trapping (residual volume z-score 1.88 ±1.6) and mildly reduced 
DLCO (% predicted 78±15%). All MBNW indices were higher than normal and 
also did not change after two months of treatment: median (IQR) z-score: 
Scond 3.3 (3.1-4.2) L-1, Sacin 2.8 (2.1-3.8) L-1 and LCI 4.6 (2.3-7.8); paired t-
test: p=0.2, p=0.4 and p=1.0 for Scond, Sacin and LCI respectively).   
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Table 3.1 Demographics and lung function results. 
Number of subjects, n = 19 
(male = 11) 
Raw values Z-score or % predicted 
Age, years  62.8 ±9.4 - 
Age asthma onset, years 
(median (IQR)) 
19 (2-50) - 
Asthma duration, years  38.2 ±22 - 
Height, m  1.69 ±0.10 - 
BMI, kg.m-2 (median (IQR)) 27.6 (25.0-30.8) - 
ACQ-5  1.03 ±0.92 - 
Pre FEV1, L  1.88 ± 0.68 -2.3 ±0.7 
Pre FVC, L  3.30 ± 1.06 -0.9 ±0.9 
Pre FEV1/FVC ratio  0.57 ±0.09 -2.6 ±0.9 
Post FEV1, L  2.01 ± 0.72 -2.1 ±0.7 
Post FVC, L  3.46 ± 1.06 -0.6 ±1.0 
Post FEV1/FVC ratio  0.58 ±0.09 -2.5 ±0.9 
FRC, L  3.78 ± 1.00 1.04 ±1.1 
TLC, L  6.39 ± 1.54 0.55 ±1.0 
RV, L  2.96 ± 0.84 1.88 ±1.6 
RV/TLC ratio  0.47 ±0.09 1.3 ±1.2 
DLCO, ml/(min*mmHg) 19.9 ± 6.1 78 ±15% 
KCO, ml/(min*mmHg*L) 4.24 ± 0.6 92 ±16% 
VA, L  4.73 ± 1.43 82 ±18% 
Scond L-1 (median (IQR) 0.048 (0.042-0.073) 3.55 (2.88-4.125) 
Sacin L-1 (median (IQR)) 0.188 (0.124-0.230) 2.80 (2.08-3.83) 
LCI (median (IQR)) 9.6 (8.4-13.9) 3.10 (1.98-7.75) 
B/A ratio (median (IQR))  0.52 (0.44-0.77) -1.18 (-0.02- -1.65) 
K, cmH20-1 (median (IQR))  0.197 (0.131-0.267) 1.58 (-1.08-3.43) 
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Data presented as mean ± SD unless otherwise stated. BMI: body mass 
index; ACQ-5: Asthma Control Questionnaire-5; FEV1: forced expiratory 
volume in one second; FVC: forced vital capacity; FRC: functional residual 
capacity; TLC: total lung capacity; RV: residual volume; DLCO: diffusing 
capacity; KCO: carbon monoxide transfer-coefficient; VA: alveolar volume; 
Scond: ventilation heterogeneity in the convection-dependent airways; Sacin: 
ventilation heterogeneity in the diffusion-dependent airways; LCI: lung 
clearance index; B/A: index of lung compliance describing the position of the 
pressure-volume curve with respect to the pressure axis; K: shape factor of 
the exponential analysis of the pressure-volume curves.  
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Lung elastic recoil was lower than normal (B/A% z-score ≤-1.64) in 5/18 
subjects and compliance was higher than normal (K z-score ≥1.64) in 9/18 
subjects (figure 3.5). Elastic recoil pressure at functional residual capacity was 
low at 1.4 (0.8-3.6) cmH20.  
Increasing age was associated with lower lung elastic recoil (B/A%, rs=-0.52, 
p=0.02) and greater lung compliance (K, rs=0.50, p=0.04) but not with MBNW 
indices. Sacin and LCI were both negatively associated with lower lung elastic 
recoil, B/A% (rs=-0.53, p=0.03 and rs=-0.52, p=0.03, respectively) (table 3.2 
and figure 3.6). There were no associations between Scond and B/A% 
(rs=0.28, p=0.3) or between any MBNW indices and lung compliance, K 
(rs=0.18, p=0.5; rs=0.002, p=1.0 and rs=0.33, p=0.2 for correlations between K 
and Sacin, Scond and LCI, respectively).  
Univariate correlations between MBNW indices and other anthropometric 
data, spirometry and asthma symptoms were also assessed and results are 
shown in table 3.2. MBNW indices were not related to asthma duration, 
gender, height, BMI, FEV1 or FVC. Only increased LCI was associated with 
older age of asthma onset (rs=0.56, p=0.01) and lower FEV1/FVC (rs=-0.47, 
p=0.04). An increase in all VH indices was associated with worse symptom 
control (ACQ-5) (rs=0.76, p<0.0001 for Scond; rs =0.54, p=0.02 for Sacin; rs 
=0.61, p=0.006 for LCI). 
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Figure 3.5 
Pressure-volume curve in asthma subjects (coloured lines) and healthy 
controls (grey lines). Healthy control curves were adapted from Turner et al 
(39) using data from non-smokers >40 years old. 
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Table 3.2 Univariate correlations between clinical variables, lung elastic recoil and 
MBNW after two months of high dose inhaled corticosteroid/long-acting beta-agonist 
treatment.  
Scond: ventilation heterogeneity in the convection-dependent airways; Sacin: 
ventilation heterogeneity in the diffusion-dependent airways; LCI: lung 
clearance index; BMI: body mass index; ACQ-5: Asthma Control 
Questionnaire-5; FEV1: forced expiratory volume in 1 second; FVC: forced 
vital capacity; B/A: index of lung compliance describing the position of the 
pressure-volume curve with respect to the pressure axis; K: shape factor of 
the exponential analysis of the pressure-volume curves. rs: Spearman 
correlation coefficient; p: p-value. Statistically significant p-value <0.05.   
 SCOND, L-1 SACIN, L-1 LCI 
 rs p rs p rs p 
Age, years 0.03 0.9 0.21 0.4 0.45 0.05 
Age of asthma onset, years 0.29 0.2 0.40 0.1 0.56 0.01 
Asthma duration, years -0.26 0.3 -0.27 0.3 -0.35 0.1 
Gender -0.22 0.4 -0.10 0.7 -0.04 0.9 
Height, m -0.12 0.6 -0.14 0.6 -0.06 0.8 
BMI, kg.m-2 -0.03 0.9 -0.08 0.8 -0.25 0.3 
ACQ-5 0.76 <0.0001 0.54 0.02 0.61 0.006 
FEV1, L -0.36 0.1 -0.40 0.09 -0.45 0.05 
FVC, L -0.18 0.5 -0.30 0.2 -0.17 0.5 
FEV1/FVC ratio -0.18 0.5 -0.15 0.5 -0.47 0.04 
B/A ratio -0.28 0.3 -0.53 0.03 -0.52 0.03 
K, cmH20-1 0.002 1.0 0.18 0.5 0.33 0.2 
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Figure 3.6 
Univariate correlations between MBNW indices (Scond, Sacin and LCI) and 
lung elastic recoil (B/A%). 
Scond: ventilation heterogeneity in the convection-dependent airways; Sacin: 
ventilation heterogeneity in the diffusion-dependent airways; LCI: lung 
clearance index; B/A: index of lung compliance describing the position of the 
pressure-volume curve with respect to the pressure axis. rs: Spearman 
correlation coefficient; p: p-value.  
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3.4 Discussion 
This study shows that in non-smoking asthmatics over the age of 40 years 
with FAO, uneven ventilation distribution in diffusion-dependent airways 
(Sacin) was associated with loss of lung elastic recoil but not with increased 
lung compliance. Conversely, convection-dependent (Scond) ventilation 
distribution was unrelated to either lung elastic recoil or compliance. These 
findings suggest the mechanical properties of the lung tissue are an important 
determinant of peripheral airway function in older people with asthma and 
FAO. Furthermore, despite maximal ICS/LABA treatment, abnormal 
spirometry and ventilation distribution or increased heterogeneity (VH) did not 
change over a two-month period, suggesting a steroid-unresponsive process. 
Moreover abnormal or increased VH in the small airways was associated with 
poor symptom control, implying that small airway function plays a role in the 
clinical manifestation and expression of symptoms in asthma with FAO. 
B/A represents the position of the pressure-volume relationship, but not the 
shape of the curve (K). B/A and K however, were weakly correlated in our 
study (r=-0.53, p=0.03). There are no data on the functional, clinical or 
pathological correlates of B/A and therefore, it is difficult to be certain what the 
relationship between B/A and Sacin is due to. We speculate that the loss of 
lung recoil could alter diffusion-dependent ventilation and make it more 
heterogeneous if, as computational modeling suggests, Sacin is determined 
by heterogeneity in the cross-sectional areas of the intra-acinar airway 
openings (10). Elastic recoil arises from the elastic forces generated by alveoli 
and intra-acinar airways. Colebatch et al suggested that a loss of lung elastic 
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recoil may be manifested as a left-ward shift of the P-V curve (i.e. reduced 
B/A%) (19) or an increase in K or both (33). If reduced lung elastic recoil due 
to asthma were heterogeneously distributed throughout the lungs, then this 
could increase acinar VH, if it resulted in alveolar and intra-acinar airway 
diameters being more variable. Both would increase the variability in specific 
ventilation, hence VH overall. Conversely, a global loss of elastic recoil could 
also increase overall VH, either by amplifying normal airway structural 
asymmetry and/or by bringing some airways towards closure, thus changing 
the distribution of airway closure.  
The loss of lung elastic recoil in asthma is likely due to changes in the 
structure of the lung tissue (14, 40, 41). Gelb et al reported a heterogeneous 
distribution of alveolar sizes in the post mortem histologic examination of 
lungs of asthmatic non-smokers who had died of non-asthma related illness 
(14, 40).  Microscopic examination confirmed mild, diffuse centri-lobular 
emphysema-like changes, predominantly in the upper to middle lobes, as well 
as areas of normal lung parenchyma (14, 40). However, the nature of the 
ultra-structural changes to the lung parenchyma, i.e. potential changes in 
elastin, collagen and proteoglycan structure, that underlie the emphysema-like 
changes are unknown. The variability in the histo-pathological abnormalities 
within an asthmatic lung make it likely that the distribution of lung elastic recoil 
pressures will also be distributed heterogeneously, thereby increasing VH. 
Age-related structural changes such as enlargement of the airspaces, alveolar 
wall thickening and reduced number of peripheral airways (42) may also be 
distributed unevenly, further contributing to increased VH.  
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Loss of lung elastic recoil (19), which is known to occur with age, may explain 
the resultant increase in closing volume and residual volume/total lung 
capacity (RV/TLC) that occurs with increasing age (19). There was a 
relationship between age and indices of lung elastic recoil in these subjects 
and this relationship is discussed in detail in Chapter 5.  
K was unrelated to any VH indices in this study. K is an index of alveolar 
distensibility and is related to alveolar size (38, 43), which is typically 
increased in the presence of emphysema in smokers (44). K has been 
reported to be increased in asthmatic non-smokers, but to a lesser extent 
compared to that seen in emphysema (43). This is consistent with Gelb’s 
findings discussed above, where there may be microscopic emphysema-like 
changes, but not macroscopic emphysema (14, 40). Furthermore, B/A%, is 
not associated with the degree of emphysema in smokers (44). The lack of 
any relationships between K and VH indices suggest that alveolar 
distensibility does not affect ventilation distribution in this cohort. The lack of a 
relationship between K or B/A% and Scond might be due to a greater 
influence of airway remodelling (rather than lung parenchymal changes) on 
Scond.  
All VH indices (Scond, Sacin and LCI) in our study were increased after 
adjustment for age, gender and height, given the high mean Z-scores for 
those indices. Age is the strongest predictor of VH indices in healthy subjects 
(12, 30, 45). However, none of the VH indices were related to age, either as 
unadjusted raw values or as Z scores. The narrow age range in our cohort 
may have influenced this (they are mostly between the ages of 55-75 years). 
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Therefore, Sacin increases in older asthmatics due to reasons other than 
simply ageing in the presence of longstanding asthma. We found that LCI was 
greater, if asthma symptoms first appeared when older.  Therefore, the 
pathological changes that occur when asthma starts may be different with 
increased age e.g. different inflammatory and remodeling processes, or that 
the process are the same but the functional consequences differ due to the 
lung being older. Both age of onset of asthma, and VH indices have important 
clinical associations. Increased VH indices correlated with worse symptom 
control (ACQ-5), in keeping with results from previous asthma studies of 
younger patients with less airflow obstruction (8). Furthermore, adult-onset 
asthma is associated with decreased lung function and frequent 
exacerbations (46).  
Limitations to our study include the use of raw values rather than predicted 
values for analyses of MBNW indices. Raw values were used because when 
data was analysed using two currently available predictive equations (30, 45) 
(data not shown), the predicted values from these equations were markedly 
different. One of the predictive equations (30) used the same MBNW device 
as our study, however the upper age limit of subjects in this study was only 71 
years and they also used a multiplying factor of the tidal volume to calculate 
their MBNW indices. The other predictive equation (45), although studied 
older subjects >80 years used a different MBNW device (bag-in box). 
Statistical analysis was performed using pre-bronchodilator rather than post-
bronchodilator measurements. For practical reasons and due to the invasive 
nature of the test, lung elastic recoil measurements were only performed pre-
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bronchodilator. Furthermore, the effect of bronchodilators on lung elastic recoil 
is controversial. Lung elastic recoil does not change post-bronchodilator 
therapy in stable asthma (20) however may improve post-bronchodilator 
during an asthma exacerbation (47, 48) and once asthma control has been 
optimized and improved (14). The effect of bronchodilators on VH in asthma 
with FAO is not known, however in COPD there appears to be no effect (49). 
The effect of medications prior to study enrolment were not accounted for 
however subjects were treated with a standardized ICS/LABA dose for a two-
month period prior to lung elastic recoil measurements. The study treatment 
also appeared to have no effect on lung function and symptoms, as there 
were no significant differences in spirometry or MBNW indices and ACQ-5 
scores over the two-month study period.  
In summary, we found that a loss of elastic recoil, but not lung compliance, 
was associated with increased VH in diffusion-dependent airways in older 
asthmatics with FAO. The mechanisms causing loss of lung elastic recoil in 
asthma needs further investigation as it may provide insight into causes of 
small airway dysfunction in asthmatics who develop FAO despite negligible 
smoking history. The role of inflammation needs further exploration, as high 
dose ICS/LABA did not change lung function over a two-month period, 
suggesting steroid unresponsiveness. Whether immunosenescene, asthma or 
both contribute to the underlying cellular mechanisms remains elusive. This 
may represent a potential pathway by which the asthma-COPD overlap 
phenotype is manifest and therefore highlights the need for development of 
novel treatments that target loss of elastic recoil in asthma. 
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Chapter 4 
4 The Contributions of Small Airway Obstruction and 
Reduced Lung Elastic Recoil to Airflow Obstruction 
in Asthma 
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4.1 Introduction 
Asthma is characterised by variable airflow obstruction that occurs 
intermittently and in response to inhaled stimuli. However, airflow obstruction 
may persist despite bronchodilator inhalation or optimal therapy with inhaled 
corticosteroids and long-acting bronchodilators, i.e. it may become fixed and 
irreversible (1). Fixed airflow obstruction (FAO) is associated with 
longstanding disease duration (2), persistent airway hyper-responsiveness 
AHR (3), persistent eosinophilic (3) or neutrophilic airway inflammation (4) and 
mucous hyper-secretion (5). The underlying mechanisms of FAO however, 
are poorly understood.  
FAO in asthma is most commonly attributed to airway remodelling.  Airway 
remodelling refers to alteration of the structural organisation of the airway wall, 
which includes the entire wall from the mucosa through to the adventitia. This 
results in an increase in airway wall thickness and altered airway mechanical 
properties. Hence, airway remodelling is the most well known explanation for 
impaired spirometry in asthma. However, there is strong evidence that in 
addition to airway remodelling, mechanical and structural changes to the lung 
parenchyma (6, 7), a type of ‘lung remodelling’, contributes to FAO in asthma, 
particularly in older subjects.  
The elastic recoil of the lung provides outward recoil to the airways and 
alveolar driving pressure during exhalation. Therefore, any processes that 
reduce lung elastic recoil pressure will also reduce airway calibre at any given 
lung volume i.e. increase airway resistance (8, 9) and increase airway closure. 
Consequently reduced lung elastic recoil will have the same effects on 
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spirometry as airway remodelling. Reduced lung elastic recoil in asthmatics 
has been described repeatedly (8-12) however the underlying cause is 
unknown.  
Analysis of lung pressure-volume (P-V) curves by mathematical curve fitting 
(13) and construction of maximal flow static recoil (MFSR) curves (14) 
produces indices of the mechanical properties of the lung and airways, 
respectively. Indices derived from the MFSR curves represent changes in 
peripheral airway calibre (conductance) and increased collapsibility of the 
airways during forced expiratory flow (14). Determining whether the lungs 
elastic or intrinsic airway properties contribute to expiratory flow limitation can 
be assessed using these methods.  
Therefore, the aim of this study was to determine the contributions of lung 
elastic recoil and peripheral airway mechanics, to the impairment of lung 
function measured by spirometry (FEV1/FVC ratio) and by forced oscillatory 
impedance, in non-smoking older adults with asthma. We hypothesised that 
reduced lung elastic recoil and abnormal airway mechanics contribute 
independently to airflow obstruction.   
4.2 Methods 
4.2.1 Subjects 
Adult subjects were recruited from a volunteer database and from referrals by 
local respiratory physicians. Subjects were eligible if they were aged 40 years 
or older, as abnormalities in elastic recoil are increasingly common from 
middle age onwards (12). All subjects had a physician-confirmed diagnosis of 
asthma based on typical symptoms, previous evidence of variable airflow 
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obstruction and a history of asthma medication use. Exclusion criteria were a 
past smoking history of ≥5 pack-years, an asthma exacerbation within the 
past 8 weeks, the presence of cardiac disease or respiratory disease other 
than asthma. Written informed consent was obtained from all subjects.  Ethics 
approval was granted by the Sydney Local Health District Human Research 
Ethics Committee (#HRECT/14/CRGH/75).  
4.2.2 Study design 
Eligible subjects were treated with maximal dose inhaled corticosteroid/long-
acting β-agonist (ICS/LABA) using Fluticasone/Eformoterol 250μg/10μg 
metered dose inhaler via a holding chamber, two puffs twice daily for two 
months.  The rationale was to ensure that any abnormalities that were related 
to steroid-responsive inflammation would be eliminated by this standardised 
treatment (15). Subjects answered a standard clinical and symptom 
questionnaire, Asthma Control Questionnaire (ACQ-5) (16). After one month 
of ICS/LABA treatment, pre and post-bronchodilator spirometry was 
performed. After two months, in a single session subjects underwent 
measurements of standard lung function, skin prick tests, bronchial challenge, 
forced oscillation technique and lung elastic recoil. If subjects developed an 
exacerbation during the study period, lung function testing was delayed for a 
minimum period of one month after clinical improvement. ICS/LABA 
medication was withheld for at least 24 h and short acting β2-agonist 
medication for at least 6 h prior to testing.  
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4.2.3 Lung function tests 
4.2.3.1 Spirometry, lung volumes and diffusing capacity.  
Spirometry, lung volumes and diffusing capacity were performed using a 
Medisoft BodyBox 5500 (Medisoft Corp; Sorrines, Belgium) according to 
ATS/ERS guidelines (17-19). Predicted values were reported according to 
published reference equations (20-22). 
4.2.3.2 Skin Prick Test 
A skin prick test (23) to assess atopy was performed to a standard set of 8 
allergens. Subjects were instructed to withhold antihistamines for 48h prior to 
the skin prick test. A positive reaction was a wheal size of ≥ 4mm and atopy 
was defined as ≤1 positive reaction. 
4.2.3.3 Bronchial challenge testing 
Methacholine challenge tests were performed using handheld DeVilbiss No 45 
nebuliser (Sunrise Medical; Carlsbad, California), with doses ranging from 0.1 
to 12.2 µmol using the Rapid Method (24). Response to challenge was 
measured by the dose-response slope (DRS), which is calculated as ([% fall 
in FEV1/μmol methacholine]+3). AHR was defined as DRS >8% fall in 
FEV1/μmol (equivalent to FEV1 provocative dose causing a 20% reduction in 
FEV1 <4μmol). 
4.2.3.4 Forced oscillation technique (FOT) 
Respiratory system impedance was measured by the forced oscillation 
technique (tremoFlow C-100 device, Thorasys Medical Systems, Montreal, 
QC, Canada), with a multifrequency forcing signal composed of 5, 11 and 
19Hz. Recordings were made with patients seated, wearing a nose clip and 
supporting the cheeks and under the chin with their hands. After stable tidal 
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breathing, data was acquired for 60 seconds. Technically acceptable 
recordings were obtained in triplicate. Respiratory system resistance for the 
5Hz signal (R5) and respiratory system reactance at 5Hz (X5) were used for 
analyses. The predicted values were those of Oostveen et al (25). 
4.2.3.5 Lung pressure-volume curves 
Pressure-volume curves were constructed as described in Chapter 3. 
4.2.3.6 Maximal flow static recoil (MFSR) curves 
MFSR curves were constructed as previously described using maximal 
expiratory airflow obtained from the flow-volume curves against static lung 
elastic recoil pressure from the P-V curve at corresponding lung volumes (12). 
The slope of the MFSR curve between 70% and 30% of the forced vital 
capacity (FVC) and X-axis intercept were determined by least-squares linear 
regression. According to the analysis of Leaver et al (14) the slope of the line 
represents conductance (calibre) of the upstream segment (Gus) i.e. between 
the alveolus and flow limiting segment, while the X-axis intercept represents 
collapsibility of the flow limiting segment (CFLS). The X-axis intercepts are 
usually negative in healthy subjects and may increase and become positive in 
airways disease, i.e. airway collapse may occur at higher pressure. 
4.2.4 Statistical analyses 
Data are presented as means ±SD for normally distributed data and as 
medians (interquartile range IQR) for non-normally distributed data. 
Spirometry, FOT and lung elastic recoil indices were expressed as z-scores 
and percent predicted. Univariate relationships between dependent variables 
(FEV1/FVC ratio and R5) and lung elastic recoil and MFSR indices were 
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examined using Spearman correlation coefficients. Pre-bronchodilator 
spirometry values were used for analysis as this was performed on the same 
day as lung elastic recoil measurements. Stepwise linear regression was used 
to determine the independent predictors of elastic recoil and MFSR 
abnormalities to FEV1/FVC or R5. A threshold p-value of <0.2 was used to 
identify potential predictors for the multiple-linear regression model. The 
distributions of the residuals of the linear regression model were checked for 
normality. P<0.05 was considered significant.  
4.3 Results 
4.3.1 Subjects and lung function data 
A total of 21 subjects were enrolled and two were excluded because they 
were unable to complete the lung function tests. Elastic recoil measurements 
were performed in 18 of the remaining 19 subjects. Anthropometric and lung 
function data are presented in table 4.1. Subjects were older, with a mean age 
of 63 ±9 years and long duration of asthma (38.2 ±22years). Most subjects 
were taking regular asthma medications prior to enrolment – 18 were taking 
ICS (in LABA combination or as a single inhaler) and five were taking LAMA 
(one subject in LABA/LAMA combination). One subject was on long-term low 
dose oral corticosteroids (Prednisone dose 5 mg) for treatment of rheumatoid 
arthritis. Five subjects were ex-smokers with 2.2 ±2.5 pack-years smoking 
history. Subjects had mildly uncontrolled asthma symptoms (ACQ-5 1.03 
±0.92). Atopy was present in 13/19 subjects and 8/18 subjects demonstrated 
AHR (FEV1 was <50% of predicted in 1 subject which precluded bronchial 
challenge testing).  There was mild-moderate impairment of spirometry and 
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respiratory impedance. Spirometry did not change after the two-month study 
period however respiratory resistance increased (see chapter 3 results). 
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Table 4.1 Anthropometric and lung function data. 
 
Number of subjects, n = 19 (male = 11) Raw values Z-score or % predicted 
Age, years  62.8 ±9.4 - 
Age asthma onset, years (median (IQR)) 19 (2-50) - 
Asthma duration, years  38.2 ±22 - 
Height, m  1.69 ±0.10 - 
BMI, kg.m-2 (median (IQR)) 27.6 (25.0-30.8) - 
Pre FEV1, L  1.88 ± 0.68 -2.3 ±0.7 
Pre FVC, L  3.27 ± 1.09 -1.0 ±1.1 
Pre FEV1/FVC ratio  0.58 ±0.10 -2.4 ±0.9 
Post FEV1, L  2.01 ± 0.72 -2.1 ±0.7 
Post FVC, L  3.46 ± 1.06 -0.6 ±1.0 
Post FEV1/FVC ratio  0.58 ±0.09 -2.5 ±0.9 
FRC, L  3.78 ± 1.00 1.04 ±1.1 
TLC, L  6.39 ± 1.54 0.55 ±1.0 
RV, L  2.96 ± 0.84 1.88 ±1.6 
RV/TLC ratio  0.47 ±0.09 1.3 ±1.2 
DLCO, ml/min/mmHg  19.9 ± 6.1 78 ±15 
DLCO/VA  4.24 ± 0.6 92 ±16% 
VA, L  4.73 ± 1.43 82 ±18% 
R5, hPa.s.L-1 (median (IQR)) 5.8 (4.3-7.5) 2.7 (1.8-3.2) 
X5, hPa.s.L-1 (median (IQR)) -2.7 (-1.8 - -5.1) -3.9(-2.0--7.3) 
A, L 6.55 ±1.59 - 
B, L 3.93 ±1.94 - 
K, cmH20-1 (median (IQR)) 0.197(0.131-0.267) 1.58(-1.08-3.43) 
B/A ratio (median (IQR))  0.52 (0.44-0.77) -1.18(-0.02--1.65) 
GUS, L.s.cmH20-1 (median (IQR)) 0.34 (0.27-0.480) - 
CFLS, cmH20 (median (IQR)) 0.69 (-0.09-3.16) - 
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R5: respiratory system resistance at 5Hz; X5: respiratory system reactance at 
5Hz; A: asymptote of the exponential analysis of pressure-volume curves; B: 
distance on the Y-axis between A and the extrapolated Y-axis intercept of the 
pressure-curve; K: shape factor of the exponential analysis of the pressure 
volume-volume curves, B/A: index of lung compliance describing the position 
of the pressure-volume curve with respect to the pressure axis, GUS: 
conductance of the upstream segment determined from MFSR curves, CFLS: 
collapsibility of the flow limiting segment determined from MFSR curves. Data 
presented as mean ±SD unless otherwise stated. 
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The PV curves are shown in chapter 3. In five subjects, the lower limit of the 
PV curve was fitted to a volume ≥60% of TLC (rather than 50%) as they were 
mild-moderately hyperinflated with a FRC > 50% of TLC (mean ±SD % 
predicted FRC 134±11%, for these five subjects). Mean FRC for these five 
subjects was also greater than mean FRC for the whole group (117±19%). 
Median (IQR) values for B/A and K were 0.52 (0.44-0.77) and 0.197 (0.131-
0.267) cmH20-1, respectively. Lung elastic recoil was lower than normal (B/A% 
z-score ≤-1.64) in 5/18 subjects and compliance was higher than normal (K z-
score ≥1.64) in 9/18 subjects. There was a moderate correlation between B/A 
and K z-scores (rs=-0.54, p=0.02). The MFSR curve for each subject is shown 
in figure 4.1.   
  
  202 
 
 
 
Figure 4.1 
Maximal flow static recoil (MFSR) curves in asthma subjects. 
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4.3.2 Univariate correlations with spirometric ratio 
Spirometric ratio (FEV1/FVC) z-score correlated negatively with K z-score (rs=-
0.60, p=0.008) (figure 4.2). FEV1/FVC z-score also correlated negatively with 
age (rs=-0.49, p=0.03) and positively with BMI (rs=0.65, p=0.003) (table 4.2) 
but was unrelated to asthma duration, B/A z-score or MSFR indices (CFLS and 
GUS). 
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Table 4.2 Correlation between clinical and lung elastic recoil parameters with 
measures of airflow obstruction. 
 
 
 
 
 
 
 
BMI: Body Mass Index; FEV1/FVC: Forced Expiratory Volume in 1 
second/Forced Vital Capacity; R5: respiratory system resistance at 5Hz; B/A: 
index of lung compliance describing the position of the pressure-volume curve 
with respect to the pressure axis; K: shape factor of the exponential analysis 
of the pressure-volume curves, GUS: conductance of the upstream segment 
determined from MFSR curves, CFLS: collapsibility of the flow limiting segment 
determined from MFSR curves. rs: Spearman correlation coefficient; p: p-
value. Statistically significant p-value <0.05.  
 
  
Variable FEV1/FVC (z-score) R5 (z-score) 
 rs P rs P 
Age, years -0.49 0.03 0.31 0.20 
Asthma duration, years -0.15 0.54 -0.05 0.85 
BMI, kg.m-2 0.65 0.003 -0.09 0.72 
B/A ratio (z-score) 0.21 0.40 -0.52 0.03 
K (z-score) -0.60 0.008 0.13 0.60 
GUS, L.s.cmH20-1 -0.006 0.98 -0.13 0.59 
CFLS, cmH20-1 0.33 0.18 -0.31 0.22 
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Figure 4.2 
Univariate correlation between airflow obstruction (forced expiratory volume in 
1 second/forced vital capacity, FEV1/FVC) and lung compliance, K. 
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4.3.3 Univariate correlations with forced oscillatory impedance 
There was a negative correlation between R5 and B/A z-scores (rs=-0.52, 
p=0.026) (figure 4.3) but no correlation with K z-score. R5 z-score did not 
correlate with age, BMI, asthma duration or MFSR indices. There was a 
strong negative correlation between R5 and X5 z-score (rs=-0.62, p=0.005). X5 
z-score did not correlate with B/A or K z-scores, age, BMI, asthma duration 
and CFLS. There was a positive correlation with Gus (rs=0.50, p=0.04). 
 
 
Figure 4.3 
Univariate correlation between airway narrowing (resistance, R5) and lung 
elastic recoil, B/A. 
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4.3.4 Multivariate correlations with spirometry and forced oscillation 
impedance 
Table 4.3 show the results from multiple linear regression analyses. The 
following co-variates were used in the model: age, BMI, disease duration, K z-
score, B/A z-score, GUS and CFLS. The only independent predictor of 
FEV1/FVC z-score was K z-score (model r2=0.38, p=0.007). B/A z-score and 
Gus were independent predictors of R5 z-score (model r2=0.44, p=0.01). The 
only independent predictor of X5 z-score was GUS (model r2=0.38, p=0.006).   
 
 
 
 
Table 4.3 Stepwise multiple linear regression to identify the independent predictors of 
forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) and resistance 
at 5Hz (R5). 
  
 Predictor β-coefficient ± SE Partial r2 Adjusted 
model r2 
P 
FEV1/FVC K (z-score) -0.62 ±0.06 0.38 0.34 0.007 
      
R5 B/A (z-score) -0.63 ± 0.18 - - - 
 GUS -0.45 ± 2.26 0.44 0.37 0.007 
  208 
4.4 Discussion 
In this study, older non-smokers with asthma demonstrate FAO, increased 
resistance and loss of lung elastic recoil. Importantly airflow obstruction is 
associated with loss of lung elastic recoil, independent of intrinsic airway 
narrowing. This suggests there are changes occurring outside the airway wall 
in the surrounding lung tissue, likely contributing to the loss of lung elastic 
recoil. Furthermore, the ageing process is an additional factor contributing to 
FAO. To our knowledge the novel correlations between these measures of 
airflow obstruction (FEV1/FVC and R5) and lung elastic recoil (K and B/A) 
have not been reported in the literature, in particular in older non-smokers with 
asthma and FAO.  
Our results are consistent with findings from previous studies showing a loss 
of lung elastic recoil in asthma (8, 9, 12, 26, 27), especially in older people 
(12). Gelb et al recruited older clinically stable asthmatics with moderate 
airflow obstruction and showed an unexpected significant loss of lung elastic 
recoil (12). The P-V curves were compared to age matched controls and were 
left shifted, which suggested that as a group, their elastic recoil was abnormal. 
Our P-V curves were also leftward shifted which we quantified using the index 
B/A (13, 28). We also quantified loss of lung elastic recoil using the index K 
(13, 28). The high z-scores indicate a loss of elastic recoil compared to 
healthy (28) subjects and compared to that reported previously in asthmatic 
adults (8). Our asthma subjects were older and had worse lung function 
compared to this asthma study (8), which likely explains the differences in 
findings. In addition, K values in our study are similar to that measured in post 
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mortem lungs in smokers with emphysema (29, 30), in which elastic recoil is 
reduced as a result of alveolar destruction.   
The cause of loss of elastic recoil in asthma is not clear however there is 
limited evidence from post-mortem (6, 7) and imaging studies (31-35) 
confirming alteration in lung tissue.  Microscopic examination of post mortem 
lungs from three lifelong non-smokers, who died of causes unrelated to 
asthma showed diffuse, mild centrilobular emphysema with upper-lobe 
predominance (6). Abnormal alveolar attachments and decreased elastic fibre 
content has also been shown in post mortem lung tissue in fatal asthma (7). 
Furthermore, decreased lung parenchymal density (lung attenuation) from 
computer tomography scans has been described qualitatively and measured 
quantitatively in asthma (31-35). We can speculate that decreased lung 
attenuation is consistent with alveolar space enlargement and consequent 
reduced lung elastic recoil (36). K is thought to resemble alveolar size (30, 
37), with increased K reflecting an increase in alveolar size or alveolar 
enlargement. Increased K in our study supports the concept of alveolar 
enlargement however the underlying pathological process is unknown. We 
cannot confirm emphysema in our subjects however mean % predicted DLCO 
was reduced (mean ±SD:!78 ±15%). Additionally % predicted DLCO was lower 
in those who had a K z-score greater than 1.64 SD from the predicted value, 
compared to those with a K z-score less than 1.64 SD (73!±18%!and!81!±11%,!
respectively). Reduced DLCO is not typically associated with asthma however 
we could speculate that this result reflects alteration in the lung tissue 
resulting in subsequent loss of elastic recoil.  
  210 
The ageing process is an additional factor contributing to FAO in asthma, 
highlighted by the negative correlation between FEV1/FVC and age, which still 
exists even after accounting for age.  It is known that lung elastic recoil 
declines with age (38-41) and has been attributed to changes in the alveolar 
wall, collagen and elastic fibres (42-46). Uniform reduction in the number and 
thickness of elastic fibres has been shown in the ageing human lung. These 
changes were confined to the alveolar ducts and alveoli, resulting in dilatation 
of the alveolar ducts (46). Subsequently lung over-inflation may occur and can 
explain the emphysema-like physiological abnormalities seen in older people 
such as increased FRC and RV (40). New insights suggest that chronic 
obstructive disease starts in childhood or in utero with genetic, environmental 
and lifestyle factors influencing lung function early in life (47-50). Extrapolating 
from these studies, we can speculate that lung elastic recoil may also be 
reduced early in life therefore continue to decline from a lower starting point. 
B/A and K show a moderate correlation with age (rs=0.50, p=0.035 and rs=-
0.54, p=0.02 for B/A and K, respectively) and when age is taken into account 
using z-scores, there is a similar trend (rs=0.44, p=0.07 and rs=-0.45, p=0.06 
for B/A and K z-scores, respectively). However there is no correlation between 
the age of asthma onset or disease duration with FEV1/FVC, B/A or K. This 
lack of relationship suggests the ageing process rather than disease 
contributes to these functional abnormalities. Nevertheless, it is likely the 
combination of ageing and disease contributing to loss of lung elastic recoil 
and FAO in older people with asthma. Inflammation may play a role as 
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chronic airway inflammation is transmural therefore affecting the full thickness 
of the airways and surrounding lung tissue (51).   
The loss of lung elastic recoil contributes to airflow obstruction independent of 
intrinsic airway narrowing. This is consistent with findings by Gelb et al, who 
found maximal expiratory airflow limitation at low lung volumes to be due to 
loss of lung elastic recoil alone in four elderly asthmatics (12). We found 
different indices of airflow obstruction correlated with different indices of loss 
of elastic recoil, namely FEV1/FVC and K and R5 and B/A, independent of age, 
asthma duration, BMI and CFLS. Surprisingly we also found that loss of elastic 
recoil was associated with lower CFLS (i.e.: less collapsible airways); B/A: 
rs=0.77, p<0.0001 and K: rs=-0.58, p=0.01. This suggests that in those with 
higher CFLS (i.e.: more collapsible airways) perhaps loss of elastic recoil is 
unlikely to be the main contributor to airway obstruction, instead airway 
obstruction is more likely to be due to intrinsic airway narrowing (i.e. altered 
mechanics of the airway itself). However, the contribution of loss of elastic 
recoil to FAO in asthma cannot be ignored. The lung is a complex structure 
and these different correlations highlight the heterogeneous nature of asthma.  
Limitations in our study include the effect of prior medications, construction of 
the PV curves and lack of healthy controls and imaging or lung tissue data. 
Any effects of prior medications have not been accounted for, however 
treatment over the two-month study period was standardized to minimize this 
cofounder. Construction of the PV curves in five subjects only included points 
to a volume ≥ 60% of TLC, rather than 50% of TLC, due to these subjects 
being hyperinflated. Two of the five subjects had B/A z-scores less than 1.64 
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SD and four subjects had K z-scores greater than 1.64 SD. This may 
introduce bias as the PV curve would be more left shifted and show greater 
curvature (i.e.: B/A reduced and K increased) therefore the remaining 15 PV 
curves were not adjusted to the same volume. A healthy control group was 
not included in our study as this was a mechanistic study and we wanted to 
determine physiological mechanisms in the diseased state. Our lung function 
results are however similar to previous studies in asthmatics of a similar age. 
Chest imaging and lung tissue would also be helpful to confirm alterations in 
lung tissue however this data is not available for our cohort.  
In conclusion we have further evidence that FAO in older non-smokers with 
asthma can be attributed to loss of lung elastic recoil and not just airway 
remodelling. Our findings also suggest there are similarities in the underlying 
mechanisms of FAO in non-smokers with asthma and emphysema, as the 
loss of lung elastic recoil probably reflects physiological alveolar-lung 
parenchymal abnormalities. This study confirms the heterogeneous nature of 
asthma presentation and clinical expression inferring there are different 
pathological mechanisms driving the disease. Research into the underlying 
cellular mechanisms that relate loss of lung elastic recoil to airway narrowing 
needs further investigation. Perhaps an alternate paradigm for asthma needs 
to be considered and the contribution of ‘lung remodelling’ warrants further 
study with potential implications on prevention of FAO in asthma. 
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Chapter 5 
5 Steroid insensitive fixed airflow obstruction is not 
related to airway inflammation in older non-
smokers with asthma. 
 !
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5.1 Introduction 
Irreversible or fixed airflow obstruction (FAO) can develop in long-standing 
asthma despite no or minimal smoking history and is associated with 
moderate to severe disease (1, 2). The mechanisms of FAO in asthma are 
poorly understood; therefore prevention and treatment remain a challenge. 
Inhaled and/or oral corticosteroids improve lung function and reduce 
exacerbations, yet may not necessarily prevent FAO from occurring (3, 4). 
Asthma severity (1, 5) and FAO development may be attributed to 
corticosteroid resistance or insensitivity resulting in persistent airway 
inflammation (6) and structural airway changes. Both eosinophilic and 
neutrophilic inflammation may be associated with lung function impairment 
and FAO in asthma, however evidence is limited and contradictory (4, 7).  
In this prospective study, we investigated whether lung function impairment in 
older non-smokers with long-standing asthma and FAO is associated with the 
airway inflammation which remains after treatment with maximal dose inhaled 
corticosteroid (ICS). We hypothesized that the degree of lung function 
abnormalities would positively correlate with persistent airway inflammation in 
patients with asthma and FAO, thereby providing a potential mechanism for 
the development of FAO and its apparent steroid insensitivity. 
5.2 Methods 
Patients were >40 years old, non-smokers or had a negligible smoking history 
with a respiratory physician diagnosis of asthma. All patients were treated with 
a standardized maximal dose of ICS/long-acting beta-agonist (ICS/LABA) 
using fluticasone/eformoterol 250μg/10μg metered dose inhaler via a holding 
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chamber, two puffs twice daily, if not already taking this treatment. A baseline 
test skin prick test to common allergens was performed to assess atopic 
status (8). During enrolment and after two months of treatment, patients 
completed a symptom questionnaire (Asthma Control Questionnaire, ACQ-5) 
(9) and performed pre-bronchodilator lung function measurements. 
Measurements included spirometry (10) and the forced oscillation technique 
(FOT) to derive airway resistance (R5) and reactance (X5) at 5 Hz (11), as 
described in previous chapters. After two months of treatment an 
oesophageal balloon was used to derive the pressure-volume (P-V) curve to 
assess the elastic recoil properties of the lung via the indices K, reflecting lung 
compliance, and B/A, reflecting lung elastic recoil (12), as described in 
chapter three. FAO was assessed following one month of treatment and was 
defined as a spirometric ratio less than the lower limit of normal (13) and/or a 
<200 ml and <12% change in spirometry post-bronchodilator (400mcg inhaled 
salbutamol) (14). ICS/LABA medication was withheld for at least 24 h and 
short acting beta-agonist medication for at least 6 h prior to testing. 
Following two months of ICS/LABA treatment and within a week of the lung 
function measurements, patients then underwent bronchoscopy with 
bronchoalveolar lavage (BAL) from the right middle lobe (15-21). 
Bronchoscopy was performed as per standard clinical practice. Patients were 
pre-medicated with 2.5-5 mg Salbutamol via nebulizer and local anaesthetic 
gel and spray was applied to the nose and throat. Intravenous midazolam (1-5 
mg) and alfentanil (100-500 mcg) was used to sedate the patients and doses 
were titrated as necessary. Bronchoscope intubation was via the oral or nasal 
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route and 1% xylocaine was applied to the vocal cords, carina and right main 
bronchus. The bronchoscope was wedged into the right middle lobe sub-
segmental bronchus and BAL was performed using x4 60 ml aliquots of 0.9% 
saline pre-warmed to 37°C (22). Each aliquot was immediately recovered 
using gentle continuous negative pressure (23). BAL samples were 
immediately placed on ice then combined for processing and strained through 
a monolayer of surgical gauze to remove mucus (15). BAL was centrifuged at 
1,500 rpm for 5 minutes at 4 °C and cell-free supernatant was aliquoted and 
stored at -80 °C until assayed (19). Cell counts were performed using a 
haemocytometer and trypan blue exclusion testing (16). Differential cell 
counts were obtained on cytospin preparations, using a Diff-Quik™ stain, 
counting 400 cells. Concentrations of IL-1b, IL-4, IL-6, IL-10, IL-17A, IL-17F, 
IL-21, IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, scD40L and TNF-α (Bio-Rad® 
Bio-Plex Multiplex Immunoassay) were simultaneously evaluated using a 
commercially available multiplex bead-based sandwich immunoassay kit on 
the Lumiex Magpix system (Advanced Tissue Regeneration Group at UTS). 
Assays and data analysis heat maps were generated using DanteR software 
as previously described (24). Univariate correlations (Spearman rank test) 
between lung function indices (using z-scores) and BAL samples (using raw 
values) after two months of treatment were assessed.  
5.3 Results 
Nineteen patients were recruited (11 male; mean ±SD age 63±9 years, 
asthma duration 38 ±22 years, height 1.69±0.10 metres, body mass index 
28.4±5.8 kilogram/metre2); 18 completed the study. Five patients were ex-
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smokers with 2.2 ±2.5 pack-years smoking history and 14/19 patients were 
atopic. Patients were symptomatic (ACQ-5 1.03 ±0.92) despite taking regular 
asthma medications prior to enrolment (ICS 18/19; with LABA 18/19; 
ICS/LABA/long-acting muscarinic antagonist 5/19). One patient was on long-
term low dose oral corticosteroids (Prednisone dose 5 mg) for treatment of 
rheumatoid arthritis.  
Post-bronchodilator spirometry after one month of treatment showed 
moderate FAO (mean ±SD z-score: FEV1 -2.05 ±0.75, FVC -0.61 ±0.95, 
FEV1/FVC -2.46 ±0.90). After two months of treatment FOT indices were 
abnormal: R5 (median (IQR) z-score: 2.7(1.8-3.2)) and X5 (z-score: -3.9(-2.0--
7.3)). Spirometry did not change between enrolment and after two months of 
treatment, however R5 worsened. Eighteen patients performed lung elastic 
recoil measurements (median (IQR) z-score: K 1.57(-1.08-3.43) and B/A -
1.18(-1.65--0.02)). Increased compliance was demonstrated in 9/18 patients 
(K z-score ≥1.64) and loss of elastic recoil in 5/18 (B/A% z-score ≤-1.64). 
Eighteen patients performed bronchoscopy and BAL neutrophil and eosinophil 
cell counts were obtained in 10 patients (mean ±SD: neutrophils 9.1±18.1% 
and eosinophils 1.9±1.6%). No patients had evidence of neutrophilic airway 
inflammation whilst 4/10 patients had eosinophilic airway inflammation. BAL 
cytokines were obtained in 17 patients and results are shown in figure 5.1. 
BMI, spirometry, FOT and elastic recoil indices did not correlate with BAL 
neutrophil or eosinophil count and inflammatory cytokines (figure 5.2). 
Occasionally, statistically significant correlations were observed however 
these were the result of a single outlier.   
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Figure 5.1 
Cytokine levels measured in bronchoalveolar lavage fluid from each patient. 
Each row represents a patient and each column represents different 
cytokines. Red indicates highest levels and bright green lowest levels. IL: 
interleukin, IFN-g=interferon gamma, sCD40L: soluble CD40 ligand, TNF-a: 
tissue necrosis factor alpha.  
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Figure 5.2 
Univariate relationships between lung function measurements and BAL IL-
17a. No significant correlations were demonstrated and similar findings were 
seen with other cytokines. FEV1/FVC: forced expiratory volume/forced vital 
capacity, X5: reactance at 5Hz, K: reflects lung compliance, BAL: 
bronchoalveolar lavage, IL: interleukin. R: Spearman correlation coefficient; P: 
p-value.  
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5.4 Discussion 
Variable levels of neutrophils, eosinophils and cytokines were detected in this 
small cohort however there was a disconnect between measures of airway 
inflammation and lung function. The lack of a relationship in this cohort 
suggests persisting airway inflammation does not affect lung function 
following ICS treatment. However, the effect of previous inflammation and 
inflammation over time on lung function and FAO development remains 
unknown. A standardized period and dose of ICS treatment was used to 
minimize potential confounders however most patients were not steroid naïve 
thus the study treatment may have had minimal additional effect on the 
inflammatory profile. This is supported by the absence of any significant 
change in spirometry from enrolment and after the two-month study period. 
Adherence to study treatment was assessed after one month and at the two-
month mark to ensure non-adherence did not play a role. 
Somewhat surprisingly and in contrast to previous studies (25), this older 
cohort did not demonstrate neutrophilic airway inflammation although small 
subject numbers are a limiting factor. Furthermore, neutrophil activation was 
not measured and may have been increased due to inhibition of neutrophil 
apoptosis by inhaled corticosteroids. Despite treatment with high-dose 
ICS/LABA, eosinophilic inflammation persisted in a few patients and cytokines 
were still detectable, suggesting a steroid unresponsive inflammatory 
pathway. The fact that FAO develops despite treatment suggests inhaled 
corticosteroids may have minimal effect on airway remodelling in older people 
with asthma. Instead FAO in this cohort may predominantly be due to other 
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mechanisms such as the loss of elastic recoil observed in this study, which in 
turn may occur as a result of lung tissue changes (i.e. lung remodelling) (2). 
Lung tissue changes could be due to proteolytic enzymes disrupting lung 
parenchyma-terminal bronchiole attachments (26). Inflammation in the lung 
tissue cannot be ignored, however our study lacks the ability to assess this. 
Less invasive tests such as a computer tomography (CT) scan to assess for 
possible lung tissue changes like emphysema was also not done. A recent 
study demonstrated micro-emphysema, only on microscopic examination of 
post-mortem asthmatic lungs, which was not evident on CT imaging (2), 
therefore inclusion of CT imaging may not have be adequate to demonstrate 
lung tissue changes in our study. 
5.5 Conclusion 
In summary, this exploratory cross-sectional study has shown a lack of 
relationship between persistent airway inflammation and lung function 
impairment following a short period of maximal ICS treatment. However, other 
cellular mechanisms, lung tissue inflammation and the potential longitudinal 
effect of inflammation over time in the development of FAO in asthma warrant 
further investigation. 
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Chapter 6 
6 Conclusion 
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Fixed airflow obstruction (FAO) occurs in non-smokers with asthma (1-4) and 
the underlying mechanisms are not clear. The small airways are the major site 
of airflow obstruction (5, 6) and the paradigm underpinning asthma 
pathogenesis is airway remodelling driven by and/or as a consequence of 
complex inflammatory pathways (7). However other factors such as the lung 
tissue (8, 9) also contribute. The overall aim of this thesis was to explore 
physiological and inflammatory mechanisms contributing to fixed airflow 
obstruction in older non-smoking adults with asthma. Airway physiology and 
lung mechanics were assessed using standard lung function tests; the 
multiple breath nitrogen washout (MBNW) test to determine ventilation 
heterogeneity; the forced oscillation technique to determine respiratory 
resistance and reactance; and the oesophageal balloon technique to 
determine the lungs elastic properties. Inflammation was measured using 
bronchoalveolar lavage samples. A summary of the main findings from this 
thesis and future directions are discussed below.  
6.1 Functional residual capacity and ventilation heterogeneity 
measurements between commercial MBNW devices are not 
comparable. 
Functional residual capacity (FRC) is a quality control metric for the MBNW 
test therefore accuracy of its measurement is paramount. This thesis has 
shown there are differences in both in vitro and in vivo FRC, as measured by 
currently available commercial MBNW devices. The pattern of FRC difference 
between devices was similar however a larger discrepancy was demonstrated 
in vivo compared to in vitro. In vivo ventilation heterogeneity (VH) indices 
(Scond, Sacin and LCI) in asthma and in healthy people were highly variable 
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between different MBNW devices but did not follow the same pattern of 
differences as FRC. These findings are important because currently available 
commercial MBNW devices have become increasingly available. Differences 
in MBNW results between the different devices suggest these devices are not 
comparable. Therefore tests performed on different MBNW commercial 
devices cannot be used interchangeably. VH indices must be interpreted with 
caution and attention paid to device and software specific calculation 
algorithms and reference equations.  
6.2 Loss of lung elastic recoil is associated with small airway 
dysfunction in the diffusion-dependent airways (Sacin) and 
airflow obstruction (FEV1/FVC). 
The patient group studied in this thesis was older non-smokers with asthma 
and FAO. A majority of the patients in this study already had impaired lung 
function, as measured by spirometry during enrolment, therefore would likely 
have small airway dysfunction. Chapters three and four of this thesis explores 
how lung function impairment in this cohort may be affected by the elastic 
properties of the lung tissue. Elastic properties were quantified using an 
exponential equation fitted to the pressure-volume curve to derive indices 
reflecting lung elastic recoil and compliance (10).  
Small airway dysfunction was measured using the MBNW test to derive 
indices that provide mechanistic information about ventilation heterogeneity 
(VH) in the conductive (Scond) and diffusion-dependent (Sacin) airways. 
Following on from chapter 2, one of the commercially available MBNW 
devices described in this chapter was used to measure VH. Sacin, yet not 
Scond was associated with a loss of lung elastic recoil suggesting the elastic 
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properties of the lung tissue play a role in determining VH in the very 
peripheral or diffusion dependent airways. This novel finding supports 
theoretical modelling evidence proposing that heterogeneity of diffusion-
dependent ventilation can arise due to the heterogeneity of cross-sectional 
areas of airway openings in terminal airways and the acini (11). The outer wall 
of the distal airways are connected to lung tissue, therefore we can infer that if 
the lung tissue were altered this could lead to a loss of lung elastic recoil. 
Consequently, the lungs ability to hold the small airways, including the 
terminal airways and acini, open and patent would be affected. Therefore 
these airways could be more prone to collapsing and premature closure thus 
affecting VH.  
This leads on to the results in chapter four, which shows that airflow 
obstruction (FEV1/FVC) was associated with increased lung compliance and 
airway resistance (R5) was associated with a loss of lung elastic recoil. These 
results provide further support that the elastic properties of the lung tissue 
contribute to lung function impairment in older non-smoking asthmatics with 
FAO. These novel findings do not refute the role of airway remodelling in 
asthma however, suggests that factors other than the airways play a role in 
the mechanisms leading to FAO in asthma.  
6.3 The ageing process contributes to fixed airflow obstruction. 
Another interesting finding was the association between worse airflow 
obstruction (FEV1/FVC) and increasing age. It is well known that lung function 
declines with age (12, 13), however as discussed in chapter 4, this 
association remained even after accounting for age (i.e. the association was 
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present using z-scores, which already accounts for age). It is also known that 
lung elastic recoil declines with age (14-17) and an association between loss 
of lung elastic recoil and increasing age was demonstrated in chapter 4. This 
association was no longer significant when age (i.e. using z-scores) was 
taken into account however there was a trend. These results suggest the 
ageing process is an additional factor contributing to lung function impairment 
and FAO in asthma. 
The associations between the lungs elastic properties and Sacin, airflow 
obstruction and airway resistance may be related to this patient cohort being 
older. Functionally, older lungs can behave similarly to smokers with chronic 
obstructive pulmonary disease (COPD), probably because of the structural 
changes that occur with age (18, 19). Similarly non-smokers with asthma who 
are of an older age group, may demonstrate lung function abnormalities that 
are akin to that seen in COPD (i.e. FAO) (8). Quantifying the contribution of 
age is difficult to determine, however it is likely that the combination of age 
and asthma have a synergistic effect on lung function impairment and FAO 
development. The role of age on inflammation and immunosenescence in 
asthma and FAO also remains to be determined.  
6.4 Steroid insensitive fixed airflow obstruction is not related to 
airway inflammation in older non-smokes with asthma. 
Chapter five explores airway inflammation in older non-smokers with asthma 
and FAO. Variable levels of neutrophils, eosinophils and inflammatory 
cytokines were detected in bronchoalveolar (BAL) fluid in this small cohort. 
However there was a disconnect between measures of airway inflammation 
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and lung function (spirometry, resistance and reactance and lung elastic 
recoil). The lack of a relationship between lung function and inflammation 
measured in this cross-sectional analysis suggests persisting airway 
inflammation does not affect lung function following high dose ICS/LABA 
treatment. However, the effect of previous inflammation and inflammation over 
time on lung function and FAO development was not assessed, therefore is 
not known. A standardized period and dose of ICS/LABA treatment was used 
to minimize potential confounders however most patients were not steroid 
naïve thus the study treatment may have had minimal additional effect on the 
inflammatory profile. This is supported by the absence of any significant 
change in spirometry from enrolment and after the two-month study period. 
Resistance (R5) did decline after two months of high dose ICS/LABA and 
could potentially have been related to mucus impaction. 
6.5 Future directions 
6.5.1 MBNW and measurement of small airway function 
MBNW provides important complimentary information to currently available 
lung function tests however is not yet widely used in clinical practice. MBNW 
use is predominantly in the research setting. Its role may be more relevant in 
detecting disease early, before abnormalities are detected by spirometry (20-
23), at which point it may be too late because the damage may be 
irreversible. Integrating MBNW use into routine clinical practice will help 
improve our understanding and management of lung disease. However, more 
work is needed to validate commercial MBNW equipment to ensure 
measurements are robust, reliable and accurate. Large multi-centre studies 
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comparing measurements between commercial devices in health and 
disease, also covering a wide age range and ethnicities, would be required. In 
addition, longitudinal studies using birth cohorts would assist with determining 
the expected change in MBNW indices over time/with age in health and 
disease. Other future work in the MBNW field could involve expanding on the 
simple syringe-based lung model described in chapter 2, to allow simulation of 
paediatric lung volumes. This would also require a lung model with the ability 
simulate breathing techniques used in paediatric testing (i.e. free breathing 
rather than a fixed volume of 1 L used in adult testing (24)). In addition, 
modifying the physical lung model to enable measurement of the more 
complex VH indices may help with ongoing standardization efforts.  
6.5.2 Exploring mechanisms contributing to the loss of lung elastic 
recoil in asthma 
Loss of lung elastic recoil may occur as a result of lung tissue changes (i.e. 
lung remodeling) (8), however needs further investigation, ideally using lung 
tissue. Obtaining lung tissue is a challenge due to the risks involved; hence 
there are very limited studies that include lung tissue assessment in living 
asthmatics. However less invasive tests such as imaging could be used as a 
substitute. Future studies could incorporate the use of high-resolution 
computed tomography scans to assess for lung tissue changes such as 
emphysema or enlarged alveoli, in addition to changes of airway remodeling 
that are known to occur in asthma.  
The contribution of the ageing process to the loss of lung elastic recoil is 
difficult to disentangle from asthma itself. Either longitudinal studies in non-
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smokers with asthma and/or comparing results from this thesis to a control 
group would be required. The control group would consist of younger non-
smoking asthmatics and/or a healthy control group of a similar age range (i.e. 
older). Longitudinal assessment of the lungs elastic properties would be 
important to measure, to help determine the rate of change or decline in loss 
of elastic recoil. The oesophageal balloon test is also somewhat invasive and 
this approach may not be practical. Therefore, future studies could utilise a 
more practical and less invasive method of assessing the elastic properties of 
the lung tissue. Use of the forced oscillation technique (FOT) may be the 
answer. Future studies could build on previous work in COPD, which has 
used the FOT indices inspiratory and expiratory reactance (Xrs) to determine 
the presence of expiratory flow limitation (25). Using these parameters may 
identify those with asthma who have enhanced airway narrowing due to lung 
tissue alteration and subsequent loss of lung elastic recoil.  
The role of inflammation and possibility of proteolysis of the lung tissue also 
needs further exploration. Surrogate markers of tissue turnover and 
degradation such as YKL-40 could be assessed in BAL, endobronchial 
biopsies and/or peripheral blood samples, because lung tissue samples may 
be more challenging to obtain. Pro-inflammatory markers that may contribute 
to the proteolytic cascade could also be measured, such as matrix 
metalloproteinases (MMPs) and neutrophil elastase. In addition, the effect of 
inflammation and possible proteolysis over time warrants further investigation 
with longitudinal studies. 
  238 
6.6 Final conclusions 
Asthma is a heterogeneous disease that is genetically complex and cannot be 
explained by one mechanism alone (26). FAO is one of many asthma 
phenotypes yet current tools do not readily identify those who are at risk of 
developing FAO or provide definitive mechanisms leading to FAO. FAO in 
asthma demonstrates functional similarities with COPD, however the 
underlying mechanisms and pathogenesis cannot be the same, as a smoking 
history may not be present. Airway-lung tissue inter-dependence is extremely 
important and the role of both the airways and lung tissue need to be 
accounted for, in addition to the contribution of the inflammatory pathways. 
Studies focusing on treatment of FAO in asthma seem far off because the 
mechanisms are not well understood.  
Findings from this thesis highlight the importance of mechanisms other than 
airway remodeling that play a role in FAO in asthma. Changes to the lungs 
elastic properties resulting in increased compliance or reduced lung elastic 
recoil are suggested to make a significant contribution. ‘Lung remodeling’ is a 
potential pathological process leading to lung tissue changes and may be an 
alternate asthma paradigm to airway remodelling. This FAO phenotype tends 
to occur in older people with asthma thus contribution of the ageing process 
should not be ignored. Additionally, the underlying cellular mechanisms, which 
may lead to a loss of elastic recoil in asthma needs further investigation. 
Whether immunosenescence, asthma or both contribute to the underlying 
cellular mechanisms remains elusive. This may represent a potential pathway 
by which the FAO phenotype is manifest and highlights the need for 
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development of novel treatments that target ‘lung remodelling’ and loss of 
elastic recoil in asthma. This may involve targeting multiple rather than single 
inflammatory pathways because the inflammatory pathways are complex. 
! !
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ABSTRACT Functional residual capacity (FRC) accuracy is essential for deriving multiple-breath
nitrogen washout (MBNW) indices, and is the basis for device validation. Few studies have compared
existing MBNW devices. We evaluated in vitro and in vivo FRC using two commercial MBNW devices,
the Exhalyzer D (EM) and the EasyOne Pro LAB (ndd), and an in-house device (Woolcock in-house
device, WIMR).
FRC measurements were performed using a novel syringe-based lung model and in adults (20 healthy
and nine with asthma), followed by plethysmography (FRCpleth). The data were analysed using device-
specific software. Following the results seen with ndd, we also compared its standard clinical software (ndd
v.2.00) with a recent upgrade (ndd v.2.01).
WIMR and EM fulfilled formal in vitro FRC validation recommendations (>95% of FRC within 5% of
known volume). Ndd v.2.00 underestimated in vitro FRC by >20%. Reanalysis using ndd v.2.01 reduced
this to 11%, with 36% of measurements ⩽5%. In vivo differences from FRCpleth (mean±SD) were
4.4±13.1%, 3.3±11.8%, −20.6±11% (p<0.0001) and −10.5±10.9% (p=0.005) using WIMR, EM, ndd v.2.00
and ndd v.2.01, respectively.
Direct device comparison highlighted important differences in measurement accuracy. FRC
discrepancies between devices were larger in vivo, compared to in vitro results; however, the pattern of
difference was similar. These results represent progress in ongoing standardisation efforts.
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LUNG FUNCTION
Introduction
Abnormalities in the small airways can be detected using the multiple-breath nitrogen washout (MBNW)
test, which provides a more sensitive measure of small airway function than spirometry [1–3]. MBNW
provides insightful information about the small airways, using indices that assess gas-mixing efficiency in
the lung (Lung Clearance Index, LCI) and mechanistic information about ventilation heterogeneity in the
conduction and diffusion-dependent airways (Scond and Sacin). These indices rely on accurate functional
residual capacity (FRC) measurements [4].
Advances in technology have allowed the development of new commercial MBNW devices; however, there
are still limited published data comparing measurements between devices. Previous studies have compared
in-house and/or commercial devices against standard body plethysmography as well as mass spectrometry,
often considered the gold standard [5–8]. Many of these studies have used lung models, assessed
measurements in the paediatric population and used inert gases rather than N2 [9–11]. Limited published
data have also shown inconsistencies between lung model and adult measurements [6].
Furthermore, the effect of software upgrades in a rapidly evolving field has not been studied extensively.
Previous studies in one specific device have shown that software changes can have a significant impact on
results [12, 13]. Recommendations for MBNW techniques have been published in the European
Respiratory Society/American Thoracic Society (ERS/ATS) Consensus statement [4]; however, ongoing
work is still needed to improve the standardisation of equipment, technical specifications and algorithms
for the calculation of indices.
The aim of this study was to evaluate FRC measured using two commercial MBNW devices, the Exhalyzer D
(EM) from Eco Medics AG (Duernten, Switzerland) and the EasyOne Pro LAB (ndd) from ndd Medical
Technologies (Zurich, Switzerland). We also examined a third, independent, previously published [2]
in-house device at the Woolcock Institute of Medical Research (WIMR), which measures N2 directly, in
contrast to the commercial devices. FRC measurements from the devices were compared against a known
volume using a syringe lung model (in vitro) and against plethysmographic lung volume in healthy and
asthmatic adult subjects (in vivo). In addition, we compared analyses using two different software versions
of the ndd device, because a software update involving major changes to N2 calculation has recently
become available. Previous data [14, 15] have shown significant FRC underestimation using the older,
widely available software.
Methods
Study design
In vitro and in vivo FRC measurements were performed using the three different MBNW devices, in
random order as determined by a computer-generated randomisation sequence. The study was approved
by the Northern Sydney Local Health District Human Research Ethics Committee (protocol no. LNR/16/
HAWKE/11). Written informed consent was obtained from all recruited participants.
The lung model
In vitro measurements were performed using an optimised syringe lung model (figure 1). A 3 L volume
calibration Hans Rudolph syringe (5530 series) was modified to produce the physiological expirogram
a
d
b
c
FIGURE 1 Physical lung model composed of a) a 3 L Hans Rudolph syringe, b) an attachment made from 18
flexible tubes, c) a helical mixer device inserted at the syringe entrance, and d) an adjustable syringe stopper.
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encountered during in vivo testing. This was accomplished by incorporating an attachment on the front of
the syringe consisting of 18 flexible Tygon (S3 E-3603) tubes of varying lengths (internal diameter of
0.048 cm and lengths ranging from 10 to 49.5 cm) and permeability coefficients for CO2 of
360×10−11 cm2·s−1·cmHg−1, N2 of 40×10
−11 cm2·s−1·cmHg−1 and O2 of 80×10
−11 cm2·s−1·cmHg−1, to
produce the phase I and II portions of the expirogram, and a 3D-printed helical mixer device inserted at
the syringe entrance to optimise gas mixing and produce a smooth phase III.
The target FRC was calculated by adding the known syringe volume to the dead space of the lung model
attachments. The syringe volume was adjusted via a stopper on the syringe plunger to predetermined
positions. The dead space of the attachments was 0.310 L, determined from the computer-aided design
specifications and confirmed with water displacement.
In vitro study
In vitro measurements were performed in triplicate on each device using four different FRC volumes
(1.51 L, 1.81 L, 2.11 L and 2.31 L). A standardised adult protocol (tidal volume of 1–1.3 L) [2, 4, 16–18]
was used. After at least 5 syringe strokes with a stable end expiratory volume, the washout phase was
commenced and 100% oxygen was switched on. Syringe strokes were continued until end-tidal N2
concentration decreased to 1/40th of the starting end-tidal N2 concentration [4]. Between measurements,
at least 10 strokes were first performed to expel any residual oxygen within the syringe lung model and to
ensure the N2 had returned to baseline. A single operator (K.O. Tonga) performed all measurements
under ambient temperature and pressure dry (ATPD) conditions.
In vivo study
Healthy volunteers were recruited from the WIMR and defined as current non-smokers with <10
pack-years smoking history and with no history of acute respiratory illness within the preceding month.
Subjects with asthma were recruited if they had a physician diagnosis of asthma: history of asthma
symptoms, previously documented significant bronchodilator reversibility on spirometry and/or a positive
bronchoprovocation challenge test and on inhaled bronchodilator and/or inhaled corticosteroid
medication. Short acting β-agonists were withheld for 6 h and long-acting β-agonists for 24 h before
testing.
All participants were over the age of 18 years and completed a standardised interview on respiratory and
general health before performing pulmonary function tests (PFTs) in the following order: MBNW,
spirometry and body plethysmography. All tests were performed in a single session at the Woolcock
Institute of Medical Research.
Spirometry and body plethysmography were performed according to ATS/ERS Guidelines, using a
BodyBox 5500 (Medisoft Corporation, Sorrines, Belgium). MBNW was performed in triplicate in the
seated position, using a noseclip and device-specific bacterial filter and mouthpiece attachments. Tests
were conducted according to ERS/ATS consensus statement [4], using a standardised adult protocol (tidal
volume of 1–1.3 L) [2, 16–18]. After at least 5 breaths with a stable end expiratory lung volume, the
washout phase was commenced and 100% oxygen was switched on. Breaths were continued until end-tidal
N2 concentration decreased to 1/40th of the starting end-tidal N2 concentration [4]. The time interval
between measurements was standardised to twice the previous washout time [4].
MBNW hardware and software
Details of the WIMR, EM and ndd devices are provided in the supplementary material. Briefly, the WIMR
device measures N2 directly via a side-stream N2 analyser [2]. The commercial devices both measure N2
indirectly, based on side-stream CO2 and O2 in the EM device and molar mass and CO2 in the ndd device [6].
Daily calibration and/or verification of each device was performed as described in the supplementary
material.
FRC was calculated as the net volume of N2 expired divided by the difference between end-tidal N2
concentration at the start and end of the washout portion of the test [4]. FRC values were corrected for
the pre-capillary dead space volume for each device. MBNW data were analysed using software specific to
each device. For the WIMR device, custom-written software (Solver Version 1.3.2.18) was used. For the
EM device, Spiroware Version 3.1.6 was used. For the ndd device, the same measurements were analysed
using two different software versions (described in the supplementary material): clinical software Version
2.00.01.05 (termed “ndd v.2.00”) and the recent upgrade released in March 2016, Version 2.01.00.09
(termed “ndd v.2.01”). The ndd v.2.01 software contains updates to the N2 calculation method and
improved flow-gas delay synchronisation.
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Measurements were included for analyses if acceptability criteria were met. For the in vitro study,
measurements were deemed acceptable if three tests were within 10% of the mean FRC [19] value across
the triplicate measures. For the in vivo study, measurements were deemed acceptable if two or more tests
were performed adequately according to the ERS/ATS Consensus statement [4]. Tests were excluded if
there was evidence of leak during testing, the tidal volume of the first breath or more than a third of
breaths during washout was outside 1–1.3 L, and if the end-tidal N2 concentration did not reach the
recommended 1/40th of the initial concentration during data acquisition.
Statistical analysis
FRC data were analysed using IBM SPSS Version 22, and graphs were generated using GraphPad Prism
Version 6.0. Summary data are presented as mean±SD. The accuracy of in vitro FRC was assessed
according to the consensus statement [4] (FRC values within 5% of the known volume for at least 95% of
values) and expressed as absolute (L) difference (measured FRC – lung model FRC) and relative (%)
difference (absolute difference×100/lung model FRC). In vivo FRC was compared with body
plethysmography FRC (FRCpleth). FRC differences between devices were assessed using Bland and Altman
plots with 95% limits of agreement and by non-parametric one-way repeated measures ANOVA
(Friedman’s test) and post hoc tests. p-values <0.05 were considered statistically significant.
Results
In vitro comparison
A total of 108 measurements were performed across the three MBNW devices (table 1). Differences
between measured and lung model FRC values are shown in figure 2 and table 2. FRC accuracy was
within the specified 5% accuracy range of the lung model FRC for 100% of WIMR measurements and
97% of EM measurements. All FRC measurements using ndd v.2.00 were underestimated and not within
the specified 5% accuracy range. Using ndd v.2.01, accuracy improved, although only 36% of
measurements were within the 5% accuracy range.
In vivo comparison
A total of 29 subjects (20 healthy controls and 9 asthmatics) were included in the analyses, and their
characteristics are outlined in table 3. The mean (±SD) FRC measured by the WIMR (3.27±0.82 L) and EM
(3.56±0.92 L) devices did not differ significantly from FRCpleth (3.44±0.77 L) or from each other, and FRC
measured by ndd v.2.00 (2.71±0.64 L) was significantly lower than FRCpleth, WIMR and EM (p<0.0001)
(figure 3 and table 4). The same pattern of FRC differences was observed in healthy control and asthmatic
subjects.
When the ndd data were reanalysed using ndd v.2.01 software, end-tidal N2 concentrations became
systematically higher, such that only 9 of the 29 subjects had measurements that reached an acceptable
end-tidal N2 concentration. However, a majority of the measurements exhibited a stable plateau at the end
of the washout. For the purposes of this study, all 29 subjects were included for analysis to allow
comparison of the effect on FRC. FRC increased when reanalysed using ndd v.2.01 (3.06±0.71 L) and was
also significantly lower than FRCpleth (p=0.011) and the EM device (p<0.0001); however, it did not differ
from the WIMR device.
Discussion
Summary of results
This is the first study to compare in vitro and in vivo FRC measurements in healthy and asthmatic adults,
using two currently available commercial devices and one in-house MBNW device. The WIMR device
TABLE 1 In vitro functional residual capacity (FRC) measurements on each device
Lung model FRC volume Trials WIMR EM ndd v.2.00 ndd v.2.01
2.31 9 2.30±0.02 2.39±0.02 1.78±0.14 2.16±0.04
2.11 9 2.10±0.02 2.17±0.02 1.72±0.12 2.00±0.03
1.81 9 1.84±0.02 1.88±0.02 1.37±0.11 1.72±0.03
1.51 9 1.53±0.03 1.53±0.02 1.25±0.05 1.43±0.02
Data presented as mean±SD, unless otherwise stated. Measurements are in litres. WIMR: Woolcock
in-house device; EM: Exhalyzer D device; ndd v.2.00: EasyOne Pro LAB device Version 2.00.01.05; ndd
v.2.01: EasyOne Pro LAB device analysed in Version 2.01.00.09.
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measured in vitro FRC closest to the known lung model volume. The mean overestimation of in vitro FRC
and FRCpleth was 3% by the EM device, in comparison to a mean 21% underestimation by the ndd device.
However, on reanalysis using ndd v.2.01, underestimation was reduced to 5% (in vitro) and 11% (in vivo),
respectively. There were statistically significant differences in FRC measurements between commercial
MBNW devices, although this difference was relatively small between EM and ndd v.2.01. Furthermore,
the pattern of differences (i.e. over-estimation or under-estimation of FRC) between devices was consistent
using both the in vitro physical lung model and the in vivo measurements.
Comparison to other studies
The Consensus recommendations based on expert opinion stated that 95% of the in vitro FRC
measurements should be within 5% of the target volume [4]. WIMR and EM devices fulfilled this
criterion; however, the ndd device did not achieve 5% accuracy for any measurements (v.2.00). When
measurements were reanalysed using ndd v.2.01, 36% fulfilled this criterion. Both commercial devices were
reported previously to be highly accurate in measuring FRC using a physical lung model [14]. This lung
model was water-based and incorporated BTPS (body temperature, ambient pressure, saturated)
correction, whereas ours did not. Despite this, our results showed the same pattern of over/
underestimation in vitro and in vivo. This is consistent with their in vivo results in 10 healthy adults,
where EM overestimated FRCpleth by 14% and ndd underestimated by 23%. A recent paediatric study with
healthy control and cystic fibrosis patients also reported the same pattern, i.e. higher FRC measurements
using the EM device compared to the ndd device [15]. Other in vitro and in vitro paediatric studies exist
[9, 11], but they involve different tracer gases, which limits comparison.
Impact of N2 estimation method
Differences in FRC across the three devices are probably attributable to device and software variations.
This includes the method used to calculate N2 concentration. The WIMR device measures N2 directly,
whereas the EM device uses Dalton’s law to compute N2 by simple subtraction of other constituent gases
in the expired air. These two methods were found to be similar. In contrast, the ndd v.2.00 device uses the
concept of a prototype expirogram, derived from the shape of the molar mass versus expired volume curve
in the early breaths of the washout. The expired N2 volume for each breath is then determined by scaling
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FIGURE 2 Bland–Altman plots of in vitro functional residual capacity (FRC) measurements on each device. Data are plotted as measured FRC
minus lung model FRC, expressed as the absolute difference versus mean of measured and lung model FRC values. Absolute differences
(circles), mean difference and upper and lower limits of agreement (mean difference±SD of differences) are shown as dashed lines. a) Woolcock
in-house device; b) Exhalyzer D device; c) EasyOne Pro LAB device analysed in Version 2.01.00.09.
TABLE 2 Differences in in vitro functional residual capacity (FRC) measurements from the lung model functional residual
capacity for four different lung volumes
Lung model
FRC volume
Subjects WIMR EM ndd v.2.00 ndd v.2.01
Absolute Relative Absolute Relative Absolute Relative Absolute Relative
2.31 9 −0.01±0.02 −0.2±0.8% 0.07±0.02 3.3±1.0% −0.54±0.14 −23.4±6.1% −0.15±0.04 −6.3±1.7%
2.11 9 −0.01±0.02 −0.43±0.9% 0.06±0.02 2.9±0.9% −0.39±0.12 −18.5±5.7% −0.11±0.03 −5.2±1.5%
1.81 9 0.03±0.02 1.6±1.4% 0.07±0.02 3.7±1.0% −0.44±0.11 −24.1±6.4% −0.09±0.03 −4.7±1.6%
1.51 9 0.02±0.03 1.7±13.1% 0.02±0.02 1.1±1.3% −0.26±0.05 −17.1±3.0% −0.08±0.02 −5.0±1.2%
Data presented as mean±SD, unless otherwise stated. Absolute measurements are in litres. WIMR: Woolcock in-house device; EM: Exhalyzer D
device; ndd v.2.00: EasyOne Pro LAB device Version 2.00.01.05; ndd v.2.01: EasyOne Pro LAB device analysed in Version 2.01.00.09.
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the prototype expirogram to match the end-expiratory N2 concentration for that breath. Potential
inaccuracies could occur if the expirogram shape changed greatly during the course of the washout, as is
typically observed in more severe obstructive airways disease. However, ndd v.2.01 uses a combination of
molar mass measurements and Dalton’s law to compute N2, on a point-by-point basis for the entire
expirogram. This could partly explain the improved accuracy of ndd v.2.01 and the reduced FRC
discrepancy between the new software and the WIMR and EM devices.
Impact of other software changes
The other major change in ndd v.2.01 involve modifications to the estimation of delay between the flow
and respective gas measurement points, which are more robust to variation in breathing patterns,
particularly very brief pauses in flow (personal communication with the manufacturer). Differences in
delay time potentially have a large effect on FRC calculations [20, 21].
Newer software versions were available at the time of writing (v.2.2.0.15 onwards). These involve major
changes to the user interface; however, they fundamentally employ the same indirect N2-based FRC
calculation and delay estimation method. Our results thus have significant implications on the reanalysis of
old data and are relevant to ndd v.2.01 as well as any newer versions. Furthermore, they illustrate the
importance of analysis methods and any preprocessing algorithms that may be used, as well as the need
for software transparency [22]. They also highlight the importance of ongoing validation and that
standardisation efforts are gradually working.
It should be noted that this study was unable to confirm whether collecting data using ndd v.2.01 would
have further improved the FRC accuracy for the ndd device. A large proportion of the in vivo tests
reanalysed using the new software failed to meet end-of-test criteria, possibly due to the underestimation
TABLE 3 Subject demographics and standard lung function measurements
All subjects Controls Asthmatics
Subjects n 29 20 9
Males/females n 12/17 8/12 4/5
Age years 37±12 36±12 37±13
Height cm 172±12 174±12.5 168±10
BMI kg·m−2 24.1±3.63 23.9±3.48 24.6±4.10
Smoking history pack-years 2.5±3.2 2.75±3.31 0.70±0.00
FEV1 L 3.66±0.93 3.75±0.93 3.47±0.95
FVC L 4.75±1.17 4.77±1.16 4.71±1.25
FEV1/FVC 0.77±0.06 0.79±0.05 0.74±0.08
TLC L 6.51±1.38 6.55±1.41 6.42±1.41
FRCpleth L 3.44±0.77 3.49±0.78 3.34±0.80
Data presented as mean±SD unless otherwise stated. BMI: body mass index; FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity; TLC: total lung capacity; FRCpleth: functional residual capacity
measured using body plethysmography.
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FIGURE 3 Bland–Altman plots of in vivo functional residual capacity (FRC) measurements on each device. Data are plotted as body
plethysmography FRC (FRCpleth) minus multiple-breath nitrogen washout (MBNW) FRC, expressed as the absolute difference versus mean of
FRCpleth and MBNW FRC. Absolute differences (circles), mean difference and upper and lower limits of agreement (mean difference±SD of
differences) are shown as dashed lines. a) Woolcock in-house device; b) Exhalyzer D device; c) EasyOne Pro LAB device analysed in Version
2.01.00.09.
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of N2 in the old software. One could speculate that if acceptable end-tidal N2 concentration had been met,
in vitro FRC may have been slightly closer to the true lung volume and in vivo FRC closer to FRCpleth.
Impact of patient factors
Other factors that may affect FRC measurements include the effect of breathing patterns during the
washout. Different mouthpieces, resistances, the nature of the real-time displays of volume and patient
breathing incentives, and even different open bypass systems delivering oxygen [15], may have affected
breathing patterns. However, dead space correction was applied in each device and the same 1 L breathing
protocol was used. More importantly, the direction of over/underestimation was preserved regardless of
in vitro and in vivo FRC comparisons, i.e. independent of BTPS correction, breathing pattern and the
presence of CO2. Thus, it is unlikely that patient factors contributed significantly to the differences
between devices. In addition, the differences between MBNW FRC and FRCpleth on each device were of
similar magnitude between healthy controls and subjects with asthma with well-preserved spirometry. It is
unknown whether the same results would hold in subjects with more airway obstruction, or other patient
groups such as chronic obstructive pulmonary disease (COPD).
Limitations
Our study had a number of limitations. First, we compared differences only in FRC between devices;
however, LCI, Sacin and Scond are the more clinically relevant MBNW indices. There are no known lung
models to evaluate these other indices and a formal comparison of these indices in vivo was not
performed. Nevertheless, high-quality FRC measurement is necessary for evaluation of these indices.
Second, between-session variability for FRC has not been defined, so it is not known whether differences
between in vivo measurements are within the limits of normal test variability. Third, the applicability of
our results to the paediatric population is unknown. However, the simplistic design of the lung model
could be easily adapted to a smaller syringe. Also, we only evaluated the standardised 1 L breathing
protocol [23], so the effect of the free breathing protocol used by other groups [24], and especially in
infants and children, is unknown. Furthermore, the syringe is an ATPD model rather than a BTPS model,
which is less representative of the actual physiological situation but more practical for routine laboratory
use. Despite this, the same pattern of accuracy was seen in vitro and in vivo, suggesting that incorporation
of BTPS correction has a minimal effect on the relative errors reported. Finally, as discussed above, we did
not evaluate the accuracy of data collected using the ndd v.2.01, which is scope for further work.
Conclusion
We have shown differences in the measurements of FRC between three MBNW devices in a physical
syringe model of the lung. The syringe lung model used in this study was simple, portable and relatively
easy to produce compared to that used in other studies [6, 25, 26]. It would allow a simple and practical
way to calibrate or check the MBNW setup, because it tests the combined accuracy of volume and N2
concentration measurement during a more realistic expirogram and the correct alignment of these signals.
The use of such a syringe model may be beneficial for comparison between devices and laboratories and
for quality assurance monitoring. FRC differences were also reflected in vivo in healthy and asthmatic
subjects, in relation to plethysmographic FRC. While further work is required to improve accuracy, the
in vivo differences observed are small and probably not clinically significant. Differences are likely to
reflect the method of calculating N2 concentration and other software factors. How these FRC errors
translate to the accuracy of other indices has been explored for LCI [15], but not Sacin and Scond so far.
Nevertheless, our results show that the state of the art is closer to achieving better comparability and
standardisation for FRC accuracy across existing MBNW devices.
TABLE 4 Differences in in vivo functional residual capacity (FRC) measurements from body plethysmography FRC on each
device
Subjects n WIMR EM ndd v2.00 ndd v2.01
Absolute Relative Absolute Relative Absolute Relative Absolute Relative
Controls 20 −0.13±0.46# −3.3±13.0% 0.17±0.41 4.7±11.8% −0.73±0.36 −20.6±8.9% −0.36±0.32 −10.1±8.4%
Asthmatics 9 −0.24±0.45 −6.8±13.8% 0.01±0.39 0.12±12.0% −0.73±0.59 −20.7±15.3% −0.42±0.57 −11.2±15.8%
All subjects 29 −0.17±0.45 −4.4±13.1% 0.12±0.40 3.3±11.8% −0.73±0.43 −20.6±11% −0.38±0.40 −10.5±10.9%
Data presented as mean±SD, unless otherwise stated. Absolute measurements are in litres. WIMR: Woolcock in-house device; EM: Exhalyzer D
device; ndd v.2.00: EasyOne Pro LAB device Version 2.00.01.05; ndd v.2.01: EasyOne Pro LAB device analysed in Version 2.01.00.09. #: missing
data for one subject.
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In vitro and in vivo functional residual capacity comparisons between 
multiple breath nitrogen washout devices. 
Supplementary material 
Description of MBNW devices: 
Custom built in-house device (WIMR) 
WIMR measures flow via a standard mesh-type pneumotachograph (Hans 
Rudolph® Inc, Shawnee, KS, USA, model no. 3700) and pressure transducer 
(Sensortechnics GmbH, Puchheim, Germany, model no. HCLA02X5EB) (1). 
N2 is measured directly via a side-stream N2 analyser (Medgraphics 
Corporation, St Paul, MN, USA, model no. 762033-001). A fixed orifice valve 
(Bird Precision, Waltham, MA, USA, Ruby type model no. RB82453) was 
incorporated which served to improve the linearity response of the N2 
analyser. The pre-capillary dead space of the set up, which comprised the 
mouthpiece (Jaeger silicon adult size), bacterial filter (Respigard II 303E), 
fixed orifice valve attachment and the pneumotachograph flowhead, was 35 
ml. The post-capillary deadspace was 17.67 ml. 
Daily calibration and verification of gas and flow signals was performed as per 
a standardised protocol for the in-house device (1). Flow verification was 
performed using a 1-L Hans Rudolph® calibration syringe connected to the 
flow head via a standard bacterial filter.  Verification was performed over five 
full syringe strokes and measured within ± 3% accuracy, respectively. A two-
point N2 calibration was performed by blocking the expiratory port in order to 
direct all bias flow gas to the N2 analyser, with room air and 100% O2 gas as 
reference points.  
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A fixed delay of 50 ms was used to align the flow and N2 channels. This delay 
was calculated by injecting a bolus of 100% O2 gas using a syringe attached 
to the entrance of the fixed orifice valve (i.e. the gas measurement point), 
resulting in a step increase in N2. The delay was then defined as the 
difference between time at 50% of the step change in flow and 50% of the 
step change in N2. 
 
ECO MEDICS AG Exhalyzer® D device (EM) 
EM measures N2 indirectly via a main-stream infra-red CO2 sensor 
(CapnostatH 5®, Respironics Novametrix LLC, Wallingford, CT, USA) and a 
side-stream laser oxygen sensor (Oxigraf, Inc, Mountain View, CA, USA) (2). 
Since the concentrations of both O2 and CO2 are obtained, the concentration 
of N2 is then simply calculated using Dalton’s law (see Equation 1).  
fN2 + fO2 + fCO2 + fH2O + fAr = 1  (Equation 1) 
with assumptions regarding the partial pressures of water vapour and Argon 
(2). The pre-capillary deadspace of the setup, which comprised the 
mouthpiece (VacuMed thermoplastic adult size), bacterial filter (Respigard II 
303E), and half the internal volume of the ultrasonic flowmeter with a dead 
space reducer insert (adult size #3), was 58 ml. The post-capillary deadspace 
was 22 ml. 
Calibration of flow and gas channels were performed daily, as outlined below. 
Flow was calibrated as per manufacturer’s guidelines for the adult set up, 
using a 1-L Hans Rudolph® calibration syringe connected to the flow head via 
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a standard bacterial filter.  Ten full syringe strokes were performed and 
measured within ± 3% accuracy. Two-point gas channel calibration of the O2 
sensor and zero calibration of the CO2 sensor were conducted as per 
manufacturer’s guidelines and as previously described (2).  
Synchronization of the flow and gas channels was performed monthly, again 
as previous described (2). The delays between the flow and respective gas 
channels were calculated and verified based on the 50% rise time in the step 
response in both gases seen when post-capillary dead space was reinspired, 
and averaged over 10 breaths in a typical human subject. These delays were 
used to synchronise the gas channels to the flow channel. 
 
ndd EasyOne Pro® LAB device (ndd) 
The ndd measures N2 indirectly via a side-stream ultrasonic transducer for 
sampling of side-stream molar mass (MMss), with an additional infra-red 
carbon dioxide (CO2) analyser (ndd Medizintechnik AG, Switzerland). The 
pre-capillary deadspace of the setup, which comprised the spirette, FRC 
barriette, and half the internal volume of the ultrasonic flowmeter, was 24.75 
ml. The post-capillary deadspace was 15.85 ml.  
The previous clinical software (“ndd old”) used the concept of a prototype 
expirogram, derived from the shape of the molar mass versus expired volume 
curve in the early breaths of the washout (3). The expired N2 volume for each 
breath is then determined by scaling the prototype expirogram to match the 
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end-expiratory N2 concentration for that breath, and integrating the flow with 
the scaled expirogram. 
In the updated software (“ndd new”), the N2 concentration is determined by 
solving Dalton’s law (Equation 1 above) and Equation 2 below simultaneously 
for the respective fraction of N2 and O2, i.e. fN2 and fO2: 
fN2.MMN2 + fO2.MMO2 + fCO2.MMCO2 + fH2O.MMH2O + fAr.MMAr = MM  (Equation 
2) where MM is the molar mass measured in the side stream 
as all other quantities are either measured (fCO2 and fH2O), known (molar 
masses of all the gas constituents, MMxx), or assumed (fAr). The fraction of 
Argon is assumed to be related to the N2 concentration (fAr = 0.0093 * 
fN2/0.7809) as it is not absorbed by the body. Two Nafion sampling tubes are 
used to ensure the gas in the molar mass sensor has the same humidity as 
ambient.  
The molar mass sensor was two-point calibrated automatically by software 
using room air and 100% O2 as reference points. CO2 gas sensor calibration 
was conducted automatically using a single point reference point, i.e. room 
air, prior to each trial. The calibration was manually verified prior to each 
testing session as follows. Flow verification was performed using a 1-L Hans 
Rudolph® calibration syringe connected to the flow sensor via the 
manufacturer’s calibration adapter. One full inspiratory pump stroke was 
performed followed by an expiratory pump stroke at moderate speed. Flow 
verification was completed after three full trials were performed and measured 
within ± 3% accuracy. 
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The new software also introduces changes to the estimation of delay between 
the flow and gas measurement points. In ndd old, delay was calculated 
automatically from the time-based cross correlation between the mainstream 
and sidestream molar mass signals, at the start of each trial. In contrast, ndd 
new uses a volume-based cross correlation method to estimate the delay, 
which are more robust to variation in breathing patterns particularly very brief 
pauses in flow (personal communication with the manufacturer). 
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To the Editor:
Small airways are abnormal in asthma [1]. One measurement of small airway function is Sacin, derived
from the multiple-breath nitrogen washout (MBNW) test. Sacin reflects ventilation heterogeneity in
diffusion-dependent airways, and is correlated with airway hyperresponsiveness [2] and asthma control
[3]. Theoretically, heterogeneity of diffusion-dependent ventilation can arise due to the heterogeneity of
cross-sectional areas of airway openings in terminal airways and the acini [4]. Therefore, Sacin may be
affected by structural changes in those airways. The elastic properties of the lung may also affect Sacin, as
the phase III slope, a marker of ventilation heterogeneity derived from the single-breath nitrogen washout,
correlates with lung compliance in explanted lungs of smokers and in healthy lungs [5].
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K. O. Tonga1,2,3,4,9* , G. G. King1,2,4, C. S. Farah1,3,4,5, C. Thamrin1,4, F. S. Tang1, J. Santos6,7,8, P. Sharma1,6,7,
D. G. Chapman1,6,7 and B. G. Oliver1,6,7
Abstract
There is limited evidence linking airway inflammation and lung function impairment in older non-smoking
asthmatics with fixed airflow obstruction (FAO), which can develop despite treatment with inhaled corticosteroids
(ICS). We assessed lung function (spirometry, forced oscillation technique (FOT)), lung elastic recoil and airway
inflammation using bronchoalveolar lavage (BAL) in non-smoking adult asthmatics with FAO, following 2 months
treatment with high-dose ICS/long-acting beta-agonist. Subjects demonstrated moderate FAO, abnormal FOT
indices and loss of lung elastic recoil. This cross-sectional study showed a lack of a relationship between BAL
neutrophils, eosinophils, inflammatory cytokines and lung function impairment. Other inflammatory pathways or
the effect of inflammation on lung function over time may explain FAO development.
Keywords: Fixed airflow obstruction, Asthma, Reduced lung elastic recoil, Airway inflammation
Irreversible or fixed airflow obstruction (FAO) can de-
velop in long-standing asthma despite no or minimal
smoking history and is associated with moderate to severe
disease [1, 2]. The mechanisms of FAO in asthma are
poorly understood; therefore prevention and treatment re-
main a challenge. Inhaled and/or oral corticosteroids im-
prove lung function and reduce exacerbations, yet may
not necessarily prevent FAO from occurring [3, 4].
Asthma severity [1, 5] and FAO development may be at-
tributed to corticosteroid resistance or insensitivity result-
ing in persistent airway inflammation [6] and structural
airway changes. Both eosinophilic and neutrophilic in-
flammation may be associated with lung function impair-
ment and FAO in asthma, however evidence is limited
and contradictory [4, 7].
In this prospective study, we investigated whether lung
function impairment in older non-smokers with
long-standing asthma and FAO is associated with the
airway inflammation which remains after treatment with
maximal dose inhaled corticosteroid (ICS). We hypothe-
sized that the degree of lung function abnormalities would
positively correlate with persistent airway inflammation in
patients with asthma and FAO, thereby providing a poten-
tial mechanism for the development of FAO and its appar-
ent steroid insensitivity.
Patients were > 40 years old, non-smokers or had a negli-
gible smoking history with a respiratory physician diagnosis
of asthma. All patients were treated with a standardized
maximal dose of ICS/long-acting beta-agonist (ICS/LABA)
using fluticasone/eformoterol 250 μg/10 μg metered dose
inhaler via a holding chamber, two puffs twice daily, if not
already taking this treatment. A baseline test skin prick test
to common allergens was performed to assess atopic status.
During enrolment and after 2 months of treatment, patients
completed a symptom questionnaire (Asthma Control
Questionnaire, ACQ-5) and performed pre-bronchodilator
lung function measurements. Measurements included spir-
ometry and the forced oscillation technique (FOT) to derive
airway resistance (R5) and reactance (X5) at 5 Hz. After
2 months of treatment an oesphageal balloon was used to
derive the pressure-volume (P-V) curve to assess the elastic
recoil properties of the lung via the indices K, reflecting lung
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compliance, and B/A, reflecting lung elastic recoil [8]. FAO
was assessed following 1 month of treatment and was
defined as a < 200 ml and < 12% change in spirometry
post-bronchodilator (400mcg inhaled salbutamol). ICS/
LABA medication was withheld for at least 24 h and short
acting beta-agonist medication for at least 6 h prior to
testing.
Following 2 months of ICS/LABA treatment and
within a week of the lung function measurements, pa-
tients then underwent bronchoscopy with bronchoalveo-
lar lavage (BAL) from the right middle lobe [9].
Neutrophil and eosinophil counts were obtained from
BAL samples as previously described [10]. Cytokines in-
cluding IL-1b, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21,
IL-22, IL-23, IL-25, IL-31, IL-33, IFN-γ, scD40L and
TNF-α were measured in BAL supernatant using a
multiplex immunoassay (Bio-Rad® Bio-Plex Multiplex
Immunoassay). Univariate correlations (Spearman rank
test) between lung function indices (using z-scores) and
BAL samples (using raw values) after 2 months of treat-
ment were assessed.
Nineteen patients were recruited (11 male; mean ± SD
age 63 ± 9 years, asthma duration 38 ± 22 years, height
1.69 ± 0.10 m, body mass index 28.4 ± 5.8 kg/metre2); 18
completed the study. Five patients were ex-smokers with
2.2 ± 2.5 pack-years smoking history and 14/19 patients
were atopic. Patients were symptomatic (ACQ-5 1.03 ±
0.92) despite taking regular asthma medications prior to
enrolment (ICS 18/19; with LABA 18/19; ICS/LABA/
long-acting muscarinic antagonist 5/19). One patient
was on long-term low dose oral corticosteroids (Prednis-
one dose 5 mg) for treatment of rheumatoid arthritis.
Post-bronchodilator spirometry after 1 month of treat-
ment showed moderate FAO (mean ± SD z-score: FEV1–
2.05 ± 0.75, FVC -0.61 ± 0.95, FEV1/FVC -2.46 ± 0.90).
After 2 months of treatment FOT indices were abnormal:
R5 (median (IQR) z-score: 2.7(1.8–3.2)) and X5 (z-score:
− 3.9(-7.3 - -2.0)). Spirometry did not change between
enrolment and after 2 months of treatment, however
R5 worsened. Eighteen patients performed lung elastic recoil
measurements (median (IQR) z-score: K 1.57(− 1.08–3.43)
and B/A -1.18(− 1.65--0.02)). Increased compliance was
demonstrated in 9/18 patients (K z-score ≥ 1.64) and loss
of elastic recoil in 5/18 (B/A% z-score ≤ − 1.64).
Eighteen patients performed bronchoscopy and BAL
neutrophil and eosinophil cell counts were obtained in
10 patients (mean ± SD: neutrophils 9.1 ± 18.1% and eo-
sinophils 1.9 ± 1.6%). No patients had evidence of neu-
trophilic airway inflammation whilst 4/10 patients had
eosinophilic airway inflammation. BAL cytokines were
obtained in 17 patients and results are shown in Fig. 1.
BMI, spirometry, FOT and elastic recoil indices did not
correlate with BAL neutrophil or eosinophil count and
inflammatory cytokines (Fig. 2). Occasionally, statisti-
cally significant correlations were observed however
these were the result of a single outlier.
Fig. 1 Cytokine levels measured in bronchoalveolar lavage fluid from each patient. Each row represents a patient and each column represents
different cytokines. Red indicates highest levels and bright green lowest levels. IL = interleukin, IFN-g = interferon gamma, sCD40L = soluble CD40
ligand, TNF-a = tissue necrosis factor alpha
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Variable levels of neutrophils, eosinophils and cyto-
kines were detected in this small cohort however there
was a disconnect between measures of airway inflamma-
tion and lung function. The lack of a relationship in this
cohort suggests persisting airway inflammation does not
affect lung function following ICS treatment. However,
the effect of previous inflammation and inflammation
over time on lung function and FAO development re-
mains unknown. A standardized period and dose of ICS
treatment was used to minimize potential confounders
however most patients were not steroid naïve thus the
study treatment may have had minimal additional effect
on the inflammatory profile. This is supported by the ab-
sence of any significant change in spirometry from
enrolment and after the two-month study period. Adher-
ence to study treatment was assessed after 1 month and
at the two-month mark to ensure non-adherence did
not play a role.
Somewhat surprisingly and in contrast to previous stud-
ies [11], this older cohort did not demonstrate neutro-
philic airway inflammation although small subject
numbers are a limiting factor. Furthermore, neutrophil ac-
tivation was not measured and may have been increased
due to inhibition of neutrophil apoptosis by inhaled corti-
costeroids. Despite treatment with high-dose ICS/LABA,
eosinophilic inflammation persisted in a few patients and
cytokines were still detectable, suggesting a steroid unre-
sponsive inflammatory pathway. The fact that FAO de-
velops despite treatment suggests inhaled corticosteroids
may have minimal effect on airway remodeling in older
people with asthma. Instead FAO in this cohort may pre-
dominantly be due to other mechanisms such as the loss
of elastic recoil observed in this study, which in turn may
occur as a result of lung tissue changes (i.e. lung remodel-
ing) [2]. Lung tissue changes could be due to proteolytic
enzymes disrupting lung parenchyma-terminal bronchiole
attachments [12]. Inflammation in the lung tissue cannot
be ignored, however our study lacks the ability to assess
this. Less invasive tests such as a computer tomography
(CT) scan to assess for possible lung tissue changes like
emphysema [13] was also not done. A recent study dem-
onstrated micro-emphysema, only on microscopic exam-
ination of post-mortem asthmatic lungs, which was not
evident on CT imaging [2], therefore inclusion of CT im-
aging may not have be adequate to demonstrate lung tis-
sue changes in our study.
Conclusion
In summary, this exploratory cross-sectional study has
shown a lack of relationship between persistent airway
inflammation and lung function impairment following a
short period of maximal ICS treatment. However, other
cellular mechanisms, lung tissue inflammation and the
potential longitudinal effect of inflammation over time
in the development of FAO in asthma warrant further
investigation.
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